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Abstract
Haemoglobin and nitric oxide (NO) strongly induce the stress protein haem 
oxygenase-1 (HO-1), which degrades haem to carbon monoxide (CO), a 
signalling and vasoactive molecule, the anti-oxidant biliverdin (BV) and iron. 
Raised HO-1 levels have been detected in the endothelium and kidneys of 
animals, as well as leukocytes of patients, suffering from sickle cell disease 
(SOD). A genetic mutation of haemoglobin causes SOD, pathologic symptoms 
of which include vaso-occlusive crises and high concentrations of free 
haemoglobin liberated during red blood cell haemolysis. Although HO-1 and its 
products have been linked to SOD, their potential role in this condition has not 
been examined. The work of this thesis aimed to: 1) investigate the interaction 
of haemoglobin and NO in modulating endothelial HO-1 expression; 2) examine 
the effect of human sickle cell blood on HO-1 induction and vascular function; 
and 3) assess the role of HO-1 and its products on sickle cell blood adhesion 
and regulation of vessel contractility. Experiments were performed using a 
combination of in vitro (cell culture and biochemical assays) and ex-vivo 
(isolated aortic rings) models. The results of the study indicated that NO 
synergises with haemoglobin to amplify HO-1 expression and haem 
incorporation by endothelial cells, suggesting that similar mechanisms might 
contribute to changes in vascular function occurring in haemolytic disorders. It 
was also found that sickle cell blood induces haem oxygenase to a greater 
extent than normal blood, an effect which is magnified under hypoxia. The 
increased haem oxygenase elicited by sickle cell blood depends on the time 
elapsed since the last vaso-occlusive crisis experienced by the patient. Finally, 
CO and BV diminish sickle blood adhesion to the endothelium and sickle blood
can alter CO-mediated vessel relaxation. These findings support a functional 
role for the HO-1 pathway in SCO and may help to identify therapeutic 
strategies to counteract the vascular damage caused by SCO.
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Chapter 1. Introduction
1.1 The haem oxygenase pathway
1.1.1 History of haem oxygenase
The degradation of haem to biliverdin (BV) was first demonstrated in vitro 
by Wise and Drabkin (Wise CD. and Drabkin DL, 1964). The protein responsible 
for this degradation was subsequently demonstrated to be haem oxygenase by 
Tenhunen (Tenhunen et al., 1969), who confirmed that this enzyme is 
responsible for the catabolism of haem as well as characterizing the enzyme 
and its cellular location. The initial presumption was that haem oxygenase was 
a member of the cytochrome P450 family of enzymes (Tenhunen et al., 1969); 
however, subsequent investigations established haem oxygenase as a rapidly 
and transiently inducible mono-oxygenase that functioned independent of 
cytochrome P450 (Maines et al., 1986). The inducible isoform of haem 
oxygenase, haem oxygenase-1 (HO-1 ), was later found to be identical to heat 
shock protein 32 and this resulted in interest in HO-1 as a stress response 
protein. The production of specific stress proteins is the cellular response to 
metabolic and stressful changes and HO-1 was found to be induced by various 
stimuli that directly and indirectly exert oxidative stress. Therefore, it was 
proposed that this particular stress protein may provide a role in cellular 
protection (Maines, 1988; Stocker, 1990), as both haem and HO-1 are found to 
be highly conserved molecules across almost all forms of life suggesting that 
they most likely have a necessary and fundamental purpose. Indeed, the case 
of a boy born with HO-1 deficiency highlighted the importance of this enzyme 
(Yachie et al., 1999). The child suffered growth retardation, anaemia, tissue iron
1
deposition, lymphadenopathy, leukocytosis, a marked sensitivity to oxidant 
injury and unfortunately succumbed to an early death. The child was found to 
have both intravascular haemolysis and endothelial cell injury. In particular, the 
lymphoblastoid cell line derived from the patient was shown to have increased 
sensitivity to haem toxicity (Nagy et al., 2005). There were also fatty streaks and 
fibrous plaques in the aorta that were reported as a sign of severe 
atherosclerosis, as well as mesangioproliferative glomerular changes in the 
kidney (Ohta et al., 2000), Transgenic HO-1 knockout mice have also shown 
similar endothelial damage as well as hepatic and renal tubular cytotoxicity 
(Poss and Tonegawa, 1997).
Consequently, HO-1 was seen as necessary for the survival of 
organisms and experimental evidence supported the hypothesis that this enzyme 
was protective against oxidative stress (Maines, 1984). Indeed, the beneficial 
effects of HO-1 have now been described in many diseases (Maines, 1988) 
(Morse and Choi, 2002). The mechanism by which HO-1 confers this protection 
has been an area of immense interest, because the discovery of how the cell can 
protect itself from oxidative stress will lead to new therapeutic avenues in treating 
and possibly preventing diseases. HO-1 can function as an anti-oxidant by 
preventing the participation of free haem in pro-oxidant reactions (Keyse and 
Tyrrell, 1989), but a major area of research has concentrated on the 
cytoprotective properties of its breakdown products. Haem oxygenase cleaves 
the a-meso carbon bridge of haem molecules, which is the first rate-limiting step 
of haem degradation resulting in the production of equimolar quantities of BV IXa, 
free iron and CO. BV is subsequently converted to bilirubin (BR) by biliverdin 
reductase (BVR) and free iron is sequestered by ferritin (Figure 1-1 ).
cell
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• Anti-inflammatory
• Anti-apoptotic
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Figure 1-1. The haem oxygenase pathway
Haem oxygenase-1 degrades haem (H) into carbon monoxide (CO), biliverdin 
(BV) which is converted to bilirubin (BR) through the action of biliverdin 
reductase (BVR), and iron. The breakdown products can exert various 
biological actions to protect against cellular damage from oxidative stress.
All three breakdown products, i.e. CO, BR and iron, have been shown to have 
anti-oxidant properties and are candidate molecules for the anti-inflammatory, 
anti-apoptotic and anti-proliferative functions of HO-1 (Otterbein and Choi, 2000). 
There are several isoforms of haem oxygenase, each the product of separate 
genes. Specifically, HO-1 is the inducible form, HO-2 is a constitutive form and 
the more recently identified HO-3 is structurally similar to HO-2 but is a less 
efficient haem catalyst (Maines, 1988). The specific activity of haem oxygenase 
in different organs varies, with the highest haem oxygenase activity found in the 
spleen, testes and brain. The spleen is the only organ in which, under normal 
conditions, HO-1 is the predominant form; however, stressful stimuli will 
dramatically increase the expression of HO-1 mRNA in the cardiovascular
system (Ewing et al., 1994). HO-2 is the most prevalent form found in endothelial 
and smooth muscle layers of blood vessels. HO-2  is also the isoform most 
abundantly expressed in the liver under normal conditions. The highest levels of 
HO-2 are found in the testis. The discovery that HO-2 was found prominently in 
the brain (Maines, 2000) suggested that it may serve a function other than haem 
degradation. Indeed, CO has been postulated to have an important role in signal 
transduction in the brain (Snyder et al., 1998). CO is a gas with chemical 
properties similar to NO. Soluble guanylate cyclase (sGC) can be activated by 
NO or CO to produce the signalling molecule cGMP and requires the direct 
binding of the gaseous molecules to the haem moiety of guanylate cyclase 
(Krumenacker et al., 2004). As HO-2 was found highly expressed in neurons it 
was hypothesized that CO generated by haem degradation could function as an 
activator of sGC and, therefore, cGMP production. CO has also been found to 
function as a signal for cGMP production in the cardiovascular system (Motterlini 
et al., 1998; Sammut et al., 1998).
1.1.2 Carbon monoxide
CO has been shown to be highly protective in several rodent disease 
models, mimicking the action of HO-1. For example, CO administration has 
been shown to have protective effects in models of acute lung injury, endotoxic 
shock and in mouse cardiac xenotransplantation (Otterbein et al., 1999; Yachie 
et al., 1999);(Sato et al., 2001). HO-1 expression or CO administration can 
mediate potent anti-inflammatory effects in monocytes and/or macrophages, 
probably by preventing these cells from inducing tissue injury and by modulating 
their role in the initiation of immune responses (Sawle et al., 2005; Yachie et al., 
1999). CO also exerts other actions which contribute to its anti-inflammatory
effects. Firstly, CO prevents platelet activation and aggregation (Brune and 
Ullrich, 1987), thereby suppressing thrombosis and the pro-inflammatory 
response stimulated by activated platelets. CO also down-modulates the 
expression in macrophages of plasminogen activator inhibitor type 1 ; this action 
appears to be crucial for the ability of CO to exert a protective effect in a model 
of ischemia-reperfusion of the lung (Fujita et al., 2001). Furthermore, CO 
prevents apoptosis in several cell types including endothelial cells, fibroblasts, 
hepatocytes and ft-cells of the pancreas (Brouard et al., 2002) (Gunther et al., 
2002; Petrache et al., 2000). As widespread apoptosis can exacerbate the 
deleterious effects of inflammatory reactions, including the prothrombotic 
stimulus apoptotic endothelial cells provide (Bombeli et al., 1999), the anti- 
apoptotic effect of CO may have a crucial role in its overall effect. CO has also 
been shown to have an anti-proliferative effect on smooth muscle cells that 
contribute to neointimal proliferation associated with inflammatory lesions 
(Otterbein et al., 2003b). However, it is important not to overlook the toxicity 
associated with CO, as the gas is lethal at high enough doses. In fact, CO has 
the ability to bind haemoglobin and myoglobin tightly thus preventing oxygen 
delivery to tissues and organs, which leads to tissue hypoxia. High 
concentrations of CO have also been shown to poison the respiratory chain in 
the mitochondria thereby suppressing ATP generation (Haab, 1990). The 
search for cellular targets for CO is only just beginning. However, depending on 
the cell type, one or more key signalling systems are reported to be involved in 
the response to CO, including guanylyl cyclase-cGMP, potassium channel 
activation or p38 mitogen-activated protein kinase (MARK). For example, cGMP 
but not p38 MARK is needed for the anti-apoptotic effect of CO in fibroblasts
(Gerard et al., 1993). In contrast, p38 activation is required for the anti-apoptotic 
effect of CO in endothelial cells but cGMP is not (Brouard et al., 2000). 
Furthermore, CO has been reported to mediate arterial vasodilation through 
activation of calcium-dependent potassium channels in rat models (Bolognesi et 
al., 2007). There are possible targets through which CO can mediate signal 
transduction, including proteins in which haem functions as a prosthetic group 
e.g. haemoglobin, myoglobin, guanylyl cyclase, cyclooxygenase, cytochrome 
p450 oxidase, inducible nitric oxide synthase (iNOS), NADPH oxidase (Taille et 
al., 2005) and the transcription factors Bach 1 and Bach 2, to which haem 
groups are bound in certain conditions (Otterbein et al., 2003a). CO could 
modulate the activity of these haemoproteins because of its ability to bind to the 
central iron group contained within their haem prosthetic groups. CO binding 
would then induce conformational changes that can modulate the biological 
activity of these proteins (Stevenson et al., 2 0 0 1 ), in addition CO could also 
bind to proteins that contain other metal ions, such as zinc, copper and 
manganese.
1.1.3 Biliverdin and Bilirubin
Biliverdin (BV) is converted to bilirubin (BR) by the action of biliverdin 
reductase (Singleton and Laster, 1965). The potent anti-oxidant effects of BV 
and BR are thought to contribute significantly to the overall protective effect of 
HO-1 (Stocker et al., 1987b). BR is the most abundant endogenous anti-oxidant 
in mammalian tissues accounting for the majority of the anti-oxidant activity of 
the serum. BR at low concentrations scavenges reactive oxygen species (ROS) 
in vitro, reduces oxidant-induced cellular injury and attenuates oxidant stress in 
vivo (Clark et al., 2000a; Stocker et al., 1987a; Stocker et al., 1987b). In
addition to providing protection against oxidative stress, BV and BR have been 
shown to scavenge NO (Kaur et al., 2003) and therefore could also protect cells 
against uncontrolled NO production or "nitrosative stress”. Furthermore, 
inhibition of NADPH oxidase (Kwak et al., 1991) and protein kinase C (PKC) 
activity (Sano et al., 1985) by BR has been demonstrated, both enzymes being 
implicated in angiotensin ll-lnduced vascular injury (Rajagopalan et al., 1996). 
Both BV and BR have been reported to have the ability to preserve endothelial 
cell integrity (Sedlak and Snyder, 2004) and prevent endothelial cell death or 
sloughing to enhance vascular reactivity in diabetic rats (Abraham et al., 2004). 
In addition, BR has been implicated in reducing oxidative stress in experimental 
diabetes, partly by increasing the bioavailability of NO needed for endothelial 
cell integrity (Abraham et al., 2004). In this context, BR mediated inhibition of 
PKC and NADPH oxidase may be one mechanism by which HO-1 attenuates 
the diabetes-mediated generation of oxidants and the uncoupling of eNOS. HO- 
1 derived BR also displays cytoprotective effects in the cardiovascular system 
(Clark et al., 2000b). Numerous reports indicate that a higher serum BR level is 
associated with a decrease in the risk for coronary artery disease in humans. 
Free and albumin-bound BR has also been shown to inhibit oxidation of low- 
density lipoprotein (LDL) (Neuzil and Stocker, 1994). Interestingly, the recent 
description of a cycle in which BV, derived from the oxidation of BR, is 
converted to BR by BVR suggests a mechanism to amplify the anti-oxidant 
effects of the two bile pigments (Baranano et al., 2002).
1.1.4 Iron
The degradation of haem by HO-1 leading to the release of Fe^^ from the 
core of the haem molecule, results in the rapid expression of the iron
sequestering protein ferritin (see section 1.2.5) as well as an ATPase pump that 
actively removes intracellular iron from the cell (Ferris et al., 1999). Expression 
of ferritin was originally reported to be part of the mechanisms by which HO-1 
conferred resistance to oxidative stress in endothelial cells (Balia et al., 1992a), 
as well as mediating the protection seen in a model of hyperoxic lung injury 
after HO-1 induction by haem (Taylor et al., 1998). Conversely, the potent 
cytoprotection provided by HO-1 induction in a model of endotoxic shock in rats 
appeared to be independent of ferritin (Otterbein et al., 1997). The ATPase 
pump that actively removes intracellular iron from the cell contributes to 
decreasing the overall intracellular pool of Fe^ "^  and protecting cells from 
apoptosis (Ferris et al., 1999). The respective contributions of the iron pump 
versus ferritin to the overall cytoprotective effect of HO-1 are not clear but 
presumably both mechanisms participate in a crucial manner to the overall 
homeostatic effects that follow increased HO-1 expression in a variety of 
stressful situations.
1.1.5 Induction and regulation of HO-1
A number of physiological and non-physiological stressors can stimulate 
HO-1 expression and activity, including the substrate haem, endotoxin, 
inflammatory cytokines, long wave ultraviolet A radiation (UVA), hyperthermia 
and heavy metals (Ryter and Choi, 2002) (Figure 1-2). The primary mechanism 
of induction is through activation of the hmox-1 gene (Alam and Cook, 2003). 
Investigations into the gene activation process have revealed a multitude of 
varied mechanisms of gene regulation.
Stress stimuli; 
Endotoxins
Inflammatory cytokines
UV-light
Heavy metals
Non-stressful stimulus:
Glucagon-cAMP
Oxidative Stress cAMP/cGMP
Redox
MAPKa
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f HO-1 Transcription
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Figure 1-2. Induction of HO-1
Stressful stimuli elicit haem oxygenase-1 (HO-1 ) induction through activation of 
mitogen-activated protein kinases (MAPKs), whereas non-stressful stimuli 
induce HO-1 through increasing cyclic adenosine monophosphate (cAMP) or 
cyclic guanosine monophosphate (cGMP) production which activate cAMP- 
dependent protein kinase A or cGMP-dependent protein kinase G (see section 
1. 1.6 ).
The best characterized amongst the various hmox-^ genes is the mouse hmox- 
1 locus, where analysis has revealed a 10-bp DMA sequence motif called the 
stress response element (StRE). This motif is found in multiple copies within 
two upstream enhancer regions and is involved in the mediation of transcription 
activation in response to almost all HO-1 inducers tested. The StRE are targets 
of multiple dimeric proteins made up of individual members of the Jun, Eos, 
CREB, ATP, Maf and Cap'N'Collar-basic-leucine zipper (CNC-bZIP) subclasses 
of the basic-leucine-zipper superfamily of transcription factors. Increasing
evidence suggests a particularly important role for CNC-bZIP factors in inducer 
dependent hmox-^ gene regulation (Alam et al., 2004). Mammalian CNC-bZIP 
proteins include p45, nuclear factor-erythroid 2 (NF-E2)-related factor 1 (Nrf1), 
Nrf2, Nrf3, Bach1 and Bach2. CNC-bZIP proteins do not form intrafamily dimers 
but Instead heterodimerize mostly with small Maf proteins such as MafF, Maf G 
and MafK. The small Maf proteins themselves do not contain transcription 
activation domains (Motohashi et al., 1997), therefore, the transcription 
activation of NF-E2-type factors is derived from the CNC-bZIP subunit. Nrf2 in 
particular contains a potent transcription activation domain and has been 
implicated in the induction of the hmox-1 gene in response to various stimuli, 
such as haem, heavy metals, arsenite, curcumin and various electrophiles 
(Balogun et al., 2003b);(Alam and Cook, 2003). In contrast to Nrf2, Bachi does 
not contain transcription activation domains but instead Bach-small Maf dimers 
are thought to act as repressors when bound to target sequences. Indeed, 
Ogawa and co-workers have demonstrated that Bachi-mediated repression 
plays a crucial role in the regulation of HO-1 expression (Ogawa et al., 2001).
Bachi-Maf dimers have been shown to bind to the hmox-1 StRE which then 
results in the repression of a linked reporter gene. Bachi repressor activity is 
dominant over the activator function of other StRE binding protein such as Nrf2 
under normal conditions, which results in a low level of hmox-1 activity (Sun et 
al., 2002). In vitro, it has been demonstrated that Bachi can bind to haem, and 
haem binding inhibits the DNA binding activity of Bachi. Therefore, it was 
proposed that induction of HO-1 expression may be the result of inactivation of 
Bachi mediated hmox-1 gene repression by increased levels of cellular haem 
(Ogawa et al., 2001). Indeed, Ogawa’s group also demonstrated that, in vivo,
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haem promoted the displacement of Bachi from the hmox-1 enhancer resulting 
in gene derepression. Displacement of Bachi from the hmox-1 StREs by haem 
was followed by binding of Nrf2 (probably as Nrf2:small Maf dimer) (Ogawa et 
al., 2001), suggesting that removal of Bachi alone is not sufficient to promote 
optimal hmox-1 gene activity and, therefore, high level gene transcription 
requires the subsequent StRE binding of a protein with activator function. 
Indeed, Alam and colleagues have demonstrated that Nrf2 is necessary for 
hmox-1 gene induction by haem in rat kidney proximal tubular cells (Alam et al.,
2003).
However, HO-1 is induced by many non-haem inducers, which are also 
known to act via the StRE. Due to the varied structure and nature of these 
inducers it is unlikely that they would all bind exclusively to Bachi and inhibit its 
activity. One possible model put forward for the action of these inducers was 
that they may act indirectly by increasing the intracellular concentration of 
inhibitory haem molecules by promoting the release of haem from 
haemoproteins or mobilising a "free" haem pool. However, this model has been 
challenged, and evidence has been put forward to offer different mechanisms of 
action (Alam et al., 2004). For example, cadmium, a potent inducer of HO-1, 
has been shown to promote the export of Bachi from the nucleus, as well as 
the nuclear export of Bach2, suggesting that cadmium can alleviate repression 
of hmox-1 by Bachi or Bach2 (Suzuki et al., 2003). Cadmium, like haem, can 
stimulate Nrf2 expression by inhibiting its degradation (Stewart et al., 2003), 
resulting in relative nuclear abundance of StRE activators (e.g. Nrf2:small Maf 
dimers) compared with StRE repressors (e.g. Bach-small Mac dimers) and 
hmox-1 gene activation. The overall effect after the exchange of factors at the
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StRE is an increase in the rate of hmox-1 transcription. A reduction in the stress 
environment by termination of exposure or sequestration, cellular extrusion or 
metabolic inactivation of the stressor will result in reversal of these processes 
and a return to the original state of the unstimulated cell (Alam et al., 2004).
The number of StRE, their location and sequence are highly conserved 
between the mouse and human hmox-1 genes, which infers that the StRE 
pathway is important in the induction of human HO-1 expression. However, 
there is limited analysis to date of the human StRE pathway, and further 
investigation will be required to elucidate the importance of this regulatory 
system (Alam et al., 2004).
1.1.6 HO-1 and signal transduction
Whereas haem acts as a ligand and interacts directly with DNA binding 
proteins (Bachi), this is not the mechanism of action for the majority of the HO- 
1 inducers. Increasing evidence suggests that the majority of inducers increase 
expression of HO-1 by activating one or more signalling cascades that 
eventually converge on transcription factors or repressors to regulate the 
activity of the hmox-1 gene (Alam et al., 2004). For example, protein kinases 
mediate hepatic HO-1 induction by cyclic nucleotides. cAMP and cGMP are 
second messengers which play an important role in intracellular signal 
transduction of various hormones and extracellular stimuli, increases in these 
cyclic nucleotides activate downstream-dependent protein kinase A (PKA) and 
cGMP-dependent protein kinase G. cAMP has been shown to induce HO-1 
expression in rat hepatocytes via the PKA signalling pathway (Immenschuh and 
Ramadori, 2000). PKA-dependent, cAMP mediated HO-1 induction has also 
been seen in vascular smooth muscle cells (Durante et al., 1997). The
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signalling gas NO induces HO-1 expression in many tissue and cell types 
(Motterlini et al., 1996b; Motterlini et al., 1996c; Motterlini et al., 1996a; 
Naughton et al., 2002b). As NO potently stimulates soluble guanylate cyclase, 
with a resulting high level of cGMP production, it can be proposed that cGMP 
may serve as a second messenger for NO-mediated hmox-1 gene activation. 
Indeed, cGMP treatment on its own has been shown to increase hmox-1 
transcription via activation of PKG in hepatocytes and endothelial cells 
(Immenschuh et al., 1998; Polte et al., 2000). However, other reports do not 
confirm cGMP as a mediator of HO-1 induction by NO (Chen and Maines, 2000; 
Hartsfield et al., 1997; Motterlini et al., 1996a), suggesting the role of NO in 
haem oxygenase gene modulation is complex and requires further investigation. 
A more detailed description of the interaction of NO and haem oxygenase is 
given in sections 1.6.8-11.
Mitogen-activated protein kinases (MAPKs) have also been shown to have 
an important role in stress mediated cellular responses. MAPKs are a family of 
serine-threonine protein kinases which are involved in the transduction of 
extracellular signals, leading to a wide variety of intracellular responses such as 
gene expression, cell proliferation and apoptosis. The three major subfamilies of 
MAPKs that have been identified are; extracellular regulated signal kinases 
(ERKs), c-Jun N-terminal kinases (JNKs) and p38 kinases. MAPKs are 
activated by phosphorylation of their threonyl and tyrosyl residues by MAPK 
kinases (MKKs) which in turn are phosphorylated and activated by upstream 
MKK kinases (MKKKs) (Kyriakis and Avruch, 2001 ). There have been divergent 
results reported for the stress-dependent stimulation of the /?mox-1 gene activity 
in hepatic cells from different species. For example, Kong and co-workers have
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implicated several MKKKs in arsenite mediated Nrf2 dependent HO-1 up- 
regulation in human Hep-G2 hepatoma cells (Yu et al., 2000), the response of 
which is in part dependent on the activity of JNK1 and its upstream kinase 
MKK4, but does not require p38 or its upstream kinase MKK3. In contrast, 
arsenite-induced HO-1 expression in rat hepatocytes requires both the JNK and 
MKK3/p38 pathways (Kietzmann et al., 2003). Therefore, there are clearly 
species-specific differences in the involvement of MAPK signalling cascades 
during stress-dependent induction of hepatic HO-1 expression.
UVA radiation (320-380nm) is also known to induce HO-1. UVA radiation is 
an oxidizing carcinogen whose biological effects are dependent on oxygen. 
Singlet oxygen specifically is thought to be an early intermediate in the induction 
of the hmox-'i gene. The next steps appear to involve lipid oxidation products 
and metabolites (Basu-Modak and Tyrrell, 1993). Oxidized lipids and oxidized 
membrane phospholipids are potent inducers of HO-1 induction; however, some 
evidence suggests that enzymatic processing of UVA damaged lipids to 
prostaglandins through the phospholipase A2/cyclooxygenase pathway is also 
critical to UVA activation (Basu-Modak et al., 1996), as prostaglandins are 
strong inducers of HO-1 (Grether-Beck et al., 2000). UVA radiation can also, 
through generation of lipid intermediates, potentially involve signalling 
pathways. For example, reports indicate that UVA activates each of the three 
major classes of MAPKs in both fibroblasts and epidermal cells under certain 
conditions (Klotz et al., 1999a; Le Panse et al., 2003; Silvers et al., 2003). 
Furthermore, in human fibroblasts it has been postulated that hmox-1 is 
activated through various kinases (Klotz et al., 1999b). UVA has also been 
shown to activate protein kinase C which through its anti-apoptotic properties
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could be linked to the anti-apoptotic properties of HO-1 (Matsui and DeLeo, 
1990).
1.1.7 HO-1 as a therapeutic target
The potent protective properties of HO-1 lead to the question of whether 
induction of HO-1 can be used clinically. In addressing this question it is 
important to consider the polymorphism identified in the human HO-1 gene 
promoter (Kimpara et al., 1997), which regulates the magnitude of HO-1 
response to a given stress signal. This polymorphism appears to be of 
functional significance in those patients with long GT repeats in the gene 
promoter region of HO-1 which elicit low HO-1 responses. Conversely, patients 
with short GT repeats in the HO-1 gene promoter elicit a high HO-1 response, 
and are associated with a reduced likelihood of restenosis after angioplasty 
(Exner et al., 2001). Therefore, the induction of HO-1 in certain patients with low 
responses would be ineffective therapeutically. However, the administration of 
HO-1 biproducts could also have potential therapeutic applications and provide 
an alternative approach to liberating the protective effects of HO-1 in a clinical 
setting.
Until recently, the use of CO as a therapeutic tool may have appeared to 
be an unattractive prospect due to its toxicity. However, studies using relatively 
low doses of inhaled CO (250 ppm for just 1 to 24 h) pre-operatively in rodent 
and pig models have produced beneficial results in attenuating post-operative 
ileus without producing unwanted side-effects (Moore et al., 2005). If similar 
beneficial results are seen in humans there may be a potential for the use of CO 
therapeutically, for example in the pre-treatment of patients before vascular 
surgeries to prevent restenosis or the treatment of an organ donor and/or the
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organ to suppress ischaemia-reperfusion injury and to prolong allograft survival 
in transplantation procedures (Otterbein et al., 2003a). Indeed, HO-1-derived 
CO or inhaled 0 0  have both demonstrated suppression of arteriosclerotic 
lesion development associated with chronic rejection of transplanted organs in 
rodent models (Otterbein et al., 2003b; Sato et al., 2001). However, the use of 
CO gas as a therapeutic agent has significant obstacles. The gaseous nature of 
the molecule underlies the difficulty in delivering CO efficiently and securely to 
target cells (Alberto and Motterlini, 2007). The recent identification of CO- 
releasing molecules (CO-RMs), a novel class of compounds that can carry and 
transport CO into a biological environment (Motterlini et al., 2003), offers an 
intriguing alternative to CO delivery through inhalation (see section 1.1.8 for 
more details). Accumulating evidence has demonstrated that CO-RMs can be 
used therapeutically to suppress inflammation and protect against oxidative 
stress, ischaemia-reperfusion injury, allograft rejection and myocardial infarction 
in animal models (Motterlini et al., 2005b). The potential use of CO-RMs in 
human patients would offer an accurate and safe way to deliver the therapeutic 
properties of CO. However, further studies are essential for ascertaining the 
optimal concentration of CO to be administered, as well as the length and 
frequency of CO treatment required to have a beneficial effect for a given 
condition.
Administration of BV or BR provides an additional strategy to exploit the 
beneficial effects of HO-1 induction, and could be used as an independent 
treatment regimen or in combination with CO therapy. BR is a potentially toxic 
and insoluble molecule, and in high doses can contribute to cytotoxicity, for 
example, hyperbilirubinaemia is responsible for diseases such as neonatal
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jaundice and kernicterus (Kapitulnik, 2004). However, investigators 
demonstrated that micromolar levels of exogenous BR minimised the effects of 
ischaemia-reperfusion injury in rat liver or kidney transplantation models and 
was equally as effective as HO-1 induction in protection against oxidative stress 
(Kato et al., 2003) (Adin et al., 2005). These results suggest that BR 
administration may provide organ protection during graft harvest, where its anti­
oxidant properties could protect against ischaemia and oxidative injury. Unlike 
BR, BV is a soluble and non-toxic compound; but it is rapidly converted to BR 
by BVR, and several investigators have supplied exogenous BV as a safer 
means of harnessing the anti-oxidative properties of BR. For example, BV 
administration resulted in increased survival of mouse cardiac allograft and 
transplanted rat small bowel (Yamashita et al., 2004);(Nakao et al., 2004). 
Furthermore, co-administration of BV and CO resulted in significantly more 
protection of organ function and survival in rat kidney and heart transplant 
models than observed with BV alone (Nakao et al., 2005). Therefore, BV or BR 
in combination with CO could potentially provide protection from oxidative 
damage in human organ harvesting and transplantation. However, further 
studies are required to determine the optimal dose and timing of BV or BR 
delivery, necessary for therapeutic effect in clinical settings.
1.1.8 CO-releasing molecules
Until 10 years ago, CO was considered to be nothing more than a waste 
molecule produced in living organisms with little functional use. The toxic effects 
of high levels of CO have been well documented and are primarily due to its 
binding to important biological haemoproteins such as haemoglobin and 
cytochromes which are essential for O2 transport and mitochondrial respiration.
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However, in the last decade a new appreciation of the versatile properties of CO 
as a signalling mediator and regulator of essential physiological processes has 
emerged. Endogenous generation or exogenous administration of low doses of 
CO has been demonstrated to have potent vasodilatory, anti-inflammatory, anti­
proliferative and anti-apoptotic effects (Motterlini et al., 2003). Therefore, to 
harness these potentially therapeutic effects of CO, the search for “CO- 
releasing molecules" (CO-RMs) was initiated in our laboratory. The promise of 
such compounds was to carry and deliver a therapeutic but potentially toxic 
molecule, controllably and safely into biological systems.
The initial exploration into CO-RMs identified two metal carbonyl 
complexes, Mn2(CO)io (CORM-1) and [Ru(CO)3Cl2]2 (CORM-2), which were 
observed to liberate CO. Significantly, the biological activity of these CO-RMs 
was confirmed in isolated rat heart or aortic vessel models, where both 
compounds produced powerful vasodilation (Clark et al., 2003);(Motterlini et al., 
2002a). However, these early CO-RMs were poorly soluble in water which 
would be a limitation to potential pharmaceutical development.
Two water-soluble CO-RMs were then synthesised: 
tricarbonylchloro(glycinato)ruthenium(ll) (CORM-3) and sodium 
boranocarbonate (C0RM-A1), which have demonstrated the most encouraging 
results (Alberto and Motterlini, 2007). CORM-3 and C0RM-A1, despite diverse 
chemical structures and differing rates of CO release, have elicited significant 
therapeutic effects in a variety of experimental models and will be discussed in 
more detail in the following sections. Importantly, the use of inactivated CO- 
RMs (iCORMs), which are the CO-RM molecules depleted of CO, as negative 
controls in experimental settings have confirmed that it is the effect of CO
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modulating physiological functions and not another component of the CO-RM 
molecule (Motterlini et al., 2003).
1.1.8.1 Pharmacological actions of CORM-3
CORM-3 is a metal carbonyl complex (see section 2.3.1 for synthesis), 
which can rapidly release CO into physiological buffers. It has a half-life of 
approximately 3.6 min at 37°C and pH 7.4. CORM-3 has developed into a 
versatile research tool and has been shown to liberate CO in vitro, ex vivo and 
in vivo in biological models (Motterlini et al., 2003). The vaso-active properties 
of CORM-3 have been reported in a rat isolated aortic ring model, where 
CORM-3 produced significant vasodilation (Foresti et al., 2004). The role of 
CORM-3 in attenuating inflammatory responses has also been reported in 
various experimental models. For instance, CORM-3 significantly suppresses 
the LPS-mediated inflammatory response in cultured macrophages (Sawle et 
al., 2005), as well as IPS or interferon-gamma-induced inflammation in BV2 
microglial cells (Bani-Hani et al., 2006). CORM-3 also showed therapeutic 
results in in vivo models of acute inflammation (e.g. acute peritonitis in mice), as 
well as reducing endothelial adhesion molecule expression and subsequent 
leukocyte-endothelial interactions (Urquhart et al., 2007). These studies suggest 
that CORM-3 can be used as an effective tool to modulate inflammation.
The cardio-protective properties of CORM-3 have been another major 
area of interest for investigators. CORM-3 has been shown to protect 
myocardial cells and isolated hearts against ischaemia-reperfusion injury as 
well as cardiac transplant rejection in mice (Clark et al., 2003). In further 
studies, CORM-3 was reported to limit ischaemia-reperfusion injury in an in vivo 
model of cardiac infarction in mice (Guo et al., 2004). More recently, pre­
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treatment of isolated rat hearts with CORM-3 was found to reduce infarct size, 
incidence of ventricular fibrillation and tachycardia (Varadi et al., 2007) and 
administration of CORM-3 was found to induce late pre-conditioning against 
myocardial infarction in an in vivo mouse model (Stein et al., 2005). In addition, 
the positive inotropic effects of CORM-3 in an isolated perfused rat heart model 
were recently described (Musameh et al., 2006). This mounting evidence 
suggests that CO offers powerful cardio-protective effects and CORM-3 may 
provide an effective means of delivery of this therapeutic agent.
CORM-3 has also been found to be beneficial to kidneys, as it protected 
renal epithelial cells against cisplatin induced nephrotoxicity, as well as 
preventing cisplatin-mediated renal dysfunction in a rat model of renal failure 
(Tayem et al., 2006). Furthermore, isolated rabbit kidneys flushed with CORM-3 
followed by cold ischaemia elicited at reperfusion an increased glomerular 
filtration rate, and sodium and glucose re-absorption compared to controls 
(Sandouka et al., 2006). These data corroborate the potent cytoprotective 
properties of CO and CORM-3, and also highlight the therapeutic potential of 
this molecule in a clinical setting for harvesting and transplantation of organs.
1.1.8.2 Pharmacological actions of CORM-A1
C0RM-A1 differs from the original CO-RMs in that it does not contain a 
transitional metal carbonyl but a carboxylic acid coordinated to a boron atom 
(see section 2.3.2 for synthesis). It possesses a much slower rate of CO 
release compared to CORM-3, with a half-life of 21 min at 37°C at pH 7.4 
(Motterlini et al., 2003). In parallel experiments to those undertaken with CORM- 
3, the vasorelaxant and hypotensive properties of C0RM-A1 have been 
demonstrated in aortic isolated ring and in vivo models, respectively (Motterlini
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et al., 2005c). C0RM-A1 also elicited significant coronary vasodilation in rat 
isolated perfused heart models (Musameh et al., 2006), adding to the growing 
evidence that CO released from CO-RMs has potent cardio-protective actions.
The vasodilatory actions of C0RM-A1 were further explored in an in vivo 
mouse kidney model, where CO liberated from C0RM-A1 resulted in increased 
renal blood flow and decrease in vascular resistance (Ryan et al., 2006). The 
cytoprotective effects of C0RM-A1 were also demonstrated in the kidney, 
where flushing kidneys with C0RM-A1 before cold storage produced protective 
effects on renal function similar to those observed with CORM-3 (Sandouka et 
al., 2006). Recent work has explored the cerebroprotective effects of CORM- 
A1, where systemic administration of C0RM-A1 was importantly shown to 
deliver CO to the brain in newborn pigs (Zimmermann et al., 2007). The authors 
reported that C0RM-A1 elicited the vasodilatory and cytoprotective effects of 
CO in the cerebral circulation and resulted in protection of the neonatal brain 
from cerebral vascular injury from epileptic seizures. These are intriguing results 
and emphasize the potent cytoprotective and vaso-active properties of CO 
delivered by C0RM-A1.
1.2 Haem
Haem is essential for the function of all aerobic cells. It is a complex of 
iron with protoporphyrin IX and is used as a prosthetic group in many 
haemoproteins (e.g. haemoglobin, cytochromes and guanylate cyclase). Haem 
also has a role in the control of protein synthesis and cell differentiation. Due to 
its toxicity and insolubility, the intracellular level of uncommitted haem is 
maintained at a very low concentration (<10® M). Its levels are controlled tightly 
by balancing its synthesis via the enzyme 5-aminolevulinic acid (ALA) and
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catabolism by the haem oxygenase enzyme, respectively.
1.2.1 Haem synthesis
The synthesis of haem requires the presence of eight enzymes, four of 
which are found in the cytoplasm and four in the mitochondria (Figure 1-3). The 
first step takes place in the mitochondria where ALA synthase catalyzes the 
condensation of succinyl coenzyme A (CoA) and glycine to form 5- 
aminolevulinic acid. The next four steps in the haem biosynthetic pathway take 
place in the cytosol, where ALA dehydratase converts 2 molecules of ALA to a 
monopyrrole porphobilinogen (PBG). This is followed by two subsequent 
enzymatic steps which convert 4 molecules of PBG into the cyclic tetrapyrrole 
uroporphyrinogen III, which is then decarboxylated to form coproporphyrinogen 
III. The final three steps require a return to the mitochondria (Ponka, 1999). In 
the final step of haem synthesis, ferrochelatase catalyzes the insertion of iron 
into the protoporphyrin IX ring to form protohaem. Intracellular iron regulates the 
expression of ferrochelatase. Iron has to be in the ferrous form to act as a 
substrate of the ferrochelatase reaction in biological systems; therefore, 
reduction of ferric iron to ferrous is necessary to produce haem. Hence, the 
return of the haem biosynthetic pathway to mitochondria from cytoplasm is 
supposedly due to the requirement of a considerable amount of ferrous iron for 
the final step in haem synthesis (Ponka, 1999).
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Figure 1-3. Haem synthesis
ALA-synthase catalyses the condensation of succinyl coenzyme A (CoA) and 
glycine to 5-aminolevulinic acid in the mitochondrion. Subsequent steps in the 
haem synthetic pathway are carried out in the cytosol until the production of 
coprophrinogen III, which returns to the mitochondrion for the final steps of 
haem synthesis including insertion of iron (Fe^*).
ALA synthase has an important role in the regulation of haem synthesis. The 
enzyme is present in a variety of cells, with high levels found in bone marrow 
cells and the liver, where it is inducible by chemical treatments or physiological 
stimuli. ALA synthase is the rate-limiting enzyme of haem biosynthesis in liver 
and is negatively regulated by haem (Sassa, 1988). There are two isoforms of 
the enzyme, one of which is ubiquitously expressed (ALA synthase 1 ) and the 
other specific to erythroid cells (ALA synthase 2). The mechanism by which its 
expression in the liver and other non-erythroid tissue is controlled differs from 
that occurring in haemoglobin synthesizing cells. ALA synthasel is regulated by 
haem, in that haem can suppress its transcription by decreasing the half-life of 
its mRNA or by blocking translocation of ALA synthase 1 precursor protein into
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the mitochondria. Importantly, the haem mediated repression of ALA synthase 1 
results in this enzyme being the rate limiting step in non-erythroid haem 
biosynthetic pathways. In contrast, the availability of iron, but not haem affects 
ALA synthase 2 (erythroid) mRNA translation (i.e. iron acquisition), rather than 
ALA production, is the rate limiting step in haem synthesis and subsequent 
haemoglobin synthesis in erythroid cells. Here haem does not inhibit the 
synthesis of ALAS2, but blocks the uptake of iron from transferrin, an iron- 
binding plasma protein (Taketani, 2005).
1.2.2 Haem-binding proteins
As well as the breakdown of haem by HO-1, the intra- and extracellular 
transport of haem also helps to prevent its cytotoxicity. Extracellular haem 
present in plasma can be taken up by many different cells including 
hepatocytes; however, mechanisms of haem uptake by these cells are poorly 
understood. Due to its low solubility in aqueous solutions, haem requires 
specific extracellular and intracellular proteins as transient carriers. The haem 
binding proteins in blood and culture medium are serum proteins such as 
albumin and haemopexin (Taketani, 2005). Haem is toxic in free form but it 
becomes less toxic or non-toxic in a bound state (with protein). Haemopexin 
(Hx) is a haem-binding protein and reduces the toxic effect of free haem by 
forming a complex. It is a serum glycoprotein (GOkDa) which binds to haem with 
high affinity (Delanghe and Langlois, 2001), and plays the role of transporting 
haem in the circulation. During haemolysis, free vascular haemoglobin can be 
rapidly converted into methaemoglobin, which liberates the incorporated haem 
group easily. Hx binds free vascular haem and transports it to the liver for 
degradation in the reticuloendothelial system (Muller-Eberhard and Fraig,
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1993). Two processes of Hx-mediated haem uptake are detected in isolated 
hepatic parenchymal cells. The first one, defined as the specific transport 
system, is saturable, has a high haem affinity and exhibits the characteristics of 
the receptor mediated system in vivo. The second uptake system of 
hepatocytes, normally termed selective, also requires metabolic energy but has 
a lower affinity for haem and is not readily saturable. This selective haem 
uptake requires the presence of Hx. The haem-Hx complex binds to its receptor 
on the liver parenchymal cell plasma membrane and haem is translocated 
inside the cell, while the apo-haemopexin is released back into the circulation. 
The toxic effects of haemin are found to be inhibited by Hx (Smith and Morgan, 
1981).
Albumin complexes with haem can also prevent the toxic effects of 
extracellular haem in blood plasma. The haem-albumin complex 
(methaemalbumin) can transport haem to the parenchyma cells of the liver; 
however a large proportion of the bound albumin-bound haem is transferred to 
haemopexin due to its higher affinity for the molecule (Morgan et al., 1976; 
Smith and Morgan, 1981). Therefore, in normal human subjects, only when Hx 
is depleted by repeated haem injection does haem bind solely to albumin to 
produce high methaemalbumin levels (Sears, 1970). Methaemalbumin is an 
abnormal component of blood plasma in certain diseases and is associated with 
excessive haemolysis. Under normal conditions, human serum albumin inhibits 
the toxic effects of haemin by 50-60%. For example, albumin can extract 
haemin trapped in red blood cell membranes thereby protecting them against 
the harmful effects of haemin. However, under pathological conditions such as 
haemolysis, greater accumulation of haemin in red blood cells reduces the
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lifespan of the red blood cell (Shaklai et al., 1985).
Recent findings have shown that lipocalin alpha-1 microglobulin (alpha-1 m) 
binds haem, and after cleavage of a C-terminal tetrapeptide, initiates haem 
degradation (Larsson et al., 2004). This suggests the protein functions as a 
haem scavenger. Alpha-1 m, either in plasma or in purified form displays 
concentration-dependent binding to haem. An interesting role for glutathione 
(GSH) in counteracting haem-mediated toxicity is described below. Reduced 
GSH protects cells or tissues from oxidative stress due to its anti-oxidant 
nature. GSH maintains the redox state of protein-thiol moieties and reduces the 
noxious hydrogen and lipid peroxides. In addition, GSH offers protection against 
haem-induced oxidative stress by degrading haem directly and scavenging 
reactive oxygen species generated by haem. Studies with intact erythrocytes 
indicate that haem interacts with the membrane of erythrocytes and GSH 
probably protects erythrocytes from haem-induced oxidative stress by 
degrading the membrane associated haem (Atamna and Ginsburg, 1995).
In biological systems there are also proteins that can bind selectively free 
haem. They are known as haem binding proteins (HBP) and reduce the toxic 
effects of haem by complexing with it. A specific haem binding protein (HBP23) 
has been purified from rat liver cytosol using haem-affinity chromatography. It is 
present in the cytosol of liver, kidney, spleen, small intestine and heart with the 
liver showing the highest content (Iwahara et al., 1995). HBP23 has been 
proposed to be an intracellular haem transporter i.e. a vehicle from cell 
membrane to cell (Immenschuh et al., 1995).
1.2.3 Free haem detoxification systems
Haem detoxification is a protective mechanism for the survival of cells
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against the pro-oxidant environment created by haem. There are several 
detoxification-defence mechanisms existing in humans that can be divided into 
haem oxygenase systems (HO-1, HO-2 and HO-3) and haem oxygenase- 
independent systems (haemopexin, albumin). As described earlier, haem 
oxygenase is a haem-degrading enzyme and plays a significant role in 
protecting cells from haem-induced oxidative stress. The haem oxygenase- 
independent systems detoxify free haem by forming non-toxic haem-complexes 
(e.g., haemopexin, albumin, haem-binding protein), by inducing its degradation 
(e.g., GSH, xanthine oxidase, NADPH-cytochrome P-450 reductase) or by 
scavenging free redox-active iron (ferritin) released after haem catabolism.
Ferritin is a ubiquitous and highly conserved iron-binding protein. Its 
importance in sequestering free iron is highlighted by the fact that the toxicity of 
haem is attributable to the iron released after its degradation. The liberated iron 
can participate in the generation of reactive oxygen species, which can directly 
damage DNA, lipids and proteins leading to profound cellular toxicity (Balia et 
al., 1991). Therefore, ferritin offers a counterbalance to haem oxygenase- 
dependent haem iron release by binding and storing iron in a form less likely to 
result in oxidative injury. Indeed, studies have demonstrated endothelial cells 
exposed to haem up-regulate the synthesis of haem oxygenase and ferritin, and 
ferritin offers cytoprotection against iron-driven oxidant damage (Balia et al., 
1992a).
Haptoglobin (Hp) a serum glycoprotein is a potent haemoglobin 
scavenger and offers protection against haem toxicity associated with free 
haemoglobin. For instance, liberated haemoglobin can promote the 
accumulation of hydroxyl radicals and harmful reactive oxygen species.
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Therefore, plasma Hp can be regarded as a major anti-oxidant, protecting cells 
from damage such as haemoglobin-driven lipid peroxidation. Haemoglobin 
released from erythrocytes into the circulation by intravascular haemolysis binds 
immediately to Hp and forms stable Hp-haemoglobin complexes which are 
transported to the reticuloendothelial system (Wagener et al., 2003), where as 
the haemoglobin-scavenger receptor CD 163 mediates the endocytosis of Hp- 
haemoglobin complexes and thereby counters the oxidative tissue damage after 
haemolysis (Philippidis et al., 2004). GDI63 is expressed in the monocyte- 
macrophage system and mediates the endocytosis of Hp-haemoglobin 
complexes formed on red blood cell haemolysis, and thereby leads to lysosomal 
degradation of the ligand protein and metabolism of haem by cytosolic haem 
oxygenase (Moestrup and Moller, 2004).
Although the haem oxygenase system is the principal pathway used to 
eliminate free haem, other minor haem degradation pathways are also present. 
Haem can be degraded by haem oxygenase-independent pathways such as 
NADPH-cytochrome p450 reductase, which can catalyze oxidative degradation 
of haem molecules. Unlike the haem oxygenase pathway, the major products 
do not include BV and only a small amount of CO is produced (Docherty et al., 
1984). In the cytosol, xanthine oxidase can also catalyse the degradation of 
haem to non-BV type compounds (Cantoni et al., 1981).
1.2.4 Haem receptors
Haemopexin-haem activates HO-1 after being taken up by cells in a 
receptor mediated manner (Alam and Smith, 1992). Haemopexin receptors 
have been found in various tissues such as rat liver and human placenta, but 
the properties of these receptors are still unknown (Ren and Smith, 1995;
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Taketani et al., 1987). Along with haemopexin receptors, haem receptors have 
been reported on the surface of MEL cells, Caco cells and hepatocytes 
(Galbraith et al., 1985; Galbraith, 1990; Uc et al., 2004). It has been suggested 
by some groups that haem enters these cells via an internalization process 
mediated by a haem-receptor (Galbraith et al., 1985; Galbraith, 1990; Uc et al., 
2004). However, due to the lipophylic nature of haem, it could be proposed that 
haem may readily incorporate into endothelial cell membranes. A new clue on 
the mechanism of haem transport was provided recently by Shayeghi and co­
workers (Shayeghi et al., 2005) who described the presence of a haem 
transporter that is expressed in the apical region of epithelial cells in the mouse 
duodenum. The transporter was identified as the membrane protein named 
HCP1 (haem carrier protein 1) which mediated haem uptake by cells and was 
regulated by iron. Thus, it was suggested that the transport of haem into cells 
requires specific membrane bound transporters rather than passive diffusion 
and incorporation into cell membranes (Shayeghi et al., 2005).
1.2.5 Haem in the circulation: effects on the vascular endothelium
Red blood cells which contain haem concentrations of 20 mmol/1 can 
undergo unexpected lysis and release free haemoglobin into the circulation. 
Haemoglobin in its reduced form (ferro or oxyhaemoglobin) is relatively 
harmless to cells; conversely, oxidized haemoglobin (ferri or methaemoglobin) 
greatly amplifies oxidant-mediated endothelial cell injury. This is due to 
methaemoglobin's ability to readily release its haem moieties, which can then 
be readily incorporated into cell membranes and serve as a source of highly 
toxic iron (Balia et al., 2005). However, oxyhaemoglobin can be readily oxidized 
to methaemoglobin in the presence of oxidants derived from inflammatory cells;
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for example, activated polymorphonuclear cells (PMNs) can rapidly cause 
oxidisation of oxyhaemoglobin to methaemoglobin (Balia et al., 1993), whilst NO 
is another candidate for the production of methaemoglobin. In addition, the 
reaction between oxyhaemoglobin and NO not only produces methaemoglobin 
but also results in the reduction of NO bioavailability, thus producing deleterious 
effects such as pulmonary hypertension and end-organ injury (Gladwin et al.,
2004). Nevertheless, the initial release of haem from methaemoglobin can be 
inhibited by the formation of a complex with the haemoglobin-binding protein 
haptoglobin and any released haem can bind to haemopexin, thereby limiting 
the deleterious effects of methaemoglobin on the endothelium (Bunn and Jandl, 
1968).
However, severe haemolysis that occurs in pathological states such as 
SCO, ischemia reperfusion and malaria results in high levels (up to 20 pM) of 
free circulating haem (Arruda et al., 2004). Under these conditions, the 
physiological mechanisms of removing free haem from the circulation are 
severely impaired. Because of its lypophilic nature, haem will cross cell 
membranes leading to non-specific haem uptake and haem-catalyzed oxidation 
reactions, thereby enhancing cellular oxidant damage (Reiter et al., 2002). In 
other words, when large amounts of free haem accumulate, the haem 
detoxification systems are overwhelmed and haem can exert its damaging 
effects.
The vasculature, and in particular the endothelium, may be at the 
greatest risk from exposure to toxic free haem. Vascular endothelial cells have 
adapted to oxidative stress due to their constant exposure to haem via the anti­
oxidant and cytoprotective actions of haem oxygenase and ferritin. Haem and
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various other stimuli have been shown to cause the induction of HO-1 and 
ferritin in endothelial cells and other cell types (Balia et al., 2005). HO-1 could 
serve as a provider of intracellular iron from haem; the Iron in turn may drive the 
production of ferritin synthesis. Another proposed mechanism is that haem itself 
may induce ferritin production directly by increasing RNA translation (Lin et al., 
1990). Haemoglobin has also been shown to enhance HO-1 and ferritin gene 
induction in vascular endothelial cells, though conversion of oxyhaemoglobin to 
methaemoglobin is required for this process, as methaemoglobin can easily 
release its haem (Balia et al., 1992b; Balia et al., 1993). Brief exposure to haem 
or haemoglobin can result in increased oxidant-mediated endothelial 
cytotoxicity, but longer duration of exposure induces an adaptation and 
protection in cells from further oxidant challenge. This protection is paralleled by 
the synthesis and accumulation of large amounts of HO-1 and ferritin. The 
protection provided by ferritin in endothelial cells is attributed to iron storage or 
ferroxidase activity of ferritin (Balia et al., 1993). Under aerobic conditions 
ferroxidase activity catalyses the oxidation of ferrous iron to ferric iron, which 
allows intracellular storage of iron in biological systems. The protective function 
of ferritin may also be linked to its high affinity for ferrous (Fe^"") iron formed by 
superoxide (O2 ) or endogenous reductants and, although, it's ferroxidase 
activity stores and inactivates iron in the ferric form, it is the reduced form of iron 
that can fuel production of the hydroxyl radical. Therefore, increased cellular 
ferritin may compete for ferrous iron, thereby reducing the pool of catalytically 
active iron species. Catabolism of haem by haem oxygenase may help to 
eliminate the membrane permeable form of iron from cells, since the resultant 
non-haem iron would be potentially hazardous unless sequestered by ferritin
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(Balia et al., 1992a). The cytoprotective nature of haem oxygenase and ferritin 
have been confirmed in various animal models (Balia et al., 2003).
1.2.6 Haem and oxidative stress
The presence of free haem causes toxic effects to tissues and organs 
through oxidative stress and by generating reactive oxygen species, the redox- 
active iron contained in haem playing a central role in haem-mediated toxicity. 
Haem-induced cytotoxicity has been shown to impair the function of kidney 
(Nath et al., 2001b), neurons (Goldstein et al., 2003), cardiac cells (Bhoite- 
Solomon et al., 1993), hepatocytes (Kim et al., 2004) and peripheral leukocytes 
(Tsuji et al., 1993). In addition, iron-derived reactive oxygen species are 
implicated in the pathogenesis of many vascular disorders including 
atherosclerosis, vasculitis and reperfusion injury (Balia et al., 2005). Intracellular 
haem proteins are an abundant source of redox-active iron and free haem 
damages lipids, proteins and DNA (Kumar and Bandyopadhyay, 2005). For 
instance, haemin in the aqueous phase will form aggregates in cell membranes 
and promote oxidation, which leads to enhancement of permeability and 
membrane dysfunction. In addition, oxidation of membrane components may 
promote cell lysis and death (Schmitt et al., 1993). Exposure of endothelial cells 
to haem also greatly potentiates cell killing mediated by PMNs (Balia et al., 
2003). These cells usually marginate along endothelial cells in the presence of 
inflammation. Haem has been shown to induce PMN activation (Graca-Souza et 
al., 2002) as well as enhance endothelial cell adhesion molecule expression 
(Wagener et al., 1997), thus promoting PMN adhesion and stimulating 
inflammation. In addition, haemin (the Fe^* oxidation product of haem) has been 
shown to catalyse the degradation of proteins to small peptide fragments, e.g.,
32
the serum protein HBP93 (Aft and Mueller, 1984). Haemin can also oxidise low 
and high density lipoproteins and form conjugated dienes, thiobarbituric acid 
reacting substances (TBARS) and F2-isoprostanes (Camejo et al., 1998) (see 
section 1.2.7). Interestingly, haemin also causes covalent cross-linking of 
apoliprotein B with the formation of bityrosines and simultaneous formation of 
protein aggregates. This is pathophysiologically important, as low density 
lipoprotein aggregation relates to conversion of macrophages into foam cells, 
and therefore, haemin could be considered as an endogenous trigger of 
atherosclerosis (Miller and Shaklai, 1994)
1.2.7 Haem and LDL oxidation
Haem can also cause indirect vascular endothelial damage through its 
ability to mediate oxidative modification of low-density lipoprotein (LDL). Haem- 
mediated LDL oxidation involves coupled oxidative interactions between LDL, 
haem, oxidants and anti-oxidants. The first step of this process entails the 
spontaneous insertion of haem into LDL particles, thus promoting extensive 
oxidative modification of LDL. These modifications can be amplified by small 
amounts of hydrogen peroxide, PMN derived oxidants or preformed lipid 
hydroperoxides within the LDL. Depletion of a-tocopherol (an anti-oxidant) in 
LDL results in the formation of conjugated dienes, lipid hydroperoxides and 
TBARS. Haem can oxidatively modify both the lipid moiety of LDL as well as its 
apoprotein. The reactions between haem, LDL and peroxides result in the 
degradation of the haem ring and concomitant release of free iron, which 
exacerbates LDL oxidation. The release of free iron stimulates further oxidation 
of haem, fatty acids, cholesterol and apolipoprotein B100 in LDL particles. 
Accordingly, the iron chelator, desferrioxamine has been shown to attenuate
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both oxidative modification of LDL and degradation of haem. Haemopexin also 
inhibits oxidative modification of LDL. In vivo studies have shown that activated 
PMNs potentiate oxidation of LDL catalysed by haem iron, and LDL oxidized by 
haem is extremely cytotoxic to endothelial cells. It is also hypothesized that free 
haemoglobin could damage vascular endothelial cells through haem-mediated 
oxidative modification of LDL. Specifically oxyhaemoglobin may be converted to 
methaemoglobin via inflammatory cell derived oxidants; as a consequence 
release of haem from methaemoglobin may be important in the oxidative 
modification of LDL (Balia et al., 2005).
1.2.8 Haem and inflammation
Inflammation is a defence mechanism utilised by organisms to protect 
them from pathogenic invaders, remove the damaged cells after injury and 
prevent further damage. The inflammatory response involves several stages; 
(a) the dilation of capillaries to increase blood flow; (b) microvascular structural 
changes and escape of plasma proteins from the bloodstream; (c) leukocyte 
adhesion; (d) elimination of pathogens; and (e) resolution of inflammation. 
Haem-mediated oxidation insults and inflammation are likely important in a wide 
variety of pathophysiological processes (Balia et al., 2000), such as renal 
failure, arteriosclerosis and heart transplant failure. Exposure of endothelial 
cells to haem in vitro has been shown to stimulate the expression of intracellular 
adhesion molecules (ICAM), vascular cell adhesion moleculel (VCAM1) and 
endothelial leukocyte adhesion molecules (E-selectin), most probably through 
haem-mediated generation of intracellular reactive oxygen species and 
subsequent activation of transcription factors NF-KB, AP-1 and SP-1 signalling 
pathways (Lavrovsky et al., 1994; Shono et al., 1996). These activated
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endothelial adhesion molecules will subsequently recruit leukocytes, resulting in 
one of the main characteristics of inflammation. Vascular haem can also cause 
endothelial cell injury, leading to inflammatory lesions and the formation of 
vascular inflammatory disorders (Wagener et al., 2001). Therefore, free haem 
can be termed a pro-inflammatory molecule that activates neutrophil responses. 
However, haem also up-regulates HO-1 which provides anti-inflammatory 
actions. Specifically, a small concentration of haem can have anti-inflammatory 
and cytoprotective properties through up-regulation of HO-1 and by stimulating 
the formation of the HO-1 products CO and BV (Hayashi et al., 1999). In 
contrast, a large amount of haem has deleterious effects on tissue via its pro- 
oxidative and pro-inflammatory function (Nath et al., 2001b), which cannot be 
sufficiently counter-balanced by the anti-oxidative and anti-inflammatory 
properties of HO-1. Increased levels of HO-1 expression have been clinically 
demonstrated in a wide variety of inflammatory conditions, such as 
ischaemia/reperfusion injury, atherosclerosis, asthma, Alzheimers disease and 
acute renal failure (Wagener et al., 2003). The production of HO-1 is greatly 
elevated in inflammatory cells during the resolution phase of inflammation 
(Willis et al., 1996), when the cytoprotective effect of HO-1 is mediated by 
down-modulation of adhesion molecules expression (Wagener et al., 2003).
1.3 Haemoglobins
1.3.1 Chemical structure and properties
Haemoglobin is a highly conserved molecule found in species ranging 
from single cell organisms to mammals; however, the role of haemoglobin 
varies in different organisms. For example, in bacteria haemoglobin can oxidise
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NO to nitrate (Goretski and Hollocher, 1988), while in nematodes haemoglobin 
functions to eliminate oxygen and is thus critical for anaerobe survival (Minning 
et al., 1999). In mammals, haemoglobin is found in red blood cells and has a 
primarily respiratory function by carrying oxygen in blood and transporting 
carbon dioxide and hydrogen ion (Wells, 1999). HbA is the principal 
haemoglobin in human adults, consisting of two alpha chains and two beta 
chains combined in a tetrameric molecule (Figure 1-4). Each chain is folded into 
characteristic seven or eight a-helices (labelled A-H) which are linked by non­
helical segments (e.g. EF, FG) and an N-termina! and C-terminal extension 
termed NA and HC respectively. The "haem pocket" is a crevice in each chain 
between the E and F helices, containing an oxygen binding haem group. Adults 
also have a minor haemoglobin (around 2% of total haemoglobin) called HbAa 
which has delta chains instead of beta chains found in HbA. Foetuses have 
their own distinct haemoglobin. Shortly after conception foetuses synthesize 
zeta chains (which are similar to alpha chains) and epsilon chains (similar to 
beta chains). During foetal life, the zeta chain is replaced by the alpha chain, 
and the epsilon chain is replaced by the gamma chain, which gives rise to HbF 
(0 2 / 2) the major haemoglobin in the latter two-thirds of foetal life. After birth, 
the gamma chain is substituted with the beta chain to produce HbA. 
Haemoglobin synthesis requires coordinated production of haem and globin, in 
which haem is the prosthetic group that mediates reversible binding of oxygen 
by haemoglobin whilst globin is the protein that surrounds and protects the 
haem molecule. The complex biophysical characteristics of the complete 
haemoglobin tetramer allows fine control of oxygen uptake in the lungs and 
release in the tissues that is necessary to sustain life (Weber and Fago, 2004).
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Figure 1-4. Structure of adult mammalian haemoglobin
1.3.2 Physiological role of haemoglobins
The physiological role of haemoglobins are a result of their intrinsic 
oxygen-binding properties and the effects of local environmental factors (e.g. 
pH, temperature and cofactor concentrations) that modulate oxygen binding. 
The functional adaptations are dependent on homotropic interactions i.e. 
cooperativity between oxygen binding to haem groups, and the generally 
inhibitory heterotropic ones between effector binding sites and the haems (e.g. 
decreased oxygen affinity at low pH, the Bohr effect). The homotropic and 
heterotropic allosteric interactions increase the oxygen capacitance (turnover) 
for oxygen tension differences between sites of oxygen loading (lungs) and 
unloading (tissues). Oxygen binding is associated with small changes in the 
tertiary structure of the segments near the haem moieties and a large shift in
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the quaternary structure from the T (tense) to the R (relaxed) state, as one 
dimer rotates relative to the other Many ligands such as protons, carbon 
dioxide and organic phosphates bind preferentially to deoxyhaemoglobin, 
forming salt bridges within and between the chains that stabilize the T-structure, 
lowering its oxygen affinity and resulting in cooperative oxygen binding. 
Importantly, organic phosphates such as 2, 3-diphosphoglycerate (DPG) bind to 
the central cavity of the haemoglobin molecule and reduce oxygen affinity 
(Wells, 1999). The interaction of haemoglobin and NO has also drawn 
increasing interest due to the discovery that NO is a critical regulator of 
vasodilation and vascular homeostasis (Singel and Stamler, 2005) (see section 
1.6.5).
I.3.3 Haemoglobin gene regulation
The genes that encode the alpha globin chains are on chromosome 16 
and those that encode the non-alpha globin chains are found on chromosome
I I .  There are multiple individual genes expressed at each site. Pseudogenes 
are also present at each location. The alpha complex is called the "alpha globin 
locus", while the non-alpha complex is called the "(i globin locus". The 
expression of the alpha and non- alpha genes is closely tuned as balanced 
gene expression is required for normal red cell function. Regulation of 
haemoglobin synthesis involves control of both porphyrin and polypeptide 
synthesis. The regulating factor is an accumulation of haem which, in the free 
form, is spontaneously oxidized to haemin. An accumulation of haemin 
diminishes the activity of ALA synthase, probably by repressing synthesis of the 
new enzyme, as well as directly inhibiting the existing enzyme, thereby reducing 
porphyrin synthesis. Haemin has this effect both in the primitive red blood cell
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synthesizing haemoglobin and in other cells in which the cytochromes and other 
haem proteins are made. Haemin activates the synthesis of globin peptide by 
combining with an inhibitory protein. This mechanism keeps the synthesis of 
haem and globin in balance (Bunn, 1987).
1.3.4 Haemoglobinopathies
From time to time, mutations may occur in human HbA globin chains. If 
any change occurs close to the haem-oxygen binding site, near the central 
cavity or at some other site which destabilizes the structure of the molecule, it 
has the potential to interfere with the normal function of haemoglobin in oxygen 
transport. Nearly 1000 haemoglobinopathies have been described and they 
refer to a diverse group of inherited disorders characterized by reduced 
synthesis of one or more of the globin chains (thalassaemias) or the synthesis 
of structurally abnormal haemoglobin such as sickle cell disease (SCO). 
Furthermore, some structural haemoglobin variants are also inefficiently 
synthesized or the globin chain variants are so unstable that they are unable to 
form tetramers, resulting in a functional deficiency in the globin chain and a 
thalassaemic phenotype. Another group of haemoglobinopathies is referred to 
as hereditary persistence of foetal haemoglobin (HPFH), which is characterized 
by variable increases of HbF in otherwise normal adults (Clark and Thein, 
2004).
As a group, the haemoglobinopathies are the commonest single gene 
disorder in the world and are found at high frequencies in tropical and 
subtropical regions where malaria is found to be endemic (Flint et al., 1998). 
There are four main categories of haemoglobin disorders that are associated 
with severe disease states and clinical significance (Clark and Thein, 2004):
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• Sickle cell disease (major genotypes HbSS, HbSC, HbSp^Thal or 
HbSp°Thal, and less common genotypes Hb SD Hb 80^''®^ and 
Hb S Lepore)
• fi-thalassaemia syndrome; including ôli-thalassaemias and Hb E/fi- 
thalassaemias
• a-thalassaemia syndrome
• Haemoglobin variants resulting in haemolytic anaemias, 
polycythaemias and more rarely cyanosis.
Sickle cell disease is of major interest in the context of this thesis and will be 
described in detail in the following section.
1.4 Sickle cell disease (SCO)
SCO arises from a single point mutation in the beta-globln gene (glutamic 
acid is replaced by valine), which subsequently results in the production of the 
mutant haemoglobin HbS There are a number of genotypes found in SCO, with 
the most prevalent being homozygous HbSS which accounts for two-thirds of all 
SCD cases. A smaller population of sickle patients carry the heterozygous 
genotypes, the most common being HbSC, HbSp^'Thal and HbSp°Thal, in order 
of frequency. The most severe disease is seen with the HbSS and HbSp^'Thal 
traits, followed by the milder HbSC genotype which in turn is more severe than 
HbSp'^Thal. Significantly, there can be overlap of severity within these 
genotypes, so a patient with any one of these sickle traits can present with any 
clinical complications of SCD (see section 1.4.1) (Redding-Lallinger and Knoll, 
2006).
The trigger for the diverse complications observed in SCD occurs at the 
molecular level. Specifically, the substitution of valine for glutamic acid in the
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mutant HbS molecule triggers hydrophobic interactions with other haemoglobin 
molecules resulting in the formation of polymers. Deoxygenation causes HbS to 
polymerise (Figure 1-5), which then leads to erythrocyte rigidity, membrane 
damage, haemolysis and causes damage to tissues and organs (Bunn, 1997).
Deoxygenation
Normal red 
blood cell
Sickle red 
blood cell
Figure 1-5. Deoxygenation triggers sickling of red blood cells
A fall in the partial pressure of oxygen triggers polymerisation of HbS molecules 
within the red blood cells which results in distortion of the red blood cell into the 
characteristic “sickle” shape.
Polymerisation of HbS is dependent on the cellular concentration of HbS. A 
classical feature of SCD is the presence of dense dehydrated erythrocytes, 
where the increased cellular haemoglobin concentration and an enhanced 
tendency to form polymers trigger the cell to assume the characteristic “sickle” 
shape. Cellular damage results in adhesive interaction between sickle cells, 
endothelial cells and leukocytes. The adherent cells may initiate vessel 
obstruction (vaso-occlusive crises), while the dense cells may become 
sequestered or destroyed in the microvasculature (Steinberg and Brugnara,
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2003). The development of vaso-occlusive crises is seen as a hallmark of SCD. 
Irreversibly sickled cells lead to obstruction of blood vessel, resulting in tissue 
hypoxia and infarctions (Lawrenz, 1999).
The most clinically studied approach against “sickling” is increasing HbF 
(foetal haemoglobin) concentration in SCD patients. Hydroxyurea is the most 
widely used therapy for SCD, and it acts by increasing HbF levels in red blood 
cells and reducing HbS polymerisation and cell sickling (Charache et al., 1992). 
The treatment of SCD will be discussed further in 1.4.2.
1.4.1 Pathophysiology of sickle cell disease
The clinical manifestations in SCD are brought about by the interaction of 
sickle vaso-occlusion and haemolytic anaemia. Characteristics of the sickle red 
blood cell such as levels of polymerised HbS and degree of membrane damage 
interact with environmental factors such as endothelial injury to trigger 
haemolysis and vaso-occlusion. Many factors can provoke endothelial 
activation and damage such as inflammation and circulatory shear stresses. 
Damage to the endothelial cell facilitates adhesive interactions between sickle 
red blood cell, endothelial cells and leukocytes which are mediated by several 
adhesion molecules and their ligands. These adhesive interactions between 
cells can result in delay of red blood cell passage through the vasculature, 
which could enable HbS polymerisation, cell deformity and vaso-occlusion to 
occur (Steinberg and Brugnara, 2003). Furthermore, reticulocytes have 
adhesive ligands expressed that facilitate endothelial interactions. Another 
common finding in SCD is an abundance of activated neutrophils which are also 
more adherent to endothelial cells (Jison et al., 2004).
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Elevated levels of plasma haemoglobin found in SCD are due to 
premature destruction of red blood cells. The release of haemoglobin can lead 
to further haemolysis in SCD by interaction of haem with red cell membranes 
and subsequent oxidative damage (Kumar and Bandyopadhyay, 2005). Indeed, 
the amount of incorporated haem is found to be higher in pathological cells of 
SCD than normal circulating cells, and may contribute to the removal of aged 
red blood cells from the circulation through haemolysis.
Another consequence of elevated free haemoglobin levels in sickle blood 
is the interaction with NO. Plasma haemoglobin converts NO to biologically inert 
nitrate, and lysed sickle red blood cells liberate arginase which destroys L- 
arginine, the substrate for the production of NO (Reiter et al., 2002). Therefore, 
an overall reduced concentration of NO in sickle blood and a decreased 
endothelial bioavailability of NO impairs its homeostatic vascular functions (e.g., 
inhibition of platelet activation, repression of cell-adhesion molecules), 
consequently promoting vasoconstriction which increases the possibility of 
vaso-occlusion (Steinberg and Brugnara, 2003).
The reduction in NO bioavailability has a key role in the development of 
stroke, pulmonary hypertension, leg ulcers and priapism in SCD. In addition, an 
increase in the blood viscosity of sickle patients increasing the incidence of 
vaso-occlusion and gives rise to clinical phenotypes such as osteonecrosis, 
acute chest syndrome and painful episodes (Steinberg, 2006). In fact, the most 
prevalent consequence of red cell sickling at the microscopic level is the 
development of sickle crisis, the characteristic symptom associated with the 
disease. These can be divided into vaso-occlusive (painful) crises, aplastic or 
megaloblastic crisis, sequestration crisis and haemolytic crisis. Within the sickle
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population, the severity and frequency of crisis varies due to inherited or 
acquired factors, such as sickle genotype and concomitant infection (Beutler, 
2001 ; Di Nuzzo and Fonseca, 2004).
Vaso-occlusive crises, a consequence of sickle cell-mediated vessel 
obstruction resulting in tissue hypoxia and infarction, are seen as the hallmark 
of the disease and are associated with fever and pain at the site of tissue 
infarction (Steinberg and Brugnara, 2003). SCD patients present most 
commonly with pain in their bones, chest or abdomen (due to splenic crisis), 
and the average crisis rate is less than 1 (0.8) a year (Marchant and Walker,
2003). In sickle patients with higher rates of crisis, there is an associated 
increase in morbidity and mortality. The most serious complication of SCD is 
infarction of the cerebral vessels resulting in stroke and is most commonly 
associated with childhood (Lawrenz, 1999).
1.4.2 Treatment of sickle cell disease
An acute presentation of sickle crisis is managed palliatively, with 
appropriate pain relief and blood transfusion if necessary; however, the strategy 
for long-term SCD management aims to prevent sickling of red blood cells and 
thereby reduce the consequent cellular and tissue damage. Polymerization of 
HbS is the most important factor in sickling and a rise in HbF decreases 
intracellular polymerization of HbS. Therefore, the search for an anti-sickling 
agent has focused on compounds which stimulate HbF synthesis. The drug 
hydroxyurea, which is the standard treatment in SCD, is a ribonucleotide 
reductase inhibitor that after absorption is reported to liberate NO (King, 2004). 
Hydroxyurea elicits clinical benefit by decreasing the terminal differentiation of 
erythroid stem cells, which leads to myelosuppresive-induced HbF synthesis
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(Charache et al., 1992). SCD patients on hydroxyurea therapy have shown 
significant decrease in the frequency of crisis, acute chest syndrome, 
transfusion requirements and hospitalisations (Charache et al., 1995). 
Furthermore, combination therapy with hydroxyurea and erythropoietin has 
been shown to further increase HbF production in sickle patients (Little et al., 
2006). Erythropoietin treatment has also been used on its own in SCD to 
improve the severe anaemia prevalent in this disease (Steinberg, 1991).
Transfusion therapy is also widely used in the management of SCD, 
usually administered as packed red blood cells. The key goals of red blood cell 
transfusion in SCD include: increasing total haemoglobin levels to improve the 
oxygen transport capacity of blood; reducing blood viscosity and increasing 
oxygen saturation through dilution of the HbS-containing red blood cell 
population; and suppressing endogenous production of sickle red blood cells by 
increasing tissue oxygenation. The benefits of transfusion therapy in sickle 
patients include improvement in anaemia, prevention and resolution of vaso- 
occlusive crisis that result in acute chest syndrome, stroke and other ischaemic 
organ damage in SCD (Josephson et al., 2007).
Recently, NO therapy has also been suggested as a treatment for 
complications of SCD. Inhaled NO therapy has had beneficial effects in patients 
presenting with acute chest syndrome (Vichinsky et al., 1997) and has reduced 
pain scores and opioid use in children with acute crisis (Weiner et al., 2003). 
Increasing endogenous NO production with administration of the NO substrate 
arginine has also shown promising effects in pulmonary complications (Morris et 
al., 2003). However, further clinical trials are required to elucidate the benefit of 
NO administration in SCD.
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Bone marrow transplantation in SCD would eliminate the source of the 
defective red blood cells and is the only curative therapy available. This 
procedure, however, has not been widely utilized due to its high mortality rate. 
Fortunately, recent advances in immunosuppressive therapy and supportive 
care has reignited interest in this therapeutic approach for SCD and 
encouraging results from clinical trials with children show a 90% long-term 
survival rate (Vermylen et al., 1993). However, drawbacks of this approach 
include the difficulty in finding matched donors and limitation of the procedure to 
childhood due to the increased mortality associated with transplant in adults.
1.4.3 Haem oxygenase and sickle cell disease
Chronic haemolysis in SCD results in up-regulation of haem catabolising 
enzyme systems to eliminate excess haemoglobin released. Indeed, HO-1 
induction has been demonstrated in various cell types in SCD, including 
leukocytes (Jison et al., 2004), kidney tissue and circulating endothelial cells 
(Nath et al., 2001a). In leukocytes from sickle patients an increase in HO-1 
protein and mRNA levels were observed concomitant with increase in plasma 
carboxyhaemoglobin and OR, suggestive of a concurrent increase in haem 
oxygenase activity (Jison et al., 2004). A widespread Induction of HO-1 has also 
been found in the kidney of sickle patients, where raised levels of the enzyme 
were detected in renal tubules, interstitial cells and smooth muscle cells of the 
renal vasculature (Nath et al., 2001a). Furthermore, these patients exhibited 
increased HO-1 expression in circulating endothelial cells separated from blood.
The raised levels of HO-1 in circulating leukocytes and endothelial cells 
could act as a dynamic compensatory response to the repetitive ischaemia- 
reperfusion injury that is characteristic of SCD, whereas induction of HO-1 in
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organs, such as the kidney, could also protect tissue against the deleterious 
effects of vascular injury. For instance, the induction of endothelial HO-1 has 
been well established as an adaptive mechanism to protect the endothelium 
against the damaging effects of the pro-oxidants haem and haemoglobin (Balia 
et al., 2003), and prevent endothelial cell activation and damage which are 
important contributors to SCD pathology. In addition, the vasodilatory properties 
of HO-1 generated CO could hinder the development of vaso-occlusive events, 
reducing the incidence of tissue infarction. Furthermore, the potent anti­
inflammatory properties of HO-1 may also contribute to protect against cellular 
and tissue damage in SCD. For example, increased HO-1 expression has been 
shown to be associated with inhibition of the expression of adhesion molecules 
associated with endothelial cell activation (Soares et al., 2004), which could 
reduce the incidence of red blood cell and endothelial cell interaction in SCD, 
thereby decreasing the frequency of vessel obstruction and resultant tissue 
damage.
Intriguingly, the biproducts of HO-1 induction have also been shown to 
have an action in SCD. A challenging therapeutic trial by Beutler, undertaken 
over 30 years ago, showed that CO gas administration could significantly 
prolong red cell survival in SCD (Beutler, 1975). In that study, sickle patients 
inhaled low levels of CO (1000-2000 ppm) intermittently (every 3-4 h) over 5 
day courses. Blood carboxyhaemoglobin levels reached levels up to 15% and 
no toxic effects were reported by the patients. Analysis of sickle blood after CO 
administration demonstrated a decreased rate of haemolysis and an increase in 
haemoglobin concentration, resulting in an overall increase in haematocrit. The 
increase in sickle red blood cell lifespan was attributed to the CO binding to the
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HbS molecule, which favoured the more stable oxyhaemoglobin conformation of 
the molecule and therefore reduced the likelihood of sickling and haemolysis. 
Furthermore, CO treatment also increased haemoglobin concentration by 
stimulating erythropoiesis. Therefore, CO treatment showed intriguing anti­
sickling properties as well increasing the oxygen-delivery capacity of sickle 
blood by increasing the red blood cell mass which could result in reduction of 
sickle crisis. These beneficial effects of CO were observed after continued 
administration of CO gas over a period of days. However, results from acute 
administration of CO for sickle pain relief were inconclusive, with only some 
patients reporting pain relief. The potential toxic effects of CO hindered 
continued investigation into the possible therapeutic effects of CO in SCD. 
However, mounting evidence pointing towards the potent protective properties 
of CO suggests that the therapeutic role of CO in SCD requires further 
exploration.
It has also been demonstrated that BR plays an important anti-oxidant 
role in SCD (Dailly et al., 1998). The anti-oxidant activity of BR was investigated 
in plasma from sickle patients and BR levels were shown to be the limiting 
factor in sickle plasma oxidant activity. The investigators propose that in SCD 
the increase in plasma BR levels caused by haemolysis and oxidative stress 
could confer protection on sickle erythrocyte membranes from peroxidation and 
thereby reduce the incidence of haemolysis. Intriguingly, high BR levels may 
also contribute to the surprising lack of atherosclerotic coronary heart disease in 
the sickle patient population (Barrett, Jr. et al., 1984). Therefore, the potent anti­
oxidant properties of HO-1 generated BR could counteract the pro-oxidant 
environment generated by haemolysis.
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The treatment of SCD with NO offers another potential link between HO- 
1 and SCD. It has been established that hydroxyurea exerts its effects via the 
release of NO (Gladwin et al., 2002) and inhaled NO therapy has itself shown 
beneficial effects in SCD (Reiter and Gladwin, 2003). As NO itself is a potent 
inducer of HO-1, it is possible that some of the beneficial effects of hydroxyurea 
in SCD may be mediated through the induction of HO-1. Indeed, increasing 
evidence suggests that the mechanism of clinical benefit of hydroxyurea may 
include HbF-independent components. For example, other possible 
mechanisms of action for hydroxyurea in SCD include effects on adhesion- 
molecule expression, vascular reactivity, red-cell deformability or erythropoietin 
production (Steinberg, 2006). It is possible that HO-1 induction directly or 
indirectly mediates some of these effects of hydroxyurea; for example, 
erythropoietin treatment has been demonstrated to raise HO-1 levels in patients 
with kidney dysfunction (Calo et al., 2003).
Collectively, these studies taken together suggest there may be a 
potential role for HO-1 in the treatment of SCD. The induction of HO-1 in SCD 
could be a physiological response to counterbalance the oxidative damage 
generated by haemolysis, and harnessing the protective properties of HO-1 by 
enhanced induction or administration of HO-1 biproducts CO and BR may 
present new therapeutic avenues for the treatment of SCD. Accordingly, 
Belcher and colleagues have recently shown that inducing HO-1 expression in 
transgenic sickle mice inhibited the hypoxia/reoxygenation induced stasis found 
in this model of SCD (Belcher et al., 2006). Furthermore, they reported reduced 
leukocyte-endothelium interactions as well as NF-kB, VCAM-1 and ICAM
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expression, suggesting that HO-1 plays a vital role in the inhibition of vaso- 
occlusive crises in transgenic sickle mice.
1.5 Hypoxia
Tissue hypoxia is a state of oxygen deficiency and may occur in 
biological systems as a consequence of reduction in partial pressure of oxygen, 
restricted intake and inadequate transport of oxygen or the inability of tissue to 
use oxygen. Hypoxia characterizes various physiological states such as 
arteriosclerosis, fibrosis and neoplasia. Mammalian organisms have evolved 
specific mechanisms to counteract the effect of reduced oxygen levels resulting 
in tissue adaptation to a low oxygen environment. A key physiological response 
to hypoxia is stimulation of the kidney to synthesise and secrete increased 
amounts of the hormone erythropoietin, which stimulates the production of red 
blood cells and therefore enhances the oxygen carrying capacity of the blood 
and improving oxygen delivery to hypoxic tissues. Other physiological 
responses to hypoxia include enhanced expression of promoters of 
angiogenesis and glycolytic enzymes for alternative ATP generation pathways 
(Bunn and Royton, 1996). Central to the expression of these hypoxic-sensitive 
genes is the redox modification and phosphorylation of specific transcription 
factors such as hypoxia-inducible factor-1 (HIF-1) (Bunn and Royton, 1996). A 
hypoxic environment also induces the expression of the physiologically 
important haem oxygenase and nitric oxide synthase enzymatic pathways 
which generate essential signalling molecules (Maines, 1997) and this subject 
will be explored further in section 1.5.3.
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1.5.1 Hypoxia inducible factoM
Hypoxia is able to regulate the expression of several target genes 
through the actions of the vital transcription factor HIF-1 which is expressed 
widely in mammalian cells, including endothelium and vascular smooth muscle 
(Schmedtje, Jr. et al., 1996). HIF-1 is a heterodimeric complex of basic-helix- 
loop-helix proteins comprising of two distinct subunits, HIF-1 a and HIF-1 (3. 
Regulation of the HIF-1 a subunit determines the biological activity of HIF-1 
which occurs at the protein level. Under normoxic conditions, an oxygen 
dependent HIF-specific prolyl hydroxylase enzyme targets the HIF-1 a subunit 
and hydroxylates two proline residues which allows binding of the Von Hippel- 
Lindau tumour suppression protein, priming the HIF-1 a subunit for proteosomal 
degradation. However, hypoxia diminishes the activity of the HIF hydroxylase 
which allows HIF-1 a to escape proteolysis and allows the HIF-1 complex to 
activate the transcription of hypoxia-inducible genes (Ratcliffe, 2006). The 
transcriptional targets for HIF-1 play central roles in enhanced angiogenesis 
and erythropoiesis as well as vasomotor regulation, matrix metabolism, cell 
proliferation, energy metabolism and many other cellular and systemic 
responses to hypoxia (Semenza, 2000).
1.5.2 Erythropoietin
In response to hypoxia the kidney increases erythropoietin production 
and stimulates erythropoiesis, increasing red cell production and hence the 
oxygen carrying capacity of the blood. Therapeutically recombinant human 
erythropoietin has been used to improve haematocrit and lower blood 
transfusion requirement. However, the action of erythropoietin is not restricted 
to the erythroid compartment and erythropoietin-receptors are present on
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several non-erythroid cell types and are involved in the induction of a range of 
cellular responses, including angiogenesis, chemotaxis and inhibition of 
apoptosis (Lappin et al., 2002).
Intriguingly, the anti-apoptotic action of erythropoietin has been 
postulated to act through HO-1 (Calo et al., 2006) via erythropoietin's 
stimulatory effect on protein kinase B activity; this enzyme in turn 
phosphorylates HO-1 resulting in an increase in the enzyme’s activity. 
Furthermore, increased expression of monocyte HO-1 has been observed in 
haemodialysis patients on erythropoietin treatment (Calo et al., 2003), 
suggesting a direct effect of erythropoietin on HO-1 levels. It is possible that 
induction of HO-1 by hypoxia-dependent erythropoietin could be an adaptive 
mechanism to counteract hypoxic tissue injury mediated through the potent 
protective effects of haem degradation products CO and BV. The hypoxic 
induction of HO-1 has in fact been demonstrated in various cell types and will 
be discussed further in the following section.
1.5.3 Hypoxia and haem oxygenase
The cytoprotective stress protein HO-1 is emerging as a major hypoxia- 
inducible protein in mammalian cells. Hypoxia-mediated HO-1 induction has 
been observed in both rat pulmonary endothelial and aortic smooth muscle cells 
(Lee et al., 1997), with HIF-1 determining the HO-1 response in smooth muscle 
cells and another transcription factor AP-1 responsible for endothelial induction 
(Hartsfield et al., 1999), suggesting that HIF-1 may not mediate hypoxic 
induction of HO-1 in all cell types. Indeed, bovine aortic endothelial cells 
exposed to hypoxia elicited both enhanced HO-1 and iNOS expression 
(Motterlini et al., 2000) suggesting an alternative hypoxic signal transduction
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mechanism for endothelial HO-1 induction; that is, hypoxia-mediated induction 
of iNOS can stimulate HO-1 protein production through the generation of NO. 
Furthermore, a decrease in the ratio of reduced glutathione/oxidised glutathione 
was observed in bovine aortic endothelial cells after induction of HO-1 by 
hypoxia which was postulated to be a consequence of an interaction between 
reduced glutathione and NO leading to the formation of S-nitrosothiols. These 
data, along with mounting evidence of hypoxia-mediated HO-1 induction in cells 
of vascular origin (Ryter and Choi, 2002), suggest that hypoxia-induced HO-1 
may represent an adaptive response to vascular oxidative injury. Hypoxic 
induction of both HO-1 and NOS systems would increase the availability of the 
second messenger molecules NO and CO, which are required to regulate 
vascular functions such as vasodilation, inhibition of platelet aggregation and 
expression of vasoconstrictors as well as smooth muscle proliferation.
1.5.4 Hypoxia and sickle cell disease
The role of hypoxia in SCO has many facets, ranging from the effects on 
the molecular configuration of HbS to the development of clinical phenotypes. A 
fall in the oxygen level is the trigger for the polymerisation of the mutant HbS 
molecule within the red blood cell (Bunn, 1997). Accumulation of polymers will 
eventually distort and “sickle" the red blood cell, which due to its lack of 
deformability can lodge in end-arterioles and capillaries resulting in vaso- 
occlusive crises and tissue infarction. Regional hypoxia caused by obstruction 
of vasculature by damaged red blood cells, will generate more sickled cells and 
increase the likelihood of haemolysis and subsequent free haemoglobin release 
will activate the endothelium to express adhesion molecules precipitating more 
vaso-occlusive events (Bunn, 1997). Therefore, tissue hypoxia is prevalent in
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SCO patients (Vichinsky et al., 1997) and occurs especially in venular beds 
where the sluggish flow favours the deoxygenation and polymerisation of HbS. 
Hence, hypoxia can be seen as a central factor in the pathophysiology of BCD.
The physiological response to hypoxia is also altered in SCO, where the 
hypoxia driven erythropoietin response is found to be diminished in patients 
(Sherwood et al., 1986). As red blood cells containing polymerised HbS have a 
lower affinity for oxygen, their release of oxygen to tissues is enhanced 
compared to cells containing the normal HbA, thereby blunting the normal 
erythropoietin response to hypoxia. Conversely, patients on hydroxyurea 
therapy with elevated levels of HbF display higher elevated erythropoietin levels 
than subjects not receiving hydroxyurea as HbF has increased affinity for 
oxygen and releases less oxygen at a given oxygen tension (Charache et al., 
1992). Furthermore, the Prevalence of kidney disease in the SOD population 
may further diminish the erythropoietin response to hypoxia by impairing 
hormones production. Therefore, erythropoietin has been utilised as a 
therapeutic tool in SCD to raise haematocrit and also has generated interest as 
a pharmacological agent to augment HbF production with or without 
concomitant hydroxyurea therapy (Little et al., 2006).
Respiratory complications, such as acute chest syndrome and pulmonary 
hypertension, are one of the most common causes of hospitalisation for SCD 
patients; they are a direct consequence of haemolysis and subsequent NO 
scavenging and can act as another contributor to hypoxia in this disease 
(Vichinsky et al.. 1997). Development of respiratory complications in SCD 
causes hypoventilation and hypoxaemia, thus promoting further intra-pulmonary 
sickling of red blood cells and resulting in inflammatory damage to the
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pulmonary endothelium (Vichinsky and Styles, 1996). However, inhaled NO 
therapy has been successful in ameliorating the effects of pulmonary 
hypertension (Sullivan et al., 1999).
The role of hypoxia in SCD pathophysiology is of paramount importance 
and as low oxygen levels have been shown to induce erythropoietin, NO and 
HO-1, it is tempting to suggest that there may be an inter-relationship between 
these three components. Indeed, the mechanism of action of erythropoietin or 
NO-based therapy in SCD could likely involve HO-1.
1.6 Nitric oxide
1.6.1 Chemical properties and reactions of NO
NO is an uncharged free radical that is involved in a wide array of 
physiological processes including smooth muscle relaxation, neurotransmission, 
platelet aggregation and host defense mechanisms (Nathan, 1992). NO is also 
thought to have a role in the pathology of several inflammatory disease states 
such as arthritis, myocarditis, colitis and nephritis. Furthermore, NO has also 
been implicated in other pathological conditions such as cancer, diabetes and 
neurodegenerative diseases (Davis et al., 2001). The downstream effects of NO 
depend on its local concentrations and availability of target molecules. For 
example, at low concentrations NO can activate cGMP-dependent pathways; 
cGMP in turn can regulate various physiological events such as vasodilatation 
and neurotransmission (Krumenacker, 2004). At higher concentrations, NO 
rapidly reacts with superoxide anion to form peroxynitrite, which results in 
nitration of proteins (specifically at tyrosine residues) which in turn are involved 
in diverse cellular physiological processes (Bian et al., 2003). Another
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mechanism by which NO can elicit biological effects is by S-nitrosylation, which 
is the covalent attachment of the NO molecule to sulphydryl residues of 
proteins. The resulting formation of S-nitrosothiols is a post-translational protein 
modification that is widely involved in redox-based cellular signalling (Sun et al., 
2006). Interestingly, NO can modulate calcium-activated potassium channel 
activity by either direct S-nitrosylation of the channel protein, by activation of the 
cGMP pathway or both (Weiger et al., 2002). The diverse mechanisms of action 
of NO and its numerous biological effects underlie the physiological importance 
of this molecule.
1.6.2 NO synthesis
The enzyme that produces NO is NO synthase (NOS) of which there are 
at least 3 isoforms. Each isoform comes from a distinct gene product. NOS-1, 
also called neuronal NOS (nNOS), is found in high levels in neuronal cells as 
well as in some non-neuronal tissue. Neuronal NOS is activated during 
conditions of elevated calcium by calmodulin, and is thought to produce NO as 
a neurotransmitter (Bredt and Snyder, 1992). NOS-2, also known as 
macrophage or inducible NOS (iNOS), can be induced in many cell types such 
as macrophages, hepatocytes and smooth muscle cells. Inducible NOS is not 
generally present in resting cells but is produced in response to 
lipopolysaccharide (LPS) and cytokine stimulation as a cytotoxic response 
mechanism (Nathan, 1992). The NOS-2 isoform is the only one that is activated 
independent of calcium, which therefore requires the enzyme to be permanently 
bound to calcium/calmodulin once synthesized. NOS-3, also known as 
endothelial (eNOS), was the enzyme originally discovered to produce the 
endothelium-derived relaxing factor which was later identified to be NO (Nathan,
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1992) (Figure 1-6). NOS-3 is also activated by raised levels of intracellular 
calcium and calmodulin binding. NOS-1 and NOS-3 are commonly referred to 
as constitutive NOS enzymes due to their constitutive expression and regulation 
by calcium/calmodulin. L-arginine is the substrate used by the NOS enzymes to 
produce NO. NOS enzymic activity also requires molecular oxygen, NADPH, 
tetrahydrobiopterin, flavin mononucleotide, flavin adenine dinucleotide and 
haem (Figure 1-6). The reaction results in the production of NO and L-citrulline 
(Marietta, 1994).
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Figure 1-6. NO synthesis and action
NO is produced from L-arginine through the action of NO synthase (which can 
be stimulated by various mechanisms including through acetylcholine (Ach) 
receptors or shear stress) in the endothelial cell. It has numerous physiological 
functions including platelet inhibition and regulating vascular tone through 
smooth muscle relaxation.
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1.6.3 Interaction of NO with biological molecules
NO contains an unpaired electron, making it a highly reactive and 
unstable free radical and resulting in the molecule reacting with other 
substances that have unpaired electrons. For example, its interaction with metal 
complexes, oxygen (O2) or superoxide anion (O2 ) results in multiple effects and 
downstream events depending on the localization and amount of NO and its 
substrates. NO concentrations are relatively low (<1 pM) under normal 
biological conditions and the gas will most likely react with haem complexes in 
proteins including sGC, haemoglobin, cytochrome p450 or protoporphyrin IX 
NO has also been shown to interact with non-haem proteins, other transition 
metals such as zinc, protein radicals, ribonucleotide reductases and cyclo- 
oxygenases (Davis et a!., 2001).
NO can interact with oxygen species O2 and O2' , and these reactions 
occur more frequently when higher levels of NO are produced, such as during 
an inflammatory response or when superoxide dismutase is unable to scavenge 
excess O2" (Beckman and Koppenol, 1996). They are important as the nature of 
the biological activity exerted by NO will depend not only on its concentration, 
but also on whether it has been converted to a further reactive species. For 
example, the interaction of NO with O2, electron acceptors or metals produce 
NO'*’, which can subsequently interact with thiols such as cysteine residues of 
proteins (Gaston, 1999). This can then result in S-nitrosylation of the thiol. 
Protein nitrosylation is a chemical reaction that has been shown to affect the 
function of numerous proteins, including transcription factors and signalling 
molecules; for example, DNA binding activities of NF-kB and c-junk are inhibited 
when they are nitrosylated and hence affect gene expression (Klatt et al., 1999).
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It has been proposed that due to the very short half-life of NO in plasma, S- 
nitrosylation of plasma proteins such as albumin and haemoglobin may lead to 
stabilization and prolong the pharmacological action of NO (Stamler et al.,
1992).
Under certain conditions, NO can also interact with O2' , resulting in the 
formation of the strong oxidant peroxynitrite (ONOO ) (Huie and Padmaja,
1993). Peroxynitrite can lead to tyrosine nitration which is an addition of a NO2 
group to the phenol ring in the tyrosine. Nitration of a tyrosine in proteins can 
alter their function.
1.6.4 NO and haemoglobin binding
NO is a free radical with ligand properties similar to those of O2 and CO 
which bind to oxyhaemoglobin. The affinity of NO for oxyhaemoglobin is much 
higher than that of O2 or CO (Rifkind et al., 2004). One of the most important 
biological effects of NO involves the reaction with guanylate cyclase in smooth 
muscle cells, which produces vasodilatation. The endothelial NOS in the 
vascular endothelial cells provides the NO for this reaction. Some of the NO 
produced in the endothelial cells also diffuses into the lumen and may play a 
role in red blood cell function. In fact, a role for haemoglobin in the transport of 
NO to the vasculature has been proposed (Jia et al., 1996a) (see section 1.6.5).
Other NO species will also readily interact with haemoglobin. For 
example, peroxynitrite will directly react with thiol-containing compounds as well 
as haem proteins. The reaction of peroxynitrite with oxyhaemoglobin produces 
Fe(IV)ferrylhaemoglobin. Peroxynitrite can also react with methaemoglobin 
(Rifkind et al., 2004). An interesting reaction between nitrite and haemoglobin
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has been postulated. Nitrite is present in plasma at a concentration of 150 nM - 
1 pM and it reflects NO production from endothelial NO synthase enzymes 
(Gladwin et al., 2000). Nitrite can diffuse into the red blood cell and react with 
haemoglobin, oxidizing it (Kosaka et al., 1982). As the partial pressure of O2 is 
lowered, the nitrite can react with deoxyhaemoglobin to regenerate NO and 
methaemoglobin (discussed further in section 1.6.5).
1.6.5 NO and haemoglobin interaction: physiological implications
NO produced by endothelial cells, apart from diffusing into surrounding 
smooth muscle cells, can also find its way into the flowing blood where it can 
interact with plasma constituents, especially oxyhaemoglobin. Under certain 
pathological conditions, such as haemorrhagic or subarachnoid shock, there is 
an accompanied over-production of NO, as well as raised levels of free 
haem/haemoglobin due to haemolysis. NO binds avidly to haemoglobin, and 
this interaction has led to a flurry of research and debate over the biological 
significance behind this reaction. It has been proposed that the binding of NO to 
haemoglobin may have an “oxygen-sensing” role, though the mechanism for 
this action has led to much discussion (Singel and Stamler, 2004). Stamler and 
co-workers have proposed that haemoglobin may bind NO at a specific cysteine 
residue to form S-nitroso-haemoglobin (SNO-haemoglobin) in its R 
(oxygenated) state. The NO could then be released from haemoglobin in its I  
(deoxygenated) state, resulting in NO-dependent vasodilatation in hypoxic 
conditions. Specifically, Stamler (Jia et al., 1996b) proposed a mechanism by 
which deoxyhaemoglobin could take up both O2 and NO in the lung and then, 
upon transit to a site of low PO2, liberate both gases. SNO-haemoglobin on its 
own was demonstrated to have potent vasodilatory activity and, therefore, a
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possible role for haemoglobin in transporting NO was suggested. Most 
significantly, this activity is potentiated by the deoxygenation of haemoglobin. 
Therefore haemoglobin may sense ambient O2 levels through its O2 binding 
function and adjust NO bioavailability. In turn, red blood cells can cause 
microvessels to dilate or constrict, with SNO-haemoglobin as an intermediate. 
This model offers a mechanism for matching tissue perfusion with metabolic 
demands (Singel and Stamler, 2004).
A different mechanism has been proposed by Gladwin and colleagues, 
where the anion nitrite serves as a storage pool and can be converted to NO 
through haem-based reduction by deoxyhaemoglobin. Specifically, Gladwin 
proposed that nitrite could be converted into NO in the blood, and the released 
NO could induce local dilatation and increase regional blood flow. The essential 
feature of the nitrite haemoglobin hypothesis is that the interaction of nitrite with 
deoxyhaemoglobin generates a diffusible vasodilator with similar properties to 
NO. The barrier to diffusion that exists at the red cell membrane will limit the 
ability of red cells to destroy NO generated in the extracellular space and allow 
diffusion of red-cell generated NO to smooth muscle tissue (Gladwin et al.,
2004). The major fundamental difference between the nitrite/haemoglobin 
hypothesis and the SNO-haemoglobin hypothesis is that haemoglobin does not 
carry the vasodilatory agent and that NO release is dependent upon the 
differential reactivity of nitrite with haemoglobin in the oxygenated and 
deoxygenated state, rather than oxygen-dependent conformational change that 
affects the reactivity of haemoglobin bound S-nitrosothiol (Gladwin and 
Schechter, 2004).
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1.6.6 NO and haemoglobin Interaction: pathophysiological Implications
The high affinity of haemoglobin for NO poses significant problems when 
the endothelium is exposed to high concentrations of free haemoglobin, for 
example after haemolysis (Patel, 2000). Peripheral vasoconstriction (Sampei et 
al., 2005) has been largely attributed to scavenging of NO by haemoglobin, and 
excessive vasoconstriction can limit the use of cell-free haemoglobin as a blood 
substitute to carry O2. Haemoglobin in the plasma is a more effective sink for 
NO than haemoglobin in red blood cells due to the diffusion limitation of NO in 
the red blood cell (Huang et al., 2001). Apart from causing vasoconstriction, the 
scavenging of NO by haemoglobin also has additional effects as NO serves 
many functions in maintaining a healthy vasculature. NO has been proposed to 
be an anti-atherogenic agent with mechanisms of action including stimulation of 
anti-oxidant enzyme synthesis, inhibition of platelet aggregation, down 
regulation of pro-inflammatory adhesion molecules, or direct inhibition of lipid 
peroxidation reactions (Hogg and Kalyanaraman, 1999). It is possible that the 
scavenging of NO will interfere with all these NO-dependent pathways. Under 
physiological conditions NO has been suggested to be protective against cell 
death. NO scavenging by cell-free haemoglobin may sensitise these cells 
making them more susceptible to cell death and contribute to haemoglobin- 
dependent toxicity. Indeed, haemoglobin promotes both necrotic and apoptotic 
death of endothelial cells, but whether this is NO-dependent is not known 
(Goldman et al., 1998). Scavenging of NO by haemoglobin is not always 
detrimental and has potential therapeutic benefits in the treatment of sepsis and 
conditions associated with hypertension such as stroke (Privalle et al., 2000).
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1.6.7 Haem-nitrosyl complex formation
Due to the high affinity of NO for haem or haemoglobin, it is not 
surprising that the formation of nitrosyl-haemoglobin (HbNO) or haem-nitrosyl 
(H-NO) complexes may also occur when NO and haemoglobin are co­
incubated. These complexes have been shown to form under physiological 
conditions. Indeed, ingestion of foods rich in nitrates, such as fresh fruit and 
vegetables, have been shown to increase HbNO levels in blood and have been 
suggested to have a role in the improvement of cardiovascular diseases 
(Tsuchiya et al., 2004). Circulating HbNO levels also increase in conditions 
such as endotoxic and haemorrhagic shock (Davies et al., 2005), which is not 
surprising as these conditions are characterized by increased levels of both 
haem (through haemolysis) and NO (endogenous production). In these 
situations, there is also a high level of intracellular H-NO complexes found in the 
liver, suggesting that H-NO may act as a substrate for HO-1 which is found in 
abundance in the liver (Davies et al., 2005).
1.6.8 NO interaction with haem oxygenase
Not only is NO a potent inducer of HO-1, but it can also affect the regulation 
of the enzyme. Indeed, excessive production of NO species resulting in 
nitrosative stress has been demonstrated to result in up-regulation of 
endothelial HO-1 (Foresti et al., 1999). There is a complex relationship between 
NO and HO-1, where NO can regulate HO-1 gene and protein synthesis as well 
as modulating the breakdown of haem by both HO-1 and HO-2. A direct 
reaction between NO and HO-1 breakdown products BR and BV has also been 
demonstrated (Kaur et al., 2003).
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1.6.9 Up-regulation of HO-1 by NO
NO and NO-releasing agents differentiate themselves from other 
inducers of HO-1 because as well as producing oxidative stress they inflict an 
additional cellular threat, termed nitrosative stress (Foresti et at., 
1999):(Motterlini et al., 2002b; Naughton et al., 2002a). The damage arises from 
excessive nitrosation of nucleophilic centres, thus resulting in protein 
modification and loss of function (Stamler and Hausladen, 1998). NO could 
serve as an intracellular signal to modulate the tissue stress response and the 
haem oxygenase pathway may interact with NO to control cellular homeostasis. 
It has been suggested that HO-1 could act as a feedback inhibitor of NO when 
the concentrations of the gaseous molecule exceed a critical threshold and the 
products of haem degradation might play a role in this process (Foresti and 
Motterlini, 1999). Indeed, exposure of various cell types including endothelial, 
smooth muscle, cardiac and renal cells to NO or NO species results in induction 
of HO-1 (Datta and Lianos, 1999; Motterlini et al., 1996a; Naughton et al., 
2002b);Naughton et al., 2002b). This suggests that HO-1 induction by NO is a 
generalized cellular response to excessive NO production and HO-1 may be 
one of the cells defense mechanisms against the cytotoxic actions of high NO 
levels (Motterlini et al., 2002b). In addition, NO could contribute to the induction 
of HO-1 under reduced oxygen levels (Motterlini et al., 2000). Intriguingly, 
increases in iNOS activity were observed in hypoxic endothelial cells preceding 
HO-1 induction, suggesting endothelial HO-1 could be regulated by NO under 
hypoxic conditions.
NO can up-regulate HO-1 expression and haem oxygenase activity 
through an increase in exogenous or endogenous NO concentrations (Foresti et
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al., 1997; Motterlini et al., 1996a). Therefore, NO can exert its effects not only 
through its short term pharmacological action but also by affecting the 
expression of stress responsive pathways such as HO-1, resulting in long- 
lasting physiological effects. NO may affect HO-1 at different levels, from mRNA 
to protein expression and enzymatic function. In addition, the products of haem 
oxygenase activity may exert feedback mechanisms on NO and NO synthase.
The HO-1 gene promoter region has a large number of diverse target 
DNA sequences that can bind various transcription factors. Therefore, it could 
be postulated that the wide variety of NO releasing agents with different 
chemical characteristics that can induce HO-1 may bind to their own specific 
areas within the HO-1 promoter region. However, an alternative mechanism for 
the induction of HO-1 by various NO species is that they may all inflict a single 
type of “nitrosative” stress which may act on a specific single transcription factor 
to stimulate HO-1 (Alam and Cook, 2003). For example, cardiomyocytes 
exposed to nitroxyl anion have shown elevated levels of the transcription factor 
Nrf2, which has also been found to be elevated in vascular endothelial cells 
exposed to NO (Naughton et al., 2002b). The transcription factor Nrf2 is an 
important regulator of the cellular adaptive response to oxidative stress and has 
a vital role in the activation of the HO-1 gene (Alam and Cook, 2003). HO-1 
mRNA levels can be increased by the action of NO. Furthermore, NO can 
stabilize mRNA by reducing rate of mRNA turnover, therefore, NO not only 
enhances HO-1 gene expression but also prolongs the half-life of its mRNA 
(Bouton and Demple, 2000; Hartsfield et al., 1997).
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1.6.10 Modulation of haem oxygenase activity by NO
NO has been demonstrated to inhibit the degradation of haem into CO, 
BV/BR and iron of both HO-1 and HO-2 proteins (Ding et al., 1999; Wang et al., 
2003), in other words, NO is able to attenuate the activity of the enzyme. This 
inhibitory property of NO may form part of a feedback mechanism for haem 
oxygenase induction. The mechanism of inhibition differs between the two 
isoforms of haem oxygenase. In the HO-2 isoform, NO will directly interact with 
a cysteine present in the haem-binding motif of the haem oxygenase protein, 
with a subsequent loss of HO-2 catalytic activity (Ding et al., 1999). Conversely, 
NO binding to the catalytic iron atom in the HO-1 isoform has been reported to 
be the mechanism for inhibition of enzymic activity (Wang et al., 2003). 
However, the inhibition of HO-1 activity by NO is reversible, and activity is 
restored after removal of NO. Another possible mechanism that has been put 
forward for the inhibition of haem degradation is the formation of a haem- 
nitrosyl complex (Juckett et al., 1998). This has been supported by reports that 
incubation of NO with HO-1 rich microsomes resulted in a decrease in haem 
oxygenase activity. Vascular effects of haem oxygenase inhibitors are elevated 
in the absence of NO and renal CO generation is enhanced in the presence of 
NOS inhibitors (Rodriguez et al., 2004). However, there is vast body of 
contrasting reports which show that NO greatly enhances haem oxygenase 
activity (Foresti et al., 2003; Sammut et al., 1998), suggesting that in the long­
term NO results in the enhancement of HO-1 stimulation with subsequent 
increase in haem metabolites. NO may exert transient inhibitory actions on 
haem oxygenase, but they may be tissue or organ specific or may depend on 
the presence of certain pathological states.
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1.6.11 Interaction of NO with haem metabolites
The breakdown products of haem by HO-1 have been demonstrated to 
interact with NO. For example, exposure to CO gas powerfully inhibited the 
NOS activity, and thereby NO production, from macrophages and rat 
cerebellum (White and Marietta, 1992), which the authors suggest is a 
consequence of CO binding to the haem-containing NOS. Conversely, in a 
model of liver injury, inhalation of CO gas has been shown to up-regulate iNOS 
which in turn induced HO-1, whereby the beneficial effects of CO seemed to be 
mediated through NO stimulation of HO-1 (Zuckerbraun et a!., 2003). Therefore, 
a complex interaction might exist between haemoproteins such as NOS and the 
haem-binding molecules CO and NO which results in the modulation of 
haemoprotein function.
BR and BV have been shown to interact efficiently with NO and NO 
related species, implicating novel ‘anti-nitrosative’ features for the bile pigments 
(Kaur et al., 2003). It has been suggested that BR and BV act as scavengers of 
NO, and reports have shown that interaction of bile pigments with NO species 
result in their degradation. However, the presence of thiols significantly prevents 
the loss of BR by nitroxyl ion, suggesting that the bile pigments may compete 
with sulphydryl groups to scavenge NO and protect cells from damage due to 
excessive NO (Kaur et al., 2003). Furthermore, scavenging of reactive nitrogen 
species have also reported to provide protection against tissue damage in an 
arthritic rodent model (Bezerra et al., 2004), adding support to the idea that 
removal of excess NO is advantageous in protecting against cellular injury.
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1.6.12 Potential effect of haem and NO interaction on HO-1
A potential co-operation between NO and HO-1 has been proposed, 
which would result in the increased production of BV/BR (anti-oxidant), CO 
(anti-inflammatory and signalling) and iron (signalling), occurring in 
pathophysiological situations affecting vascular functions. Stamler (Stamler, 
2003) and Gladwin’s (Gladwin et al., 2004) work deal with NO and haemoglobin 
interaction at a physiological level, but there are conditions in which free 
haemoglobin is released into the blood to interact with NO. SCD is an example 
of a condition which is characterized by high concentrations of free 
haemoglobin, secondary to acute and chronic haemolysis, as well as conditions 
of hypoxia. In fact, it has been proposed that it is the scavenging of NO by free 
haemoglobin in SCD, thereby limiting its bioavailability, that causes the vascular 
complications that are SCD’s pathological hallmarks (Reiter et al., 2002). 
Administration of NO as therapy to patients with sickle crises has been shown 
to ameliorate symptoms. The inherent hypoxia in SCD could also stimulate 
NOS and HO-1 induction (Motterlini et al., 2000), the latter occurring possibly 
through an enhanced interaction between NO and haemolysis-mediated free 
haemoglobin. These findings raise the fundamental question of the biological 
significance of NO and haemoglobin interaction in pathophysiological states 
such as SCD. If NO acts co-operatively in the presence of haemoglobin and/or 
haem to induce HO-1 in endothelial cells, then the HO-1 pathway could serve 
as an effective defensive system to the vasculature in haemolytic states. In the 
present study, we examined the effects of the interaction of haemoglobin and 
NO on endothelial haem oxygenase and investigate a possible role for this 
interaction in SCD.
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1.7 Hypothesis and objectives
The interaction of haem and NO has previously been shown to enhance 
endothelial haem oxygenase induction and endothelial haem uptake (Foresti et 
al., 2003). This is an interesting phenomenon, as both these potentially toxic 
compounds can individually trigger the protective haem oxygenase pathway in 
endothelial cells, and their co-incubation amplifies the observed effect. This 
could possibly be an adaptive mechanism for cells exposed to the dual insult of 
excess haem and excess NO that may be present in certain haemolytic 
conditions such as SCD. Therefore, the general hypothesis for this thesis is:
Increased haem oxygenase activity and induction of HO-1 protein 
expression by interaction of haemogiobin and NO is an adaptive response 
of the endothelium and may have a physiological role in conditions such 
as sickle cell disease.
To verify this theory a number of objectives were set:
e to Investigate the effect of NO and haemoglobin interaction on 
endothelial haem oxygenase induction
• to examine the effect of NO and haemoglobin interaction on endothelial 
haem uptake
• to explore the effect of sickle blood on endothelial haem oxygenase 
induction
• to examine the effect of haem oxygenase and its breakdown products on 
sickle blood interaction with vascular endothelium
• to study the effect of HO-1 inducers on erythroid progenitor cells (K562)
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Chapter 2. Materials and Methods
2.1 Reagents
Human haemoglobin-Ao ferrous stabilized (HbAo), human sickle cell 
haemoglobin (HbS), human methaemoglobin (MetHb), hydroxyurea (HU), 
curcumin, thymidine and media and cell culture media supplements (L- 
glutamine, foetal bovine serum, and bovine serum albumin) were obtained from 
Sigma. Foetal haemoglobin (HbF) was purchased from Bethyl laboratories. 
Streptomycin, penicillin and Dulbecco’s phosphate buffered saline were 
purchased from Invitrogen. Haemin, biliverdin (BV) and tin protoporphyrin IX 
(SnPPIX) were purchased from Porphyrin Products (Logan, UT, U.S.A.). S- 
nitrosoglutathione (GSNO), Angeli’s Salt (AS), (Z)-1-[2-(2-Aminoethyl)-N-(2- 
ammonioethyl)amino]diazen-1 -ium-1,2-diolate (DETA-NO), 2-(N,N- 
Diethylamino)diazenolate-2“Oxide sodium salt (DEA-NO) and 1-propanamine,3- 
(2-hydroxy-2-nitroso-1-propylhydrazino) (PAPA-NO) were obtained from Alexis 
Corporation (Bingham, UK). The nitrosyl adduct of haemin (haem-nitrosyl or 
NO-Fe"-protoporphyrin IX) and CO-RMs (CORM-3 and C0RM-A1) were 
prepared as described below. All other reagents were purchased from Sigma 
unless otherwise stated.
2.2 Synthesis of ferrous haem-nitrosyl (H-NO)
Ferrous haem-nitrosyl was prepared by our collaborators Dr. Patrick J. 
Farmer and Filip Sulc (University of California, Irvine, California). All
experiments were conducted under strict anaerobic conditions by using
standard Schlenk techniques. The nitrosyl adduct of haemin (NO-Fe"-
protoporphyrin IX) was generated by dissolving haemin (Aldrich) in carbonate
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buffer (pH=10), addition of 40-fold excess of sodium dithionite (Fisher) followed 
by addition of 20-fold excess of sodium nitrite (Sigma) under anaerobic 
conditions (Figure 2-1). During the reaction the solution turned from brown to 
deep red, indicating the formation of the ferrous nitrosyl adduct. The pH was 
adjusted to 7 by addition of excess buffer, and the nitrosyl haemin was 
extracted into methyl ethyl ketone. The extract was washed anaerobically with 
buffer (pH=7) three times, and the solution dried to an air stable solid. Re­
dissolution of the solid in buffer (pH=10) allowed spectral characterization of an 
intense Soret maxima at 420 nm, confirming the formation of the ferrous nitrosyl 
adduct. The electronic spectra were recorded on a Hewlett-Packard 8453 
spectrophotometer. Since the haem-nitrosyl adduct has limited stability in 
aerobic solutions, ultimately forming nitrate and ferric haemin, great care was 
taken to reduce the exposure of the complex to air before the experiments
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Figure 2-1. Spectrum of H-NO generation
Independent generation of H-NO by standard method: excess sodium nitrite 
and disodium dithionite were added to the haemin solution in pH 7.4 phosphate 
buffer, as described. The peak of absorbance of H-NO is 420 nm.
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2.3 Synthesis of CO-releasing molecules (CO-RMs)
2.3.1 Synthesis of tricarbonylchloro(glycinato)ruthenium (II) (CORM-3)
Thcarbonylchloro(giycinato)ruthenium(II) {[Ru(C0)3CI(g!ycinate)] or 
CORM-3) was synthesised by our collaborator Prof Brian. E. Mann (University 
of Sheffield, Sheffield, UK). The synthesis of CORM-3 starts with the use of a 
commercially available compound, thcarbonyldichlororuthenium(ll) dimer 
([Ru(CO)3Cl2]2) (Sigma, Aldrich). Briefly, ([Ru(CO)3Cl2]2) (0.129 g) and glycine 
(0.039 g) were placed under nitrogen in a round-bottomed flask. Methanol (75 
ml) and sodium ethoxide (0.034 g) were added and the reaction allowed to 
continue under stirring for 18 h at room temperature. This was followed by 
removal of the solvent under pressure and the remaining yellow residue 
redissolved in tetrahydrofuran (THF), which was then filtered and an excess of 
40- 60 light petroleum added. This yellow solution is evaporated to produce a 
pale yellow solid (0.142 g, 96% yield). CORM-3 was finally stored in closed vials 
at -20°C and used fresh on the day of experiments.
2.3.2 Synthesis of sodium boranocarbonate (C0RM-A1)
Sodium boranocarbonate (Na2[H3BC02] or C0RM-A1) was synthesised 
by our collaborator Prof. Roger Alberto (University of Zurich, Switzerland). The 
synthesis involved slowly bubbling CO through a 1 M H3B-THF solution. The 
gas stream was then passed over a reflux condenser at -50°C and then bubbled 
through a solution of NaOH in ethanol in a Schlenk tube at -78°C. After 2 h the 
Schlenk tube was disconnected and heated to reflux for 1 h. C0RM-A1 
precipitated as a white solid and was filtered and washed with cold ethanol and
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diethyl ether to yield the pure product. C0RM-A1 was finally stored in closed 
vials at -20°C and used fresh on the day of experiments.
2.3.3 Release of CO from CORM-3 and C0RM-A1
Detection of CO release from CORM-3 and C0RM-A1 was confirmed in the 
laboratory using a myoglobin assay (Figure 2-2).
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Figure 2-2. Release of CO from CORM-3 and CORM-A1 in aqueous 
solutions
(A) Chemical structure of [Ru(C0)3CI(glycinate)] (CORM-3) and detection of 
carbonmonoxy myoglobin (MbCO) formation after addition of 40 pmol/l CORM-3 
to a deoxymyoglobin (deoxyMb) solution. (B) Chemical structure of 
Na2[H3BC02] (C0RM-A1) and detection of MbCO as for CORM-3 after addition 
of 40 pmol/l C0RM-A1.
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This assay consists of measuring spectrophotometricaliy by measuring the 
conversion of deoxymyoglobin (deoxy-Mb) to carbonmonoxy myoglobin (MbCO) 
after addition of our test molecules. CORM-3 and C0RM-A1 are both water 
soluble compounds, but possess different chemical characteristics that affect 
their rate of CO release (CORM-3 has a half-life of 3.6 min, while C0RM-A1 
has a half-life of 21 min in physiological buffers). Figure 2-3 shows a 
comparison between the release of CO from CORM-3 and C0RM-A1 over an 
hour as indicated by formation of MbCO.
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Figure 2-3. Rate of CO release from CORM-3 vs. C0RM-A1
Detection of carbonmonoxy myoglobin (MbCO) after addition of 60 pmol/l 
CORM-3 or CORM-AI to a deoxymyoglobin (deoxy-Mb) solution. CORM-AI 
slowly releases CO, reaching MbCO saturation after 1 h, whereas CORM-3 has 
reached saturation after 1 min.
Inactive CO-RMs or iCORMS which were stimulated to release all their CO 
were used as negative controls. iCORM-3 was generated by dissolving CORM-
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3 in Krebs buffer (pH 7.4) and left overnight at room temperature to become 
inactive. iC0RM-A1 was generated by initially dissolving C0RM-A1 in 0.1 M 
HCI and bubbling pure N2 through the solution for 10 min to remove any 
residual CO gas.
2.4 Cell culture
Commercially available cell lines were used for the work reported in this 
thesis rather than primary cultures as they were more stable, less labour 
intensive, had longer life-spans and did not have problems of contamination 
with other cell types. Bovine aortic endothelial cells (BAEC) were purchased 
from Coriell Cell Repositories (Camden, NJ, USA). Porcine renal epithelial cells 
(LLC-PKi), human adult atrial myoblast cells (Girardi cells) and RAW 264.7 
murine macrophages were purchased from the European Collection of Animal 
Cell Culture (Salisbury, UK). Human erythroid progenitor cells (K562) were 
purchased from the American Type Culture collection (ATCC) (Teddington, UK). 
BAEC and K562 cells were received as growing cultures and were immediately 
transferred to an incubator (37°C, 95% O2 5% CO2) after addition of fresh 
culture medium and subcultured (as described in the next sections) when 
confluent. LLC-PKi, Girardi cells and RAW 264.7 macrophages were delivered 
frozen in cryoprotectant (DMSO). Upon receipt, cells were immediately thawed 
in a 37°C water bath, the cryoprotecant containing medium discarded and fresh 
medium added (Table 2-1 summarises the composition of culture medium for 
specific cell types). Cells were transferred to a 25 cm^ flask (Sarstedt Ltd., 
Leicester, UK) and incubated at 37°C in a 95% O2, 5% CO2 humidified 
atmosphere. Fresh medium was added every two days to the flask, and cells
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were subcultured once confluent. The following sections describe the specific 
subculture of each cell type in more detail.
Table 2-1. Culture medium of different cell types
Cell type Media FBS
(%)
L-glutamine
(mM)
Penicillin-
Streptomycin(U/ml)
Additives
BAEC Iscove’s 10 2 mM 100 -
LLC-PKi DMEM 10 2 mM 100 -
Girardi DMEM 10 3.5 mM 100 NEAA*
Raw267.4 DMEM 10 2 mM 100 -
K562 Iscove’s 10 3.5 mM 100 -
• NEAA=non-essential amino acids (Sigma,UK)
2.4.1 Bovine aortic endothelial cells
BAEC were cultured in Iscove’s modified Dulbecco’s medium with 
supplements as described in Table 2-1. To maintain the cell line for 
experiments, cells were subcultured approximately every 3 days. Once the 
cells reached confluence (>80% coverage of 75 cm^ flask (Sarstedt Ltd., 
Leicester, UK), they were washed with 5 ml of warm (37“C) PBS (Gibco, 
Paisley, UK) to remove any residual media before addition of trypsin (0.25% 
trypsin-EDTA solution, Sigma) for approximately 3 min at 37°C. Trypsin and 
cells resuspended in the solution were then removed and pipetted into 8 ml of 
fresh medium to neutralize its action. Cells were centrifuged (1500 x g) for 5 min 
in bench top centrifuge (SANYO, Harrier 15/80). The cell pellet was then 
resuspended in fresh medium and split (1:3) into preprepared 75 cm^ flasks 
containing fresh medium (8 ml). Cultures were maintained at 37°C in a 5% CO2 
humidified atmosphere and when the cells reached 80-90% confluence they
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underwent experimental protocol. All cell culture work was carried out using an 
ESB JBIO CL II category II hood.
2.4.2 Porcine renal epithelial cells (LLC-PKi)
Porcine renal epithelial cells were grown in Dulbecco’s modified Eagle’s 
medium (DMEM) with supplements as described in Table 2-1. To maintain the 
cell line for experiments, cells were subcultured approximately every 3 days as 
described above.
2.4.3 Human adult atrial myoblast cells (Girardi)
Girardi cells were cultured in DMEM with supplements as described in 
Table 2-1. To maintain the cell line for experiments, cells were subcultured as 
previously described.
2.4.4 RAW 264.7 murine macrophages
RAW 264.7 macrophages were grown in DMEM with supplements as 
described in Table 2-1. These cells were subcultured by removing the old 
medium and washing cells with 5 ml warm (37°C) PBS, which was discarded 
and replaced with 8 ml warm (37°C) DMEM. Cells were then scraped from the 
surface of the flask with a rubber plastic Thomas policeman, pipetted into 
prepared 75 cm^ flasks (each containing 8 ml DMEM) and returned to the 
incubator.
2.4.5 Human erythroid progenitor cells (K562)
K562 cells were cultured in Iscove’s modified Dulbecco’s medium with 
supplements as described in Table 2-1. To maintain the cell line for 
experiments, cells were subcultured approximately every 3 days. Subculturing
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of these non-adherent cells involved centrifugation of cells in old medium (100 x 
g) for 5 min followed by resuspension of the cell pellet in 8 ml fresh medium to 
split cells 1:4. 75 cm^ flasks were pre-prepared with 8 ml fresh media. Cells 
were treated when cultures had reached 1x10® viable cells/ml as determined 
using a haemocytometer.
2.4.6 Subculture of cells for incubation
Cells were cultured in 75-cm^ flasks for haem oxygenase activity and 
Western blot analysis. For determination of haem content, cells were cultured in 
24-well dishes (Fisher, UK), for the BR assay cells were cultured in 35 mm 
diameter Petri dishes (Fisher, UK) and for the cell adhesion assay cells were 
cultured in 6-well plates (Fisher, UK).
2.5 Collection of samples
Following each experimental treatment, cells were washed once with 5 
ml of cold (4°C) PBS followed by addition of 5 ml of cold (4°C) PBS to the 
flasks. Cells were gently scraped with a rubber Thomas policeman and the cell 
suspension was then transferred to a 15 ml tube (Sarstedt, Leicester, UK) and a 
further 4 ml PBS was added to the flask to collect any remaining cells. Samples 
were centrifuged for 10 min at 1800 g at 4°C, the supernatant was discarded 
and the pellet was resuspended in either: 1)100 mM PBS -  2 mM MgCb buffer 
(550 pi) for the haem oxygenase activity assay or, 2) 1% Triton PBS (250 pi) for 
Western blot Analysis. All samples were stored at -80°C until assays were 
performed.
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2.6 Preparation of liver cytosol and liver microsomes
Liver cytosol was prepared from male Sprague Dawley rats (250-300 g). 
After sacrifice by anaesthetization (pentobarbitone Lethobarb sodium BP, 500 
pi, i.p.) and cervical dislocation, a 50 ml syringe filled with cold (4°C) buffer 
(1.15% (w/v) KCI) was used to perfuse through the liver lobes and remove any 
residual blood, while clotted tissue was discarded. The organ was weighed, 
finely chopped with a scissors and homogenised in 2-3 volumes of 
homogenising buffer (20 mM Tris-HCI, pH 7.4, containing 1.15% (w/v) KCI), 
followed by partition among a set of polyallomer centrifuge tubes (Beckman 
Coulter Ltd., High Wycombe, UK). Following centrifugation (5,000 x g) for 20 
min at 4°C in a refrigerated ultracentrifuge (Optima LE 80, Beckman 
Instruments, Palo Alto, California, USA), the supernatant was retained and 
centrifuged again (105,000 x g) for 90 min at 4°C. Following each centrifugation, 
the lipid layer was removed with a Pasteur pipette. The supernatant was 
collected, and biliverdin reductase activity (using a modified haem oxygenase 
assay) and protein were measured as described in Sections 2.7 and 2.8, 
respectively, then aliquoted and stored at -70°C.
The preparation of liver microsomes is similar to that for liver cytosol with 
the following variations. The rat was pre-treated with haemin (50 mg/kg, i.p.) 24 
h beforehand to induce haem oxygenase activity. The lobes were perfused with 
cold (4°C) saline (0.9% (w/v) NaCI) and homogenised in 5 volumes of sucrose 
solution (0.25 M sucrose, 0.05 M Tris-HCI, pH 7.4) and then centrifuged as 
described above. After the last centrifugation step, the resulting microsomal 
pellet was resuspended gently in 1 ml of phosphate buffer (pH 7.4) and haem
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oxygenase activity and protein were determined according to Sections 2.7 and 
2.8, respectively, followed by storage at -70°C.
2.7 Assay for endothelial haem oxygenase activity
Haem oxygenase activity was determined in endothelial cells at different 
times after treatment. The stock solutions of the assay reagents (i.e. glucose-6- 
phoshate (G6P) (20 mM), glucose-6-phoshate dehydrogenase (G6PDH) (50 
U/ml) and NAD PH (40 mM)) were prepared with phosphate buffer (pH 7.4) and 
stored at -80°C until required. The NADPH stock solution was kept wrapped in 
foil as it is light sensitive. Haemin stock (2 mM) was prepared fresh for each 
assay by first solubilising the haemin in a small amount of 0.5% (v/v) NaOH (2 
M) and then making up the stock in phosphate buffer (PBS-MgCb, pH 7.4). Rat 
liver cytosol and liver microsomes were prepared according to Section 2.6. 
Collection of samples was as described in section 2.5. Cells were lysed by three 
rounds of freeze-thawing (-80° to 37°C), then placed on ice. Four hundred pi of 
the resulting cell suspension was added to a set of glass tubes, which were 
maintained on ice (a 100 pi aliquot of the remaining cell suspension was 
retained for protein determination according to Section 2.8). A reaction mixture 
was added to the cell suspension (final volume, 900 pi) in the following order: 
PBS-MgCl2 (pH 7.4), 20 pM haemin, 2 mM G6P, 0.5 U/ml G6PDH. 3 mg of rat 
liver cytosol as a source of biliverdin reductase, and 0.8 mM NADPH. The 
negative (PBS-MgCb, pH 7.4) and positive (rat liver microsomes) controls were 
also prepared, containing proportionate volumes of phosphate buffer (pH 7.4) 
instead of the cell suspension. The tubes containing the cell 
suspension/reaction mixtures were vortexed well and incubated in the dark for 1 
h at 37°C. Activity of the cytosolic and microsomal fractions was verified by
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replacing haemin with BV (1 mM), while the samples were incubated in the dark 
for 30 min at 37°C. After 1 h incubation, the reaction was terminated by addition 
of chloroform (1 ml), followed by thorough vortexing and centrifuging (1800 x g) 
2 times for 5 min at room temperature until three distinct layers were formed. 
Using a quartz cuvette and the UVikon 81 OP spectrophotometer the 
absorbance (at 464 nm and 530 nm) of the lower organic layer, which contains 
BR (extinction coefficient (e) for BR in chloroform, 40 mM'^cm'^), was read 
against a blank of chloroform. Haem oxygenase activity was expressed as 
picomoles of BR formed/mg protein/h using the formula:
pmoles bilirubin f  AOD (OD^g^ - O D 5 3 0 ) /  . ^
' — — /m g protein
mg protein in 60 min V 40
X 10®
Equation 1. Calculation of haem oxygenase activity
2.8 Protein determination
Protein concentration in samples was determined using the DC Protein 
Assay kit (Bio-Rad Laboratories Ltd., Hemel Hempstead, Hertfordshire, UK). 
The assay is similar to the Lowry assay and is based on protein reacting with an 
alkaline copper tartrate solution and Folin reagent. The colorimetric assay 
depends on the colour development after reaction between protein and copper 
in an alkaline medium, and a subsequent reduction of Folin reagent by the 
copper-treated protein. The presence of protein results in the production of a 
blue colour, the more intense the blue the higher the level of protein present. A 
standard curve was prepared using serial dilutions (0 to 2.8 mg/ml) of a bovine 
serum albumin (BSA) standard (Bio-Rad Laboratories Ltd.), prepared in 
triplicate, in phosphate buffer (pH 7.4). The absorbance readings at an optical 
density of 750 nm (O D 750) were plotted against their respective protein standard
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concentrations. The procedure for protein determination in cell and tissue 
samples was performed as follows. A 100 pi aliquot of the cell suspension 
(sample preparation as described in 2.4) and a blank of phosphate buffer or 
PBS Triton X-100 were added to 10 ml polystyrene tubes (Sarstedt Ltd.). To 
each tube, 500 pi of A’ (20 pi of Reagent S per ml of Reagent A) was added, 
then vortexed briefly. The next step was the addition of 4 ml of Reagent B to 
each tube, which was mixed well and then left at room temperature for 20 min 
before reading the OD750 against the blank using an UVikon 81 OP 
spectrophotometer (Tegimenta AG, Switzerland). A numerical value (mg/ml) for 
the protein concentration in the unknown samples was derived by multiplying 
the respective OD750 by the slope of the standard curve (Figure 2-4).
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Figure 2-4. Representative standard curve for protein determination
2.9 Western-blot technique for detection of HO-1 protein expression
Samples of endothelial cells also underwent Western immunoblot analysis. Cell 
samples were prepared as described in section 2.5, and protein levels of each 
sample were calculated as mentioned in 2.8. Appropriate volumes of each
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sample were combined with loading buffer (Laemmli buffer, Bio-Rad 
Laboratories Ltd.) containing 5% (v/v) p-mercaptoethanol) to a give a total 
volume of 30 pi and a final protein concentration loaded onto each lane equal to 
30-50 pg. The protein levels of (3-actin, a housekeeping gene, were also 
measured by Western immunoblot analysis to ensure equal loading of cell 
samples. Therefore the densitometric analyses of the HO-1 protein bands are 
expressed as HO-1/p-actin ratio to normalize HO-1 protein levels.
The HO-1 positive control (Bioquote Ltd., York, UK) was diluted to 1 
pg/ml in loading buffer. Samples were pulsed for 20-30 sec on a bench-top 
microcentrifuge (MSE Microcentaur, Sanyo Gallenkamp Pic., Leicestershire, 
UK) followed by denaturing of the proteins for 10 min at 100°C on a heating 
block (Techne DB2A, Techne GmBH, Germany). The molecular weight marker 
(MWM, Invitrogen LifeTechnologies Ltd.) was not heated but placed on ice until 
it was required. After heating the samples were re-pulsed and 30 pi of samples, 
10 pi MWM and positive control were loaded carefully into the wells of 12% tris- 
glycine Ready gel (Bio-Rad Laboratories Ltd.) using gel loading tips (Fisher, 
UK). Electrophoresis was carried out at room temperature in a tank containing 
running buffer (0.025 M Tris, 0.192 M glycine, 0.1% (v/v) SDS) (Fischer, UK) 
using the Mini-PROTEAN® II system and Power-Pac 300 power supply 
(Bio-Rad Laboratories Ltd.). A constant voltage of 125 V was applied until the 
loading buffer had migrated to, but not beyond, the base of the gel.
The subsequent procedures were carried out using the Mini Trans-Blot® 
electrophoretic transfer cell (Bio-Rad Laboratories Ltd.). While the gel was 
running, sheets of nitrocellulose membrane 45 pm pore size (Amersham 
Biosciences UK Ltd., Little Chalfont, Buckinghamshire, UK) and 3MM Whatman
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blotting paper were cut and pre-soaked in distilled H2O and cold (4°C) transfer 
buffer (0.025 M Tris, 0.192 M glycine, 0.1% (v/v) SDS, 20% (v/v) methanol) for 
10 and 5 min, respectively. After electrophoresis was completed a ‘gel 
sandwich’ (Figure 2-5) was prepared upon the clear (positive electrode) side of 
a gel cassette. After removing any air bubbles the cassette was closed securely 
via the latch and placed into the electrode module with the black (negative 
electrode) side facing the black panel of the module. This orientation ensures 
the proteins migrate from the gel onto the nitrocellulose membrane and not into 
the transfer buffer while transferring. Overnight transfer was carried out at 4°C 
with a constant voltage of 30 V using a 1000/500 transfer unit from Bio-Rad 
Laboratories Ltd.
Gel I 
Nitrocellulose
Foam Pad
Positive electrode | Negative electrode
Figure 2-5. Arrangement of gel sandwich assembly
All subsequent procedures were performed at room temperature on an orbital 
shaker (Denley Instruments Ltd., Sussex, UK) at low speed. Non-specific 
binding of the antibodies was prevented by incubating the membrane in 
blocking solution containing non-fat dried milk (5% (w/v)) in PBS (0.01 M 
phosphate buffer, pH 7.4, containing 0.2% Tween-20) for 2 h. This was followed 
by a single 5 min wash with 10 ml PBS (pH 7.4). The membrane was incubated
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for 2 h with anti-HO-1 (Bioquote Ltd., York, UK) diluted 1.1000 in Tris buffered 
saline (TBS) (0.05 M Tris-HCI, 0.0037 M KCI. 0.7137 M NaOH, pH 7.4). Next, 
the membrane was washed three times, once with PBS-T (PBS 0.01 M, pH 7.4, 
containing 0.05% (v/v) Tween 20), then twice with TBS (pH 7.4).
Proteins were visualised using an ExtrAvidin® alkaline phosphatase 
staining kit (Sigma), according to the following procedure. The biotinylated anti- 
rabbit IgG antibody, diluted 1:1000 in TBS (pH 7.4), was incubated with the 
membrane for 1 h. The membrane was washed three times with TBS (pH 7.4) 
and the ExtrAvidin® alkaline phosphatase conjugate, diluted 1:1000 in TBS (pH 
7.4), applied for 1 h. The three washes with TBS (pH 7.4) were repeated. After 
the last wash a freshly prepared substrate solution (9.8 ml of 0.1 M Tris buffer, 
pH 8.2, containing 200 pi of 1% (w/v) Napthol-AS-BI phosphate in N-N-N- 
dimethyl formamide and a 10 mg Fast Red DT salt tablet (Figure 2-6) was 
incubated with the membrane until red/pink bands, which indicates the location 
of the antigen-antibody complexes of the protein on the nitrocellulose 
membrane, were observed. After maximal colour change was attained (after 10 
min) any excess substrate solution was discarded and the membrane washed 
with distilled dH20. The membrane was stored in foil until it was scanned using 
the Photoshop software.
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Figure 2-6. Binding cascade for development of bands for HO-1 Western 
blot
2.10 Assay for determination of cellular haem content
Endothelial cells were grown in 24 well dishes until they reached 
confluency. The medium in each well was replaced with fresh medium and after 
the appropriate reagents were added to each well the dishes were returned to 
the incubator for various incubation times. At the end of the incubation the 
medium was removed and cells were washed twice with warm (37°C) PBS, 
followed by addition of 1 ml formic acid (95-97%, Sigma) to solubilise the 
endothelial layer. The haem concentration in the formic acid solution was 
measured spectrophotometrically at 398 nm (e = 1.56 x 10® M'^cm’ )^ using a 
UVikon 81 OP spectrophotometer. Intracellular haem concentration was 
expressed as pmol/well.
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2.11 Determination of bilirubin in culture medium
Endothelial cells were cultured in 35 mm Petri dishes. Once cells had 
reached confluency, the old media was discarded and 1 ml of fresh medium 
was added to the dishes, which were then incubated with the appropriate 
reagents. At the end of the incubation, 0.5 ml of culture supernatant was added 
to 250 mg of BaCb (Sigma) and vortex-mixed for 30 seconds. 0.75 ml benzene 
was then added to the mixture and tubes were vigorously vortex-mixed for 60 
seconds. The benzene phase containing the extracted BR was separated from 
the aqueous phase by centrifugation at 13000 g for 30 min. BR was measured 
spectrophotometrically as a difference in absorbance between 450 and 600 nm 
(e = 27.3 mM'^- cm'^) using a UVikon 81 OP spectrophotometer and was 
expressed as nM/mg protein. As benzene is a hazardous chemical, alt 
appropriate safety measures were adhered to when performing the assay. A 
potential alternative to benzene is chloroform which, although possessing lower 
sensitivity for the measurement of BR, may be is less toxic than benzene. 
However, the same safety control measures undertaken when using benzene 
should also be applied for chloroform.
2.12 Nitric oxide electrode
The NO electrode can be used to measure the release of NO into 
physiological solutions. We used the NO electrode to investigate the interaction 
of NO donors and haemoglobins in cell culture medium and to observe the 
effects of haemoglobins on NO release by NO donors. The NO chamber 
(NOCHM, W.P.I., Sarasota USA), NO electrode (ISO-NOP, W.P.I., Sarasota 
USA) and NO meter (ISO-NOTM Mark II, W.P.I., Sarasota USA) were set up as 
shown in Figure 2-7. The NO electrode was calibrated using chemical
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generation of NO by potassium nitrite. The method of calibration is based on the 
following reaction:
2KNÜ2 + 2KI + 2 H2SO4 2N0 + I2 + 2 H2O + 2 K2SO4
The following calibration solutions were prepared: Solution 1 -  0.1 M 
H2SO4 + 1.0 M Kl and Solution 2 -  50 pM KNO2. To calibrate the NO electrode 
a 2 ml volume of Solution 1 was placed in the NO chamber, and known 
concentrations of KNO2 were added to generate a known amount of NO
I I I ]
A/B  : water in/out -attached to 
waterbath (37“C)
C; Nitric Oxide Chamber
D; Solution + stirrer in chamber
E: Chamber lid with openings for 
electrode and syringe
F; Nitric Oxide electrode
G: Hamilton syringe to add 
reagents
H: Nitric oxide meter
NO Electrode:
Arrangement of apparatus
Figure 2-7, NO electrode experimental set-up
The ratio between KNO2 and NO is 1:1, therefore the amount of NO generated 
in the solution will be equal to the amount of KNO2 added. Standard 
concentrations of NO are generated to produce a standard curve (Figure 2-8) 
and calibrate the NO electrode. Once the NO electrode is calibrated, 1 ml of 
medium (Iscoves’s medium used with endothelial cells for haem oxygenase
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activity and HO-1 expression experiments) is placed in the NO chamber and the 
NO electrode was allowed to equilibrate until the baseline reading was steady 
and ready for experimentation.
1500-1
3  1000 -
0) 500
2500 500 750 1000 1250
NO concentration (nM)
Figure 2-8. Representative standard curve for NO measurement
2.13 Endothelial cell adhesion assay
Abnormal interactions between red blood cells and vascular endothelial 
cells are important factors in causing vascular pathology in many disease 
states, including vaso-occlusive crises in SCO. There are several experimental 
models that are commonly used to explore red blood cell-endothelial cell 
interactions. We used an in vitro static assay (Gravity sedimentation method), 
as this method allowed for fine control over biochemical and biophysical 
variables. Firstly, endothelial cells were subcultured into 6-well dishes 
(endothelial cell culture protocol as described in section 2.4.1). Preliminary 
experiments were designed to determine the optimal percentage of blood
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solution needed for incubation and the length of exposure to blood required to 
allow for adequate red blood cell-endothelial cell interaction (see section 6.3.1 
for details). It was found that incubation of endothelial cells for 45 min with a 
5% whole blood solution prepared in culture medium were the optimal 
conditions to obtain reproducible results. Figure 2-9 shows a summary of the 
red blood cell-endothelial cell adhesion assay; (1) endothelial cells were first 
pre-incubated with compounds diluted in culture medium; (2) after the pre­
incubation period had elapsed, the endothelial cells were exposed to whole 
blood solution for 45 min and (3) at the end of the incubation period non­
adherent red blood cells were removed by washing the endothelial layer three 
times with Hank’s Balanced Salt solution (Sigma). Adherent red blood cells 
were then visualized using a light microscope (Olympus Tokyo CK microscope) 
(x 20 magnification), counted in 10 random fields and adhesion was expressed 
as the number of adherent red blood cell/mm^.
1. Endothelial cells are 
pre-incubated with appropriate agents
2. Exposure of endothelial cells to 
20% whole blood solution for 45 min
3. Non-adherent red blood cells 
washed away and remaining cells 
expressed as number of adherent 
cells/mm^
Figure 2-9. Summary of red blood cell-endothelial cell adhesion assay 
protocol
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2.14 Isolated rat aortic ring
The isolated rat aortic ring model was used to assess the vasorelaxant 
effects of CO-RMs and NO donors in aortic rings exposed to sickle or normal 
blood. Male adult Sprague-Dawley rats were sacrificed by cervical dislocation. 
Animals were exsanguinated, the thorax opened and the descending aorta 
removed and placed into a Petri dish containing ice-cold Krebs-Henseleit buffer 
(mM): (NaCI 118, KCI 4.7, KH2PO4 12. MgS0 4 .7 H20  1.2, NaHCOs 2 2 , glucose 
11, K^EDTA 0.03, CaCl2 2.5). Indomethacin (10 pM) was also present in the 
buffer to remove the possible effect of prostaglandins on vascular tone. The 
lumen of the vessel was flushed gently with ice-cold buffer to remove any 
possible remaining blood. The aorta was carefully cleaned of fat and connective 
tissue and then cut into rings of 2-5 mm width. Each ring was mounted onto 
stainless steel hooks, with one hook being attached to a micrometer (236M 
series Micrometer, The L S Starret company, Mass., USA) and the other hook 
fixed to a clamp. The mounted rings were suspended in an organ bath under 2 
g tension in oxygenated (9 5 %02 /5 %C0 2 ) Krebs-Henseleit buffer. The 
micrometer was connected to a tension transducer (Grass Model 7D Polygraph, 
Grass Instruments Company, Quincy, Mass., USA), and data was recorded 
using Powerlab/8 SP data acquisition system (AD Instruments, Oxford) and 
Chart 4.2 Software (AD instruments, Oxford). Figure 2-10  gives an overview of 
the experimental set-up.
Rings were allowed to equilibrate for 1 h with adjustment for any 
modification in tension following washing with Krebs solution every 15 min. The 
rings were then contracted with KCI (100 mM) and 1 pM phenylephrine before 
the start of any treatment.
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4. Tension 
transducer and 
data acquisition
3. Micrometer 
attached to hook 
monitors changes 
in ring tension
1.Rings mounted 
on hooks 
suspended in 
organ bath 
containing 
oxygenated buffer 
maintained at 37°C
2. Addition of 
sickle/normal blood 
to test their response 
to vasoconstrictors 
and vasodilators
Figure 2-10. Overview of isolated aortic ring experimental set-up
2.15 Lactate dehydrogenase assay
Lactate dehydrogenase (LDH) is a stable cytoplasmic enzyme present in 
all cells and it is rapidly released into the cell culture supernatant upon damage 
of the plasma membrane. The LDH assay (Roche Diagnostics, UK) is based on 
the measurement of cytoplasmic enzyme activity released by damaged cells. 
There is a correlation between the amount of LDH activity detected in the 
culture supernatant and the proportion of lysed cells. For LDH detection, 100 pi 
of culture supernatant was collected cell-free and incubated for 15 min with 100 
pi reaction mixture in a 96 well plate, according to manufacturer’s instructions. 
LDH activity was determined in an enzymatic test: firstly, NAD* was reduced to 
NAD/H* by the LDH-catalysed conversion of lactate to pyruvate. This was 
followed by the catalyst (diaphorase) transferring H/H* to the tétrazolium salt 
INT which is reduced to formazan (Figure 2-11).
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LDH
lactate pyruvate
NAD NADH + H
formazan
Salt
(red)
tétrazolium
salt
(pale yellow)Catalyst
Figure 2-11. Principle behind lactate dehydrogenase colorimetric assay
An increase in the number of dead or plasma-membrane damaged cells 
results in an increase in the LDH enzyme activity in the culture supernatant. 
There was a direct correlation between the amount of enzyme activity and the 
amount of formazan produced during a limited time period. Therefore, the 
development of colour in the assay was proportional to the number of lysed 
cells. The water soluble dye formazan was detected spectrophotometrically at 
490 nm using a Versamax tunable microplate reader (Molecular Devices Ltd, 
Berkshire, UK).
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2.16 Statistics
Statistical analysis was performed using an unpaired two-tailed t-test to 
compare the means of two groups based on the assumption that the two 
populations are normally distributed. Analysis of variance (ANOVA) was 
performed where more than two treatments were applied. One way ANOVA 
was performed in the case of measurement of only a single variable during 
different treatments and two way ANOVA when more than one variable was 
measured during different treatments. To evaluate the statistical significance of 
one treatment versus another a Bonferonni post-test was used subsequent to 
ANOVA. Pearson’s correlation was calculated to evaluate the strength and 
direction of a linear relationship between two random variables. Analysis was 
performed with Prism 4 (Graphpad Software).
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Chapter 3. Effect of NO and haemoglobin interaction on 
endothelial haem oxygenase induction
3.1 Introduction
NO is an essential biological molecule and many of its physiological 
effects are mediated through its interaction with haem-containing proteins 
(Davis et al., 2001). In particular, the binding of NO to haemoglobin has been 
implicated in various physiological and pathophysiological processes, and can 
result in the generation of nitrosyl-haemoglobin (HbNO) or haem-nitrosyl (H- 
NO) complexes (Davies et al., 2005). Significantly, the enzyme HO-1 has been 
shown to be potently induced by both haemoglobin and NO molecules (Balia et 
al., 1993);(Motterlini et al., 1996a) and the interaction of haemin with NO has 
been shown to act synergistically in inducing endothelial HO-1 (Foresti et al., 
2003), suggesting a possible role for HO-1 in pathological conditions 
characterised by increased haemolysis or NO production.
As both NO and haemoglobin are strong inducers of HO-1, we aimed in 
the present chapter to examine the effects of co-incubation of different 
haemoglobins with NO donors on endothelial HO-1 expression and haem 
oxygenase activity and attempt to identify potential mechanisms mediating this 
effect.
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3.2 Objectives
• To investigate the effect of co-incubation of various haemoglobins with 
NO donors on the induction of endothelial haem oxygenase activity and 
HO-1 protein production
• To explore the role of the haem-nitrosyl (H-NO) complex in the induction 
of endothelial HO-1 activity, HO-1 expression and BR production
• To examine the effect of co-incubation of various haemoglobins with 
hydroxyurea on the induction of endothelial haem oxygenase activity and 
HO-1 expression
• To investigate whether haemoglobins modulate the release of NO by NO 
donors in culture media
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3.3 Experimental protocol
The detailed methods used in the experiments described in this section 
can be found in the Materials and Methods chapter. Stock solutions of 
haemoglobins (methaemoglobin, HbAo, HbS, HbF) and H-NO were prepared in 
PBS (see section 2.2 for H-NO preparation). Stock solutions (10 mM) of the NO 
donors S-Nitrosoglutathione (GSNO) and Angeli’s salt (AS) were prepared in 
0.01 M NaOH. Hydroxyurea stock solutions (10 mM) were prepared in distilled 
water. Haemin (1 mM) was prepared by dissolving It in 0.1 M NaOH and then 
adding 0.01 M phosphate buffer at pH 7.4. Haemoglobins were stored at -80°C, 
whereas H-NO, haemin, hydroxyurea and NO donor stock solutions were 
prepared fresh for each experiment. Incubations were carried out in the dark 
due to the light sensitive nature of the reagents.
3.3.1 Incubation of cells with reagents
To investigate the effect of co-incubation of haemoglobins and NO 
donors on endothelial haem oxygenase activity and HO-1 expression, three 
haemoglobins were used: 1 ) HbAo, the form normally present in the adult red 
blood cell; 2) methaemoglobin, the oxidized form of haemoglobin; and 3) HbS, 
the mutated form of haemoglobin found in SCO. Cells were exposed to 15 pM 
HbAo, 15 pM HbS or 1 pM methaemoglobin for 6  or 18 h in the presence or 
absence of the NO donor GSNO (250 or 500 pM) or the nitroxyl (NO ) generator 
AS (250 pM). A lower concentration of methaemoglobin in comparison with 
HbAo and HbS was employed because preliminary experiments showed that 15 
pM methaemoglobin was toxic to cells. Further experiments were performed to 
investigate the influence of a haem-nitrosyl complex on haem oxygenase 
activity, HO-1 expression and BR production. Endothelial cells were incubated
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with either H-NO (15 |jM), haemin (15 |jM ) or co-incubation of haemin (15 |jM ) 
and AS (250 |jM ) for 6 or 24 h. Haem oxygenase activity was assessed after 6 
h, HO-1 expression was determined after 6 and 24 h and BR release in culture 
medium was measured after 24 h. To investigate the effect of hydroxyurea (the 
drug used in the treatment of SCO which may have NO releasing properties) on 
endothelial haem oxygenase activity, cells were incubated with 50 pM, 100 pM 
or 300 pM hydroxyurea for 6 h. Since hydroxyurea may possess NO donor 
characteristics, a potential interaction of the drug with haem in affecting haem 
oxygenase was explored by incubating endothelial cells with 15 pM haemin in 
the presence or absence of 300 pM hydroxyurea for 6 h. In additional 
experiments, the effect of co-incubation of hydroxyurea and haemoglobins on 
endothelial haem oxygenase activity and HO-1 expression was examined. HbF 
was investigated along with the three original haemoglobins utilized, since it is 
the form of haemoglobin produced following treatment of SCO patients with 
hydroxyurea. Therefore, endothelial cells were exposed to 15 pM HbAo, HbS, 
HbF or 1 pM methaemoglobin for 6 or 18 h in the presence or absence of 300 
pM hydroxyurea.
3.3.2 Haem oxygenase activity assay
Haem oxygenase activity was determined in endothelial cells at different 
times after treatment as described in section 2.7 Briefly, harvested cells were 
subjected to three cycles of freeze-thawing before addition to a reaction mixture 
containing NADPH, rat liver cytosol as a source of BVR, and the substrate 
haemin. The reaction was conducted at 37°C in the dark for 1 h, terminated by 
the addition of 1 ml chloroform, and the extracted BR was calculated by the 
difference in absorbance between 464 and 530 nm (e = 40 mM'^cm'^).
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3.3.3 Western-blot techniques for detection of HO-1 protein expression
Samples of endothelial cells also underwent Western immunoblot 
analysis as described in section 2.9. Briefly, an equal amount of proteins (30 
pg) for each sample was separated by SDS-polyacrylamide gel electrophoresis, 
transferred overnight to nitrocellulose membranes, and the non-specific binding 
of antibodies was blocked with 3% non-fat dried milk in PBS. Membranes were 
then probed with a polyclonal rabbit anti-HO-1 antibody (Stressgen, Victoria, 
Canada) (1:1,000 dilution in Tris-buffered saline, pH 7.4). After three washes 
with PBS containing 0.05% (v/v) Tween 20, blots were visualized using an 
amplified alkaline phosphatase kit from Sigma (Extra-3A) and subjected to 
densitometric analysis. To ensure equal loading, cell samples also underwent 
Western-blot analysis for the house-keeping gene p-actin.
3.3.4 Determination of bilirubin in culture medium
For BR measurement cells were grown in 35 mm Petri dishes as 
described in section 2.11 At the end of the incubation, 0.5 ml of culture 
supernatant was added to 250 mg of BaCb and vortex-mixed thoroughly as 
already described. 0.75 ml of benzene was then added to the mixture and tubes 
were vigorously vortex-mixed again. The benzene phase containing the 
extracted BR was separated from the aqueous phase by centrifugation at 13000 
g for 30 min. BR was measured spectrophotometrically as a difference in 
absorbance between 450 and 600 nm ( e  = 27.3 mM'^* cm'^) and was expressed 
as nM/mg protein.
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3.3.5 NO release measurement
The NO electrode was used to assess the effect of co-incubation of 
haemoglobins on NO release by NO donors. Once the NO electrode had 
equilibrated in media, additions of NO donors (250 jjM AS, 250 pM GSNO, 300 
pM hydroxyurea) in the presence or absence of haemoglobins (15 pM HbAo, 15 
pM HbS, 1 pM methaemoglobin) were made and the release of NO was 
measured over time (the length of measurement was dependent on the rate of 
release of NO in solution). Control experiments were also performed by adding 
either haemoglobins or NO donors alone to the NO electrode. All experiments 
were carried out under red light due to light-sensitive nature of the reagents.
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3.4 Results
3.4.1 Both NO* (GSNO) and NO (AS) donors synergize with haemoglobin 
to Increase endothelial haem oxygenase activity and up-regulate HO-1 
expression
NO has been shown to strongly enhance the induction of HO-1 by 
haemin (Foresti et aL, 2003):(l\/lotterlini et a!., 1996a; Naughton et al., 2002b) 
and it was investigated here whether similar effects could be observed with 
haemoglobin. Three separate haemoglobins were investigated because of their 
different behaviour in terms of haem release. In particular, HbAo, which is 
stabilized in the ferrous form, becomes susceptible to oxidation once incubated 
with cells in aerobic conditions. A correlation exists between the rate of 
autoxidation of HbAo (i.e. rate of formation of methaemoglobin) and the increase 
in endothelial haem oxygenase activity. This can be attributed to the relative 
ease with which methaemoglobin can lose its haem moiety which then acts as 
an inducer for HO-1. In preliminary experiments, we observed that endothelial 
cells tolerate exposure to 15 pM HbAo for 6 or 18 h but are severely damaged in 
the presence of 15 pM methaemoglobin, thereby forcing us to lower the 
concentration of methaemoglobin to 1 pM. The mutated HbS was also tested 
because of its role in BCD and its intrinsic property to autoxidize and release 
haem faster.
HbAo, HbS and methaemoglobin caused induction of endothelial HO-1 
and a consequent increase in haem oxygenase activity (Figure 3-1, Figure 3-2 
and Figure 3-3,) to differing levels. This effect was particularly evident after 18 h 
incubation, indicating that the time-dependent oxidation of haemoglobins and 
the subsequent release of haem from haemoglobin are important factors
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influencing HO-1 up-regulation. It was also observed that methaemoglobin 
produced greater endothelial haem oxygenase activity compared with HbAo 
(note that methaemoglobin was used at 1 pM vs. 15 pM HbAo). However, when 
compared with the same concentration of HbS, HbAo produced a higher haem 
oxygenase activity. Therefore, the potency of the three haemoglobins in 
increasing haem oxygenase activity in endothelial cells could be summarized as 
follows: methaemoglobin > HbAo > HbS.
Incubation of endothelial cells with NO donors alone was also shown to 
induce haem oxygenase activity. For example, incubation with GSNO (Figure 
3-1, Figure 3-2 and Figure 3-3) increased haem oxygenase activity in a 
concentration-dependent manner, with 500 pM GSNO showing greater haem 
oxygenase activity than 250 pM GSNO. In addition, endothelial cells treated 
with GSNO alone showed greater haem oxygenase induction at 6 h compared 
with 18 h, reflecting the fact the half-life of GSNO is less than 1 h, after which 
there is a reduction in NO release thus likely affecting the extent of haem 
oxygenase induction. The observed pattern of NO-mediated endothelial haem 
oxygenase induction was also seen with the AS (Figure 3-4), which has a half- 
life of only a few min. Specifically, AS-treated endothelial cells showed 
enhanced haem oxygenase activity at both 6 h and 18 h, with the higher of 
haem oxygenase levels at 6 h reflecting the pattern of NO release from AS. 
Therefore, treatment with GSNO and AS, independently from the NO species 
produced, resulted in enhanced haem oxygenase activity in endothelial cells.
Consistent with our previous findings using free haemin, NO in any 
oxidation state significantly enhanced the induction of HO-1 elicited by all 
haemoglobins at 6 h and 18 h (Figure 3-1, Figure 3-2, Figure 3-3 and Figure
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3-4). The pattern of NO/haemoglobin mediated haem oxygenase induction was 
similar to that seen with cells treated with haemoglobins alone. Specifically, 
endothelial cells incubated with 1 pM methaemoglobin in the presence of NO 
donors showed greater haem oxygenase induction compared with cells 
exposed to 15 pM HbAo and NO donors. In addition, cells treated with HbS and 
NO donors exhibited the lowest haem oxygenase activity. After 18 h, GSNO 
continued to markedly amplify the haemoglobin-mediated increase in haem 
oxygenase activity, while the effect of AS was less pronounced. This is probably 
due again to the short half-life of AS (2-3 min) in physiological buffer, as 
opposed to the long-lasting NO releasing properties of GSNO.
The ability of NO to enhance haemoglobin-mediated haem oxygenase 
activity was also reflected in HO-1 protein production. Western blot analysis 
(Figure 3-1, Figure 3-2 and Figure 3-3), showed that induction of HO-1 protein 
was enhanced by incubation with methaemoglobin, HbAo or HbS alone, with 18 
h showing greater HO-1 protein production than 6 h, thus reflecting the time- 
dependent release of haem. Incubation of cells with GSNO alone also produced 
enhanced HO-1 protein levels, with a higher level of protein detected at 18 h. 
Co-incubation of GSNO with all three haemoglobins showed a greater HO-1 
protein production than that seen with either haemoglobin alone or GSNO 
alone.
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Densitometry (normalised HO-1/(3-actin)
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6h 0.60±0.5 1.42±1.2 2.82±2.1 4.43±3.8
18 h 0.89±1.3 3.59±1.7 9.01±3.7 9.4±3.8
Figure 3-1. GSNO synergizes with methaemoglobin to up-regulate 
endothelial haem oxygenase activity and HO-1 expression
(A) Endothelial cells were exposed for 6 or 18 h to 1 pM methaemoglobin 
(MetHb) in the presence or absence of 250 or 500 pM S-nitrosogluthathione 
(GSNO). Cells were also exposed to GSNO or medium alone (CON). Haem 
oxygenase activity was measured as described in Materials and Methods. (B) 
The expression of HO-1 protein was determined by Western blot technique in 
cells incubated as above. The image is representative of three independent 
experiments and table C reports the mean arbitrary units of the results obtained 
by densitometric analysis of the bands (densitometry normalised to (3-actin). 
Bars represent the mean±SEM of 4-6 independent experiments per group. * 
P<0.05 vs. CON; t  P<0.05 vs. MetHb alone.
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6h 0.92±0.7 1.7811.1 4.26+1.5 8.1014.5
18 h 0.66+0.5 4.33+3.0 7.015.2 15.016.6
Figure 3-2. GSNO synergizes with HbAo to up-regulate endothelial haem 
oxygenase activity and HO-1 expression
(A) Endothelial cells were exposed for 6 or 18 h to 15 pM human haemoglobin 
(HbAo) in the presence or absence of 250 or 500 pM S-nitrosogluthathione 
(GSNO). Cells were also exposed to GSNO or medium alone (CON). Haem 
oxygenase (HO) activity was measured as described in Materials and Methods.
(B) The expression of HO-1 protein was determined by Western blot technique 
in cells incubated as above. The image is representative of three independent 
experiments and table C reports the mean arbitrary units of the results obtained 
by densitometric analysis of the bands (densitometry normalised to p-actin). 
Bars represent the mean±SEM of 4-6 independent experiments per group. * 
P<0.05 vs. CON; f  P<0.05 vs. HbAo alone.
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18 h 0.23±0.2 4.15+2.1 3.79±3.1 8.60±4.7
Figure 3-3. GSNO synergizes with HbS to up-regulate endothelial haem 
oxygenase activity and HO-1 expression
(A) Endothelial cells were exposed for 6 or 18 h to 15 pM sickle cell 
haemoglobin (HbS) in the presence or absence of 250 or 500 pM S- 
nitrosogluthathione (GSNO). Cells were also exposed to GSNO or medium 
alone (CON). Haem oxygenase (HO) activity was measured as described in 
Materials and Methods. (B) The expression of HO-1 protein was determined by 
Western blot technique in cells incubated as above. The image is representative 
of three independent experiments and the table C reports the mean arbitrary 
units of the results obtained by densitometric analysis of the bands 
(densitometry normalised to (3-actin). Bars represent the mean±SEM of 4-6 
independent experiments per group. * P<0.05 vs. CON;  ^ P<0.05 vs. HbS 
alone.
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Figure 3-4. A nitroxyl generator synergizes with different haemoglobins to 
up-regulate endothelial haem oxygenase activity
(A) Endothelial cells were exposed for 6 or 18 h to 1 pM methaemoglobin 
(MetHb) in the presence or absence of 250 pM Angeli’s salt (AS, a nitroxyl 
generator) for the haem oxygenase (HO) activity assay. Cells were also 
exposed to AS or medium alone (CON). Similar experiments were conducted to 
measure haem oxygenase activity with HbAo (B) and HbS (C). For the haem 
oxygenase activity assay, bars represent the mean+SEM of 4-6 independent 
experiments per group. *P<0.05 vs. CON; ^P<0.05 vs. each different 
haemoglobin alone.
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3.4.2 Comparison between haem-nitrosyi and haemin on the stimulation 
of haem oxygenase activity and bilirubin production
The present results show that incubation of endothelial cells with H-NO 
resulted in a higher increase in haem oxygenase activity compared to an 
equimolar concentration of haemin alone after 6 h treatment (Figure 3-6 A). 
However, the combination of haemin with AS was shown to be the most 
powerful in augmenting haem oxygenase, producing almost double the haem 
oxygenase activity observed with H-NO and almost triple the activity seen with 
haemin alone. Western blot analysis showed that HO-1 levels were similar 
following incubation of cells with equal concentrations of haemin or H-NO for 6 
or 24 h (Figure 3-5 B). However, co-incubation of cells with haemin and AS 
showed a far greater amplification in HO-1 protein levels than that observed 
with haemin or H-NO alone (Figure 3-5 B).
BR levels in the culture medium after incubation of endothelial cells with 
H-NO, haemin or haemin and AS were also measured. Incubation of cells with 
equimolar concentrations of haemin and H-NO complex showed comparable 
enhanced levels of BR production, reflecting the breakdown of haem by haem 
oxygenase. However, exposure of cells to haemin and AS together resulted in 
much higher BR levels in the culture medium than seen with either haemin or H- 
NO alone (Figure 3-5 C).
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Figure 3-5. Effect of haem-nltrosyl on haem oxygenase activity, HO-1 
expression and bilirubin production
Cells were incubated with medium alone (CON), haemin (H, 15 pM), haemin in 
the presence of 250 pM AS (H+AS) or a haem-nitrosyl complex (H-NO, 15 pM) 
for 6 or 24 h. At the end of the incubation, samples were collected for (A) the 
haem oxygenase activity assay (6 h) or (B) for determination of HO-1 protein 
levels (6 and 24 h). The Western blot is representative of three independent 
experiments; the table reports the mean arbitrary units of the results obtained 
by densitometric analysis of the bands (densitometry normalised to |3-actin). (C) 
Bilirubin released into the culture supernatant was measured 24 h following 
exposure of cells with medium alone (CON), 15 pM haemin (H), haemin in the 
presence of 250 pM AS (H+AS) or a haem-nitrosyl complex (H-NO, 15 pM). 
Data represent the mean+SEM of 5-6 independent experiments per group. * 
P<0.05 vs. CON;  ^P<0.05 vs. haemin alone.
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3.4.3 Co-incubation of hydroxyurea with haemin or haemoglobins 
enhances endothelial haem oxygenase activity
Since hydroxyurea possesses NO donor properties (Gladwin et a!., 
2002), we investigated whether the drug would influence the Increase in 
endothelial haem oxygenase activity observed upon exposure to haemin, 
methaemoglobin, HbAo, HbS and HbF. As illustrated in Figure 3-6 A, incubation 
of endothelial cells with increasing concentrations of hydroxyurea (0-300 pM, 
300 pM being the therapeutic dose of hydroxyurea) for 6 h had no effect on the 
activity of haem oxygenase. However, co-incubation of hydroxyurea with 15 pM 
haemin resulted in significant enhanced induction of endothelial haem 
oxygenase activity compared to incubation with hydroxyurea or haemin alone 
(Figure 3-6 B).
Comparable results were observed when endothelial cells were co­
incubated with hydroxyurea and various haemoglobins for 6 and 18 h. 
Specifically, co-incubation of cells with methaemoglobin and hydroxyurea 
resulted in enhanced endothelial haem oxygenase activity at both 6 and 18h 
when compared to incubation with methaemoglobin alone (Figure 3-7 A). 
However, co-incubation of 15 pM HbAo or HbS with hydroxyurea only elicited 
enhanced haem oxygenase activity at 18 h when compared with exposure to 
haemoglobins alone, possibly reflecting the time dependent release of haem 
from these two haemoglobins (Figure 3-7 B, C). In contrast, co-incubation of 
hydroxyurea with HbF showed increased haem oxygenase activity only at 6 h 
when compared to HbF incubation, suggesting a difference in the haem 
releasing properties of this particular haemoglobin.
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Figure 3-6. Effect of hydroxyurea alone or in combination with haem on 
haem oxygenase activity
Endothelial cells were incubated with (A) 50 jjM, 100 (jM or 300 [jM 
hydroxyurea (HU) for 6 h and (B) 15 nM haemin (H) in the presence (HU+H) or 
absence of 300 pM HU for 6 h. Cells were also exposed to HU or medium 
alone. At the end of the experiment, samples were collected for the haem 
oxygenase activity. Data represent the mean±SEM of 5-6 independent 
experiments per group. *P<0.05 vs. CON;  ^P<0.05 vs. haemin alone.
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Figure 3-7. Hydroxyurea synergizes with different haemoglobins to up- 
regulate endothelial haem oxygenase activity
(A) Endothelial cells were exposed for 6 or 18 h to: (A) 1 pM methaemoglobin 
(MetHb); (B) 15 pM HbAo; (C) 15 pM HbS and (D) 15 pM HbF, in the presence 
or absence of 300 pM hydroxyurea (HU). Cells were also exposed to medium 
alone (CON). Haem oxygenase activity assay was performed at the end of the 
experiment as described in Materials and Methods. Bars represent the 
meanlSEM of 4-6 independent experiments per group. * P<0.05 vs. CON; 
V<0.05 vs. each different haemoglobin alone.
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3.4.4 NO release from AS and GSNO in medium is affected by the 
presence of haemoglobins
Since incubation of endothelial cells with haemoglobins and NO donors 
enhances haem oxygenase activity we wondered if haemoglobin could 
modulate the release of N0-redox species from GSNO and AS. Our results 
obtained with the NO electrode indicate that two NO donors produced different 
profiles of NO release, consistent with the differing half-lives of the two 
compounds (Figure 3-8, Figure 3-9). In particular, 250 pM GSNO (half-life 
approx. 45 min) showed a more gradual release of NO, while 250 pM AS (half- 
life approx. 2-3 min) showed a very rapid release of NO followed by a fall after 
approximately 5 min. Interestingly, the release of NO from GSNO showed a 
marked reduction in the presence of 15 pM HbAo or HbS (Figure 3-8 B, C). The 
presence of the oxidised methaemoglobin (Figure 3-8 A) promoted a greater 
release of NO compared to GSNO alone. In contrast, all three haemoglobins 
prolonged the release of NO from AS, with methaemoglobin (Figure 3-9 A) 
producing the greatest NO release from the NO donor when compared to HbAo 
and HbS (Figure 3-9 B, C). Therefore, our data suggest that the oxidation state 
of the haemoglobin effects the releasing properties of GSNO and AS.
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Figure 3-8. Release of NO from GSNO In the presence of haemoglobins
An NO electrode was used to detect the amount of NO released from GSNO 
(250 jjM) into medium in the presence of (A) 1 pM methaemoglobin (MetHb) (B) 
15 pM HbAo, and (C) 15 pM HbS. Representative traces of NO detection over 
time are shown.
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Figure 3-9. Release of NO from AS in the presence of haemoglobins
An NO electrode was used to detect the amount of NO released from AS (250 
pM) into medium in the presence of (A) 1 pM methaemoglobin (MetHb) (B) 15 
pM HbAo, and (C) 15 pM HbS. Representative traces of NO detection over time 
are shown.
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3.4.5 NO release from hydroxyurea in the presence or absence of 
haemoglobins
In view of the results obtained with NO donors and haemoglobins, we 
investigated whether the presence of haemoglobins could also affect the 
release of NO from hydroxyurea. We found that 300 pM hydroxyurea did not 
release NO into culture medium (Figure 3-10). In addition, the presence of 1 pM 
methaemoglobin (Figure 3-10 A) or 15 pM HbAo (Figure 3-10 B) did not 
enhance the release of NO from hydroxyurea. In the case of HbS (Figure 3-10 
C), we observed the stimulation of a small amount of NO released from 
hydroxyurea.
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Figure 3-10. Release of NO from hydroxyurea in the presence of 
haemoglobins
An NO electrode was used to detect the amount of NO released from 300 jjM 
hydroxyurea (HU) into medium in the presence of (A) 1 pM methaemoglobin 
(MetHb) (B) 15 pM HbAo, and (C) 15 pM HbS. Representative traces of NO 
detection over time are shown.
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3.5 Discussion
The results reported in this chapter show that co-incubation of three 
different haemoglobins with NO-releasing agents results in enhanced up- 
regulation of HO-1 in bovine aortic endothelial cells. Specifically, we found that 
NO-related species (released by GSNO or AS) co-incubated with reduced 
(HbAo) or oxidized (methaemoglobin) haemoglobin as well as HbS from SCO 
strongly augment endothelial HO-1 expression. H-NO, a complex which forms 
in conditions where NO and haem or haemoglobin are present, was also shown 
to enhance endothelial HO-1 activity compared to haemin alone. NO release 
measurements indicated that haemoglobin affected the release of NO from the 
NO donors AS and GSNO, suggesting that NO and haemoglobin interaction 
may affect NO availability. In addition, while hydroxyurea alone did not enhance 
endothelial haem oxygenase activity, co-incubation of hydroxyurea with haemin 
or haemoglobins enhanced endothelial haem oxygenase activity when 
compared to the individual haemoglobins.
Since the NO molecule can exist in several different redox species, two 
different NO donors were used in this study to establish whether any synergism 
observed between NO and haemoglobin would be dependent on the NO 
species used or the rate of release of NO. The fact that both GSNO and AS 
produced an enhancement in haem oxygenase activity when co-incubated with 
haemoglobin indicates that the synergism observed was independent of NO 
species. However, important differences were also observed: 1) AS, which 
rapidly reacts with haemoglobin to form the ferrous nitrosyl adducts, produced 
the largest and most profound amplification at 6 h incubation; and 2) GSNO 
amplified haem oxygenase activity to a greater extent than AS after 18 h
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incubation. These results suggest that the induction of HO-1 by NO-releasing 
agents correlates better with the rate of liberation of the NO redox form (i.e. the 
half-life of the NO donor rather) than the NO species generated from the 
compound , as already observed in previous reports (Foresti and Motterlini, 
1999; Motterlini et al., 2002b).
It should be noted that incubation of endothelial cells with GSNO alone 
elicited contrasting results when haem oxygenase activity and protein levels 
were compared (Figure 3-1, Figure 3-2 and Figure 3-3). Specifically, GSNO 
enhanced haem oxygenase activity at both 6 and 18 h with the highest levels 
observed at 6 h. Conversely, GSNO stimulated higher HO-1 protein levels at 18 
h than after 6 h. An explanation for these observations could be a potential 
inhibitory action of NO on haem oxygenase activity. Indeed, NO has been 
shown to attenuate the catalytic activity of both HO-1 and HO-2 isoforms of the 
enzyme in several studies (Ding et al., 1999; Wang et al., 2003).
Interestingly, the data obtained with the NO electrode showed that 
haemoglobin may enhance NO bioavailability of NO donors. This was especially 
evident for AS, and among the different haemoglobins methaemoglobin elicited 
the greatest NO release. A possible explanation of these results could be the 
binding of haem with NO species, resulting in a complex which may prolong the 
availability of NO in the medium. Therefore, the observation that 
methaemoglobin promoted the greatest NO release from NO donors could 
result from enhanced release of haem from the oxidised haemoglobin, when 
compared to HbAo an HbS, which could potentially interact with and extend the 
availability of NO. However, a different picture was seen with NO release by 
GSNO, where the presence of HbAo and HbS accelerated the removal of NO
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from the medium, suggesting that NO had been scavenged by the 
haemoglobin. As In the case of AS, methaemoglobin elicited a large NO release 
from GSNO compared with GSNO alone, suggesting that the NO may have 
bound to free haem to form a stable complex. These observations may help to 
understand how NO donors enhanced the induction of HO-1 elicited by 
haemoglobin, although a number of different mechanisms explain this effect. 
For example, the enhanced release of NO from NO donors stimulated by 
haemoglobins could intensify HO-1 up-regulation. Furthermore, NO may form 
complexes with haemoglobin or haem, and these complexes per se may be 
more powerful in inducing HO-1.
It is important to note that many chemical transformations can occur in 
the presence of NO and haemoglobin. Both the NO"" and NO donors used have 
been shown to undergo conversion to NO; for example, GSNO is converted to 
NO by copper (Singh et al., 1996) or haem (Spencer et al., 2000), while AS is 
oxidized to NO by reaction with oxygen (Han et al., 2002). However, despite the 
many fundamental reactions that may occur between the different states of 
haemoglobin and NO or H-NO, the final products appear to be the same in as 
much as the ferrous nitrosyl complex (NO-Hb) will be formed from reactions of 
NO^ donors with deoxy or methaemoglobin, while the reactions of 
oxyhaemoglobin with NO^ generally produce the oxidized methaemoglobin 
(Pawloski et al., 2001). Methaemoglobin will also slowly convert into NO-Hb in 
the presence of NO gas, which exhibits a long half-life in oxygenated solutions 
(Herold and Rock, 2003). Based on these notions, we postulated a key role for 
the ferrous nitrosyl haem in HO-1 induction elicited by co-incubation of haem or 
haemoglobins with NO donors.
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Our findings sustain the idea that H-NO induces greater HO-1 expression 
than haem. However, the effect of H-NO was much less pronounced than that 
obtained with a simultaneous incubation of haemin plus AS, suggesting that 
formation of H-NO may not be the only mechanism involved in the synergism 
seen between haemoglobin and NO donors on HO-1 induction. Another 
potential mechanism is the enhanced release of NO by NO donors in the 
presence of haemoglobins, as highlighted by the NO electrode results.
The type of haemoglobin used appeared to be an important factor 
affecting the extent of HO-1 induction. Methaemoglobin, used at a concentration 
of only 1 pM due to its cytotoxic effects, stimulated levels of HO-1 induction 
comparable to 15 pM HbAo and HbS. In addition, 1 pM methaemoglobin 
incubated with NO donors resulted in a greater enhancement of haem 
oxygenase activity compared to that obtained with HbAo or HbS. These results 
suggest that oxidised haemoglobin is a better inducer of HO-1 and that NO- 
related species may synergize more efficiently with oxidized haemoglobin to 
induce HO-1. This point is corroborated by the observation that higher levels of 
HO-1 expression were measured after 18 h incubation compared to 6 h for both 
HbAo and HbS, suggesting that up-regulation of HO-1 relies on the time- 
dependent oxidation of haemoglobins, with subsequent conversion into 
methaemoglobin and increased release of haem. Since HbS is known to be 
more susceptible to haem loss (Reiter et al., 2002), it was surprising to observe 
that co-incubation of HbS with NO donors elicited a smaller amplification effect 
in comparison with HbAo. Recent reports highlighting the impaired reactivity and 
processing of NO by the mutated HbS molecule may explain the observed 
results, as it has been postulated that abnormal binding of NO to sickle red
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blood cells may be partly responsible for the abnormal vasodilatation seen in 
this disease state (Pawloski et al., 2005).
The increased haem oxygenase activity observed following co-incubation 
of haemin or haemoglobins with hydroxyurea is also an interesting finding. 
Although the main therapeutic benefit of hydroxyurea treatment in SCD is 
attributed to enhancement of HbF production and consequent reduction of 
unstable HbS (Gladwin et al., 2002), our findings indicate another potential 
therapeutic mechanism of action for the drug through up-regulation of haem 
oxygenase and the production of the protective breakdown products of haem. 
The variation in the magnitude of haem oxygenase induction between the 
different haemoglobins may again be explained by differences in the properties 
and haem release of the individual haemoglobins. Notably, hydroxyurea alone 
did not enhance endothelial haem oxygenase activity, but requires the presence 
of haemin or haemoglobin. If NO release by hydroxyurea is part of the 
mechanisms mediating haem oxygenase induction when the drug is incubated 
with haem or haemoglobins, it could be speculated that hydroxyurea may act by 
transferring NO to a haem or haemoglobin molecule (Jiang et al., 1997), 
thereby forming a complex responsible for up-regulation of haem oxygenase. 
Sustaining this idea are the findings that sickle cell patients receiving 
hydroxyurea treatment exhibit increased levels of nitrosylated haemoglobins 
(Gladwin et al., 2002). These patients were also found to have high plasma 
nitrite and nitrate levels, suggesting that an NO species was indeed being 
generated from hydroxyurea. We observed that HbS, but not the other 
haemoglobins tested, elicited a slight increase of NO release from hydroxyurea 
suggesting that the abnormal chemical structure of HbS has a role in promoting
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the release of NO from hydroxyurea. However, there are many other 
components in the blood of sickle cell patients which may influence the release 
of NO from hydroxyurea and it would be difficult to reproduce the same 
pathophysiological scenario in our experiments. Interpreting our results from a 
clinical perspective, enhanced haem oxygenase activity could only take place 
under conditions of haemolysis, a characteristic of SCD (Bunn, 1997) where 
both hydroxyurea and haem/haemoglobin would be present. This may provide 
beneficial outcomes, as hydroxyurea would trigger HO-1 induction only when it 
was needed, i.e. during a vascular occlusive crises when red blood cells would 
sickle and release HbS. In addition, although the scavenging of NO by 
haemoglobins has often been considered as having detrimental effects on 
vascular homeostasis (Reiter et al., 2002), this same reaction may represent a 
protective mechanism in preventing the deleterious effects of excess haem 
observed in haemolytic condition such as SCD, since the interaction of NO and 
haem/haemoglobin leads to enhanced levels of the cytoprotective HO-1.
In conclusion, our results demonstrate a synergism between NO and 
haem/haemoglobin in up-regulating HO-1 in endothelial cells and resulting in 
increased production of haem metabolic products. The formation of a H-NO 
complex may be one of the possible mechanisms involved in this effect in 
conjunction with changes in the release of NO by NO donors in the presence of 
haemoglobin. Extending these findings to hydroxyurea, the observation 
reported in this chapter may have important implications for SCD and other 
haemolytic disorders.
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Chapter 4. Effect of NO and haemoglobin interaction on 
endothelial haem uptake
4.1 Introduction
Despite haem being a vital molecule involved in many essential cellular 
functions, free haem is a highly toxic molecule and promotes oxidative stress 
(Ponka, 1999). Therefore, cells have evolved specific mechanisms to maintain 
free toxic haem or haemoglobin at low concentrations; among these are 
systems controlling the synthesis and degradation of haem by the enzymes 
ALA synthase and haem oxygenase, respectively. In addition, the binding of 
haem to specific protein carriers such as albumin, haemopexin or haptoglobin 
(Morgan et al., 1976);(Kristiansen et al., 2001) contributes to fine control of the 
potential toxicity of this porphyrin molecule.
Increased extracellular haem results in an increase in uptake of haem 
into cells and this may be important in the pathological states characterized by 
elevated haem levels such as endotoxic/haemorrhagic shock or SCD. For 
example, the incorporation of haem intracellularly, which may or may not be 
regulated by external factors, may participate in the resolution of these 
pathological states via HO-1 induction.
Our previous work investigating the influence of NO on haem-mediated 
modulation of endothelial HO-1 expression led us to some intriguing findings 
(Foresti et al., 2003), whereby co-incubation of endothelial cells with haemin 
and NO resulted in an increase in haem uptake and a subsequent magnification 
in endothelial HO-1 induction. We propose that similar reactions might take 
place when elevated levels of haem are associated with elevated levels of NO
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in disease states and the results presented in the previous chapter also support 
a synergistic action of NO and haemoglobins in up-regulating HO-1. The aim of 
the present chapter was to examine the effect of NO donors and hydroxyurea 
on the uptake of haem promoted by incubation of endothelial cells with different 
haemoglobins.
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4.2 Objectives
• To study the effect of co-incubation of various haemoglobins with NO 
donors on the uptake of haem by endothelial cells
• To investigate the effect of haem-nitrosyl complex (H-NO) on the uptake 
of haem by endothelial cells
• To investigate the effect of co-incubation of various haemoglobins with 
hydroxyurea on the uptake of haem by endothelial cells
• To explore the possible mechanism of action of NO on enhanced haem 
uptake
• To examine the effect of haem and NO incubation on various cell types
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4.3 Experimental protocol
The specific methods used in the experiments described in the following 
section can be found in the Materials and Methods chapter. Stock solutions of 
haemoglobins (methaemoglobin, HbAo, HbS) and H-NO were prepared in PBS 
and a stock solution of Angeli’s salt (AS) was prepared in 0.01 M NaOH. 
Hydroxyurea stock solutions (10 mM) were prepared in distilled water. A stock 
solution of haemin (1 mM) was prepared by dissolving it in 0.1 M NaOH and 
then adding 0.01 M phosphate buffer at pH 7.4. Haemoglobins were be stored 
at -80°C, whereas H-NO, haemin, hydroxyurea and AS were prepared fresh for 
each experiment. Incubations were carried out in the dark due to the light 
sensitive nature of the reagents.
4.3.1 Incubation of cells with reagents
To determine the influence of NO or nitroxyl on endothelial haem uptake, 
endothelial cells were incubated with 15 pM haemin, 1 pM methaemoglobin, 15 
pM HbAo or 15 pM HbS in the presence or absence of AS (250 pM) and haem 
content was measured after 2, 4 and 6 h. The effects of a pure haem-nitrosyl 
complex (15 pM) on haem uptake were also investigated. The influence of 
serum albumin on haem uptake was analyzed by incubating cells with haemin 
(15 pM) in serum-free medium or serum-free medium containing bovine serum 
albumin (5 or 30 pM). Control experiments were also carried out by exposing 
cells to medium alone or AS alone.
To investigate whether AS was increasing haem uptake due to a direct 
influence of nitroxyl on the ability of cells to incorporate haemin or because of a
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direct chemical interaction of haemin and nitroxyl, experiments were carried out 
exposing cells to AS (250 pM) 5 min prior to addition of haemin. Considering 
that AS has a half-life of 2-3 min in physiological solutions, 5 min was estimated 
to be an adequate time before addition of haemin. Also, haem content was 
measured in renal epithelial cells, Girardi cells and RAW 264.7 macrophages 
exposed to haemin in the presence or absence of AS. The influence of 
hydroxyurea on endothelial haem uptake was investigated. Cells were 
incubated with haemin (15 pM) or three haemoglobins (HbAo, HbS, 
methaemoglobin) in the presence or absence of hydroxyurea (300 pM) and 
haem content was measured after 2. 4 and 6 h.
4.3.2 Assay for determination of cellular haem content
The haem content was determined as described in section 2.10. Briefly, 
at the end of the incubation cells were washed twice with warm PBS, followed 
by addition of 1 ml formic acid to solubilise the endothelial layer. The haem 
concentration in the formic acid solution was measured spectrophotometrically 
at 398 nm (s = 1.56 X 10^ M’^cm’ )^. Haem uptake was expressed as pmol/well.
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4.4 Results
4.4.1 Effect of AS on endothelial haem uptake elicited by haemoglobins
The experiments conducted here were performed with AS based on the 
assumption that, if any modulation of haem uptake was to be observed, we 
would be able to detect it within a short period of time because of AS’s short 
half-life. Figure 4-1 shows that endothelial cells treated with AS did not exhibit 
changes in haem levels, while incubation with the different haemoglobins 
resulted in enhanced haem uptake. Interestingly, the pattern of haem uptake 
was dependent on the haemoglobin used. Specifically, exposure of cells to 
methaemoglobin showed a continuous incorporation of haem over the 6 h 
period (Figure 4-1 A), whereas HbAo caused a peak of haem uptake at 2 h 
followed by a fall over the next 4 h (Figure 4-1 B). In contrast, HbS did not 
change haem levels until 4 h of incubation and this was followed by a fall at 6 h 
(Figure 4-1 C). The data indicate that methaemoglobin elicited the highest 
increase in cellular levels, followed by HbS and HbAo.
The effect of co-incubation of AS with haemoglobins on endothelial haem 
uptake depended again on the type of haemoglobin employed. As shown in 
Figure 4-1 A, haem incorporation at 2 and 4 h was similar between cells 
incubated with methaemoglobin alone or in combination with AS; however, after 
6 h haem uptake was significantly lower with methaemoglobin plus AS than with 
methaemoglobin alone. In contrast, AS enhanced cellular haem levels in the 
presence of HbAo or HbS (Figure 4-1 B, C) at all time points considered. In 
particular, co-incubation of HbAo with AS showed enhanced haem uptake at 4 h
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followed by a fall at 6 h. In contrast, HbS caused a continuous accumulation of 
haem in the presence of AS over the 6 h period.
Overall, these results indicate that the presence of AS enhanced haem 
uptake when cells were co-incubated with HbAo or HbS, but this effect was not 
reproduced with methaemoglobin.
130
B225
75
S I
2  I  150 
Q . c
3 %
E f0) O
xi
-CON
MetHb (1 nM) 
-AS (250 hM) 
MetHbMS
II
I  ô
51
100
75
50
25
0) =  
Hlî
125
100
75
50
25
1 2 3 4 5
Time (h)
-CON
HbAo (15 |iM)
-AS (250 |iM)
HbAo+AS *t
0 1 2 3 4 5 6
Time (h)
-CON
HbS (15 nM)
-AS (250 MlVI) _ 
HbS-t-AS
2 3 4 5 6
Time (h)
Figure 4-1. A nitroxyl generator synergizes with different haemoglobins to 
up-regulate endothelial haem uptake
For the haem uptake experiments, endothelial cells were exposed to medium 
alone (CON), Angeli’s salt (AS) or MetHb in the presence or absence of AS and 
haem levels were assessed after 0, 2, 4 or 6 h incubation (A). Similar 
experiments were conducted with HbAo (B) and HbS (0). Data represent the 
mean±SEM of 6 independent experiments per group. * P<0.05 vs. CON; 
^P<0.05 vs. each different haemoglobin alone.
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4.4.2 Comparison between haem-nitrosyl and haemin on changes of 
cellular haem levels
Based on the findings showing enhanced haem uptake when haemin 
and NO were co-incubated, we postulated in the previous chapter that the 
formation of H-NO complexes could partially explain this effect. To test this 
hypothesis, we performed experiments using a pre-synthesized H-NO complex 
and compared its effect on cellular haem levels with that elicited by free haemin 
alone or by free haemin incubated with AS.
We observed that treatment with 15 pM haemin alone enhanced haem 
uptake, with a peak at 4 h followed by a fall at 6 h indicative of degradation of 
haem by haem oxygenase (Figure 4-2). Co-incubation of endothelial cells with 
haemin and AS confirmed an enhancement of haem uptake at all time points 
compared to incubation with haem alone. The highest haem uptake was 
observed at 2 h and was followed by a fall over the remaining time points, 
possibly reflecting enhanced degradation of haem. Incubation of cells with 15 
pM H-NO showed greater incorporation of haem at all time points when 
compared to equimolar concentrations of haemin alone. However. H-NO 
caused lower haem incorporation at 2 and 4 h compared to co-incubation with 
haemin and AS. H-NO also elicited a continuous increase in incorporation of 
haem over the 6 h period, possibly reflecting an impediment to haem 
degradation.
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Figure 4-2. Effect of haem-nitrosyl complex (H-NO) on haem uptake
Cells were exposed to medium alone (CON), haemin (H, 15 pM), haemin in the 
presence of 250 pM AS (H+AS) or a H-NO complex (H-NO, 15 pM) and haem 
uptake was determined at 0, 2, 4 and 6 h as described in Materials and 
Methods. Data represent the mean±SEM of 5-6 independent experiments per 
group. * P<0.05 vs. CON;  ^P<0.05 vs. haemin alone.
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4.4.3 Effect of bovine albumin on increased haem uptake mediated by AS
From the results presented in this chapter we can postulate that; 1 ) a H- 
NO complex could form during co-incubation of haemin with AS and be taken 
up more efficiently by endothelial cells; and 2) since haem uptake in cells 
incubated with haemin and AS was much higher than with pure H-NO, the 
formation of this complex may not be the only mechanism by which AS strongly 
magnifies the incorporation of haem in endothelial cells. Therefore, we 
examined whether AS could directly affect the ability of cells to uptake haem by 
pre-exposing them to the nitroxyl donor 5 min prior to addition of haemin. Due to 
the short half-life of AS, pre-incubation with AS should prevent (or considerably 
reduce) the interaction of the nitroxyl donor with haem.
Notably, we observed that the haem content of cells pre-incubated with 
AS followed 5 min later by addition of haemin was even higher than that 
measured when cells were incubated with haemin alone or haem plus AS 
(Figure 4-3 A). This observation strongly suggests that nitroxyl could possibly 
interact with cells or cell membranes and favour an increased transport of haem 
in the endothelial cell. Again, a peak of haem uptake was seen at 4 h followed 
by a fall at 6 h, reflecting the degradation of haem by haem oxygenase.
The effect of bovine albumin on haem uptake was also investigated. 
Albumin is a serum protein that binds haem non-specifically. Therefore, it was 
not surprising to observe that albumin decreased cellular haem incorporation in 
a concentration-dependent manner (Figure 4-3 B), as demonstrated previously 
in rat aortic tissue (Bui et al., 2004). AS was able to enhance haem uptake even 
in the presence of albumin. In fact, the pmol of haem/well measured at 2 h were 
665.6 ± 28, 146.4 ± 5 and 263.9 ± 19 for haemin alone, haemin incubated with
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5 fjM albumin or haemin incubated with 5 pM albumin in the presence of AS, 
respectively. Unlike the previous experiments, the data presented in Figure 4-3 
were obtained from cells incubated in serum-free medium in order to evaluate 
the real effect of AS or albumin on haem uptake without the interference of 
serum components.
In summary, the uptake of haem in endothelial cells can be influenced by 
pre-incubating cells with AS, with NO having a possible action on cellular 
membranes to enhance the incorporation of haem. The presence of albumin in 
the medium also reduces the level of haem incorporated into the cells.
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Figure 4-3. Pre-incubation with AS and bovine serum albumin modulate 
haem uptake by endothelial cells
(A) Cells were exposed to medium alone (CON), 15 pM haemin (H), 250 pM 
AS, haemin and AS (H+AS) or pre-incubated with AS for 5 min prior to addition 
of haemin (AS(PI)+H). Haem uptake was assessed at 0, 2, 4 and 6 h as 
described in Materials and Methods. (B) Cells were incubated in medium alone 
(CON), haemin (H, 15 pM) or haemin in the presence of 5 or 30 pM bovine 
albumin (H+Alb). Haem uptake was determined at 0, 2, 4 and 6 h. All sets of 
experiments were performed in the absence of foetal bovine serum to avoid 
interference with serum components. Data represent the mean+SEM of 5-6 
independent experiments per group. * P<0 05 vs. CON;  ^ P<0.05 vs. haemin 
alone.
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4.4.4 Measurements of haem uptake in different cell types
With the constant exposure of the vasculature to free haemoglobin and 
NO, it is possible that endothelial cells might have evolved specific adaptive 
mechanisms to deal with these potentially toxic compounds. Haemolytic 
conditions such as SCO and thalasseamia can increase deposition of haem- 
derived iron in organs such as the kidney and heart due to elevated levels of 
circulating haem leading to tissue dysfunction (Cohen et al., 2004; Kirkizlar et 
al., 2007). Furthermore, increased levels of circulating haem also provoke 
inflammatory responses in conditions such as SOD (Chies and Mardi, 2001), 
resulting in high numbers of circulating activated macrophages. We therefore 
were interested in Investigating whether NO could modulate the transport of 
haem in renal cells, cardiac cells and macrophages, as these particular cell 
types would be vulnerable to high levels of toxic haem in haemolytic conditions.
Figure 4-4 shows the haem levels measured in porcine renal epithelial 
cells (Figure 4-4 A), human adult atrial myoblast cells (Girardi cells) (Figure 4-4 
B) and murine RAW 264.7 macrophages (Figure 4-4 C) following incubation 
with haemin in the presence or absence of AS. Treatment of cells with AS alone 
did not change the haem content of cells. In contrast, incubation with haemin 
alone enhanced haem uptake in the three cell types to varying degrees. Girardi 
cells showed the highest levels of haem incorporation. It is important to note 
that Girardi cells displayed an intrinsically higher haem content at basal 
conditions compared to renal cells and macrophages. This is explained by the 
fact that cardiac cells contain high levels of myoglobin and many mitochondria 
enclosing haem-dependent cytochromes. Co-incubation of the three cell types 
with AS and haemin increased the uptake of haem with the effect being more
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pronounced in Girardi cells and macrophages. In fact, exposure of Girardi cells 
and macrophages to AS and haem doubled cellular haem incorporation when 
compared to haem alone, a result that was comparable to earlier experiments 
with endothelial cells.
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Figure 4-4. Haem uptake in different cell types
Renal epithelial cells (A), Girardi cells (B) and RAW 264.7 macrophages (C) 
were exposed to medium alone (CON), 15 pM haemin (H), AS. (250 pM) or 
haemin in the presence of AS (H+AS). Haem uptake was measured at 0, 2, 4 
and 6 h. Data represent the mean±SEM of 5-6 independent experiments per 
group. * P<0.05 vs. CON;  ^P<0.05 vs. haemin alone.
139
4.4.5 Co-incubation of hydroxyurea with haemin or haemoglobin does 
not affect endothelial haem uptake
Hydroxyurea is thought to act in a similar way to NO donors (King, 2004) 
so it was of interest in the present studies to investigate the effect of co­
incubation of hydroxyurea with haemin or haemoglobin on haem uptake in 
endothelial cells.
We found that co-incubation of either haemin or haemoglobin with 
hydroxyurea did not affect the endothelial haem uptake when compared to 
haemin (Figure 4-5) or haemoglobin (Figure 4-6) alone at any of the time points 
considered.
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Figure 4-5. Effect of hydroxyurea and haemin on haem uptake
Endothelial cells were exposed to medium alone (CON), 15 pM haemin (H), 
hydroxyurea (HU, 300 pM) or haemin in the presence of HU (H+HU). Haem 
uptake was measured at 0, 2, 4 and 6 h. Data represent the mean±SEM of 5-6 
independent experiments per group. * P<0.05 vs. CON;  ^ P<0.05 vs. haemin 
alone.
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Figure 4-6. Effect of hydroxyurea and haemoglobins on haem uptake
Cells were exposed to medium alone (CON), 300 pM hydroxyurea (HU) or 1 pM 
methaemoglobin (MetHb) in the presence or absence of HU and haem levels 
were assessed after 0, 2, 4 or 6 h incubation (A). Similar experiments were 
conducted to measure haem uptake with 15 pM HbAo (B) and 15 pM HbS (C). 
Data represent the mean±SEM of 6 independent experiments per group. 
*P<0.05 vs. CON.
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4.5 Discussion
Endothelial cells can incorporate haem where it is subsequently 
degraded by the haem oxygenase system, thereby limiting its pro-oxidant 
effects (Ponka, 1999). However, the mechanism behind the uptake of haem into 
endothelial cells is yet to be elucidated and receptors involved in the transport 
of haem have not been discovered on the surface of endothelial cells. Our 
group has previously shown that haem transport into endothelial cells and the 
consequent induction of haem oxygenase can be modulated by NO (Foresti et 
al., 2003) and in the present chapter we have demonstrated that NO synergizes 
with three distinct haemoglobins to enhance the increase the uptake of haem 
and subsequent induction of HO-1 in bovine aortic endothelial cells. We also 
observed that the haem content is higher in cells exposed to a H-NO complex 
compared to an equal concentration of haemin, suggesting that H-NO might 
have enhanced lipophylic properties. Therefore, we postulate that NO is an 
important exogenous factor in modulating the uptake of haem and consequent 
induction of endothelial HO-1. In contrast, we found that hydroxyurea did not 
enhance the endothelial haem uptake elicited by haemin or haemoglobins.
Although, all three haemoglobins synergized with NO to enhance 
endothelial haem uptake, methaemoglobin alone caused a continuous 
accumulation of cellular haem during the time course of our experiments. An 
explanation for this observation could be enhanced haem generation from 
methaemoglobin in comparison to the HbAo and HbS over the time period of the 
experiment. Exposure of cells to methaemoglobin in the presence of NO 
resulted in a fall in haem content after 4 h, indicating endogenous degradation 
of haem by haem oxygenase and suggesting that NO donors stimulate haem
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catabolism. Following co-incubation of cells with NO and HbAo or HbS we 
observed enhanced haem uptake compared with the haemoglobins alone, but 
the profiles of haem incorporated differed between the two haemoglobins. The 
fact that the combination of NO and HbS promoted a continued accumulation of 
haem over 6 h whereas haem levels started to decrease after 4 h of incubation 
with NO and HbAo suggest that the interaction of the two haemoglobins with NO 
is different. Indeed, there is indication in the literature of an abnormal reactivity 
of HbS with NO which influences vascular functions (Pawloski et al., 2005) . 
Since the interaction of NO and reduced haemoglobin results in the production 
of methaemoglobin and nitrate, we envision that in our experiments the 
oxidation of HbAo and HbS leads to formation of methaemoglobin, which easily 
releases haem that is more readily incorporated into cells. NO could also bind 
haemoglobins and form H-NO complexes that are easily taken up by cells. Our 
findings that the H-NO complex enhanced the uptake of haem in endothelial 
cells and induction of HO-1 compared to haemin alone support this hypothesis. 
It is conceivable that H-NO may bind to potential membrane receptors with a 
higher affinity compared to haemin, although we recognise this to be a 
speculative idea. Alternatively, H-NO and haemin might incorporate into cells in 
a similar manner but H-NO may be more difficult to degrade by HO-1 than 
haemin alone. This interpretation is supported by the results showing that H-NO 
only caused marginal enhancement in BR levels compared to haemin alone and 
has been proposed previously by another group (Juckett et al., 1998). Indeed, 
Juckett and co-workers have suggested that H-NO complexes aggregate in 
microsomal membranes to sequester free haem intracellularly, protecting it from 
haem oxygenase-mediated catabolism, which was reflected in their observation
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that H-NO inhibits HO-1 activity. In contrast, we have seen that pure H-NO 
enhances HO-1 induction compared to haemin alone. Intriguingly, high levels of 
H-NO complexes have been found to form in ischaemic heart tissue, where 
nitrite-mediated H-NO formation occurs progressively during ischaemia 
(Tiravanti et al., 2004). In this context, haem molecules, through formation of H- 
NO, act as potential stores of NO, with subsequent activation of NO signalling 
pathways on reperfusion. It is possible that the formation of H-NO is a 
mechanism to limit the potential oxidative and nitrosative damage exerted by 
free haem and NO, especially in pathophysiological conditions characterized by 
raised levels of both these potential hazardous substances.
Our findings have shown that H-NO induces HO-1 and increases haem 
levels to a greater extent than haemin alone but to a lower degree than haemin 
plus AS. This suggests that H-NO formation is implicated in the HO-1 induction 
and haem uptake observed upon co-incubation of haemoglobins and NO, but 
also emphasises that such a mechanism cannot fully explain this phenomenon. 
Our results showing that pre-incubation of endothelial cells with AS increased 
the ability of cells to uptake haem, suggest that NO affects the surface of the 
endothelial cell membrane, either in modulating the binding properties of 
potential haem transport proteins (receptors or carrier proteins) or directly 
influencing the permeability of cellular membrane thus stimulating the 
incorporation of haem into the cell.
Of interest, we found that the carrier protein albumin reduced the uptake 
of haem by endothelial cells and that the addition of AS still enhanced haem 
uptake in the presence of albumin. This suggests the mechanisms underlying
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AS-mediated increase in cellular haem incorporation occur even in a more 
complex biological solution containing albumin.
Significantly, we found that AS could also enhance the incorporation of 
haem in renal epithelial cells, Girardi cells and macrophages in a comparable 
manner to that observed in endothelial cells. These data suggest that the effect 
of NO on enhancing cellular haem uptake is not limited to endothelial cells but 
could represent an adaptive mechanism for all tissue exposed to high levels of 
haem. Indeed, in haemolytic diseases such as SCO, tissue and organ damage 
results from high levels of free toxic haem (Nath et al., 2001a; Redding-Lallinger 
and Knoll, 2006) and our observations of NO-enhanced cellular transport in 
renal and cardiac cells may provide a strategy for protection against haem- 
mediated injury and organ dysfunction in haemolytic diseases. Elevated levels 
of haem also elicit inflammatory responses in conditions such as SCD (Chies 
and Nardi, 2001), and the enhanced incorporation of haem by NO we observed 
in macrophages could provide an additional mechanism to modulate 
inflammatory responses in haemolytic states through the increased removal of 
the pro-inflammatory haem molecule.
Our initial hypothesis that hydroxyurea could influence haem uptake by 
virtue of its NO-donor properties was not confirmed in the present study, nor 
with haemin or with the different haemoglobins analysed. These results were 
partly expected, since co-incubation of hydroxyurea with haemoglobin did not 
produce an evident increase (with the exception of a slight effect with HbS) in 
NO release from hydroxyurea as measured with the NO electrode (see previous 
chapter). We can also postulate from this set of experiments that the synergism 
in haem oxygenase activation observed with simultaneous exposure of haemin
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or haemoglobin with hydroxyurea (see previous chapter) is independent from 
effects on haem. Clearly, there are a series of unidentified mechanisms 
explaining the interaction of hydroxyurea and haemoglobins that need to be 
explored.
In conclusion, the interaction of haemin/haemoglobin and NO increases 
the uptake of haem in endothelial cells as well as the activity of haem 
oxygenase. This effect has also been seen in a variety of cell types, suggesting 
a novel role for NO in the modulation of haem transport. The synergism elicited 
by NO and haemoglobin/haemin on the induction of HO-1 may have a potential 
role in the treatment of conditions characterized by increased levels of haem 
and NO such as SCD, haemolytic or haemorrhagic shock.
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Chapter 5. Effect of sickle blood on endothelial haem 
oxygenase
5.1 Introduction
SCD arises from a single point mutation in the fi-globin gene (glutamic 
acid is replaced by valine), which subsequently results In the production of HbS. 
Deoxygenation causes HbS to polymerise and red blood cells to take on the 
characteristic sickle shape. This leads to erythrocyte rigidity, membrane 
damage, haemolysis and resulting damage to tissues and organs (Bunn, 1997). 
The most successful strategy to prevent red blood cell sickling is by promoting 
increased HbF production in SCD patients, thus reducing the intracellular 
polymerization of HbS and the sickling effect. This is the mechanism by which 
hydroxyurea has been selected as the current preferential pharmacological 
approach to ameliorate SCD. However, even under hydroxyurea treatment, 
sickle patients still exhibit a persistent inflammatory state as well as haemolysis 
(Jison et al., 2004), indicating the need to find new alternative therapies for the 
disease. HO-1 induction has been demonstrated in various cell types in SCD, 
such as leukocytes (Jison et al., 2004), kidney tissue and circulating endothelial 
cells (Nath et al., 2001a) and limited evidence in the literature suggests that the 
biproducts of haem degradation by haem oxygenase exert important actions in 
SCD. In fact, Beutler demonstrated in 1975 that CO significantly prolongs red 
cell survival in SCD (Beutler, 1975) and BR was more recently reported to be a 
significant anti-oxidant in the plasma of SCD patients (Dailly et al., 1998). Taken 
together, these preliminary observations suggest that investigations into the role
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of HO-1 in SCD may have Important implications for understanding the 
pathology of SCD and for future therapeutic strategies.
We aimed in the present chapter to examine the effect of blood from 
sickle patients on haem oxygenase induction in endothelial cells and to identify 
factors, such as treatment regimen or patient characteristics that influence this 
effect.
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5.2 Objectives
To investigate whether whole sickle blood affects haem oxygenase 
activity level in endothelial cells
To assess the effect of the single blood components, sickle plasma and 
red blood cells, on haem oxygenase activity in endothelial cells
To examine whether hypoxia influences the increase in endothelial haem 
oxygenase activity elicited by sickle blood or haemoglobin
To study the effect of hydroxyurea on sickle blood or haem-mediated 
increase in haem oxygenase under normoxic and hypoxic conditions
To identify whether treatment regimen, number and timing of vaso- 
occlusive crises as well as patient characteristics (gender, age, 
haemoglobin, BR and LDH levels) are correlated with haem oxygenase 
activity
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5.3 Experimental protocol
The detailed methods used in the experiments described in the following 
section can be found in the Materials and Methods chapter. All stocks were 
freshly prepared. Hydroxyurea stock solutions (10 mM) were prepared in 
distilled water. A stock solution of DETA-NO (10 mM) was prepared in 0.01 M 
NaOH. Whole blood was collected fresh in EDTA tubes from sickle patients 
and controls as described below.
5.3.1 Patient population
One hundred and ten patients with SCD were recruited for the study. 
Patients attended the Sickle Cell Clinic at Central Middlesex Hospital (London, 
UK) and were asked to provide a blood sample for research purposes. Eligibility 
criteria included all forms of SCD (genetic backgrounds: HbSS, HbSC, and 
HbSpThal), patients over the age of 12 months, and patients either receiving or 
not receiving hydroxyurea treatment. Patient characteristics can be found in the 
results section (Table 5-1). Information provided on the samples included: SCD 
genotype, whether the patient was receiving hydroxyurea or transfusion 
therapy, the current disease status (steady state or active crisis), the date of the 
last transfusion or last crisis, the number of crises in the last year, and LDH, BR 
and haemoglobin levels. LDH and BR levels were measured by the 
haematology laboratory at Central Middlesex Hospital using an Abbott Architect 
ci8200 integrated analyzing system and haemoglobin levels were measured 
with a Beckman Coulter LH 750 analyser using standardised assay kits. The 
study was approved by the Central Office of Research Ethics Committees 
(COREC). Plasma from a subset of 13 subjects from the patient population was 
tested for albumin, urea, creatinine, cholesterol, high density lipoprotein
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cholesterol (HDL-C), total BR and uric acid with standardised kits using a ILab 
650 Clinical Chemistry system at Northwick Park Institute of Medical Research. 
Twenty healthy individuals not suffering from SCD were recruited as a control 
population for comparison (Table 5-2).
5.3.2 Incubation of cells with reagents
Sickle blood was collected in EDTA-coated tubes and stored at 4°C until 
required; blood was used within 24 h from collection. In some experiments 
sickle or normal blood components were used, therefore whole blood was 
separated by centrifugation at 100 g for 5 min. The plasma was then removed 
and red blood cells washed with PBS before use. Red blood cells were used 
immediately, whereas plasma was stored at -80°C until required.
Initially, the ability of sickle blood to affect endothelial haem oxygenase 
activity at 21% oxygen was investigated. Preliminary experiments were 
designed to explore the percentage of blood in medium which would elicit 
endothelial haem oxygenase induction. Endothelial cells were incubated with 5, 
10 and 20% whole normal blood in media for 6 h and 20% whole blood was 
found to be sufficient to induce haem oxygenase activity. Therefore, all 
subsequent experiments were conducted using medium containing 20% whole 
sickle or control blood for 6 or 18 h. In the next set of experiments, we explored 
the effect of blood components, plasma or red blood cells, on endothelial haem 
oxygenase activity. Endothelial cells were exposed for 6 or 18 h to either 10% 
plasma or washed red blood cells (from sickle or control blood) in medium.
A primary feature characterizing SCD is polymerization of deoxygenated 
HbS which leads to deformation of erythrocytes and haemolysis (Bunn, 1997). 
Therefore, the influence of hypoxia on the ability of sickle blood to induce haem
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oxygenase activity was examined by exposing endothelial cells to 20% whole 
sickle blood for 18 h under low oxygen tension (1%02). These experiments 
were also carried out in the presence or absence of hydroxyurea (300 pM).
Experiments were also conducted by incubating cells with 15 pM HbAo or 
HbS at 1% O2 for 18 h in the presence or absence of hydroxyurea (300 pM). It 
has recently been shown that NO synergises with different haemoglobins to 
stimulate endothelial HO-1 expression (Foresti et al., 2003). In the context of 
the present study, it was assessed whether a similar phenomenon could be 
replicated with sickle blood. Experiments were performed by incubating cells 
with 20% whole blood in the presence or absence of 250 pM S- 
nitrosoglutathione (GSNO, 6 h) or 300 pM hydroxyurea (18 h). Some of the 
experiments described above were also performed for determination of HO-1 
protein levels.
5.3.3 Haem oxygenase activity assay
Haem oxygenase activity was determined in endothelial cells at different 
times after treatment as described in section 2.7 Briefly, harvested cells were 
subjected to three cycles of freeze-thawing before addition to a reaction mixture 
containing NADPH, rat liver cytosol as a source of BVR, and the substrate 
haemin. The reaction was conducted at 37 °C in the dark for 1 h, terminated by 
the addition of 1 ml chloroform, and the extracted BR was calculated by the 
difference in absorbance between 464 and 530 nm (s = 40 mM'^cm'^).
5.3.4 Western-blot technique for detection of HO-1 protein expression
Samples of endothelial cells also underwent Western immunoblot 
analysis, as described in section 2.9. Briefly, an equal amount of proteins (30
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|jg) for each sample was separated by SDS-polyacrylamide gel electrophoresis, 
transferred overnight to nitrocellulose membranes, and the non-specific binding 
of antibodies was blocked with 3% non-fat dried milk in PBS. Membranes were 
then probed with a polyclonal rabbit anti-HO-1 antibody (Stressgen, Victoria, 
Canada) (1:1,000 dilution in Tris-boffered saline, pH 7.4). After three washes 
with PBS containing 0.05% (v/v) Tween 20, blots were visualized using an 
amplified alkaline phosphatase kit from Sigma (Extra-3A) and subjected to 
densitometric analysis. To ensure equal loading, cell samples also underwent 
Western-blot analysis for the house-keeping gene p-actin.
5.3.5 Statistical analysis
One way AN OVA was performed to study the effects of sickle blood 
exposure on endothelial haem oxygenase activity. Two-sided probability values 
were calculated by unpaired t-test for comparison between patients on different 
treatment regimens or in disease states. Pearson’s correlation was performed 
to evaluate the effect of patient characteristics (gender, age, haemoglobin, BR 
or LDH levels) on endothelial haem oxygenase activity after exposure to sickle 
blood. Measurements shown are meaniSEM. Analysis was performed with 
Prism 4 (Graphpad Software).
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5.4 Results
The results will be subdivided into experimental and analytical sections. 
In the first section, data from experiments investigating the endothelial haem 
oxygenase response from exposure to sickle blood under different conditions 
will be presented. The second section will involve further analysis on the 
relationship between haem oxygenase activity and patient characteristics such 
as disease state, treatment regimen, gender, age and blood parameters 
(haemoglobin, BR and LDH levels).
5.4.1 Experimental results
5.4.1.1 Patient characteristics
Within the sickle patient population, a variety of sickle variants were 
present (Figure 5-1), with the most prevalent trait being HbSS (71%), followed 
by HbSC (21%) and HbSpThal (6%). A small minority of patients had minor 
sickle traits, hereditary persistence of foetal haemoglobin (HPFH) and SD 
disease, and represented only 2% of the study population. The profile of sickle 
variants in the recruited sickle population reflects that reported in the wider 
sickle population in that approximately two thirds (66%) of sickle cases are 
characterised by the HbSS genotype (Redding-Lallinger and Knoll, 2006), 
followed in order of frequency by HbSC and HbSpThal. The average age within 
the sickle population and controls was also comparable (see Table 5-1) at 
33±13 and 36.6±4.75, respectively. There was also a similarity in the gender 
profile between the two populations, with 65% of the sickle and control groups 
being female. However, 8% of the sickle group recruited for the study were 
children whereas all the controls subjects were adults.
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As severity of SCD within the individual and within the wider sickle 
population can vary over time, there was an expected variation in the disease 
state and treatment regimens undertaken by the recruited sickle patients. At the 
time of blood collection for the present study, 22% of sickle patients were 
experiencing an acute crisis, 20% were undertaking hydroxyurea treatment and 
5% were receiving transfusion therapy.
Figure 5-1. Breakdown of sickle variants in SCD patient population
HbSC
21%
HbSpThal
6% 2%
■  HbSS
■  HbSC
□  HbSpThal
□  Other
HbSS
71%
After the collection of blood samples from both the control and sickle 
groups, blood was immediately tested for haemoglobin, LDH and BR levels. As 
shown in Table 5-1, haemoglobin levels were significantly lower in the sickle 
group (10.6 mg/d I) compared to control subjects (13.7 mg/dl). In addition, LDH 
and BR levels were significantly raised in the sickle population compared to the 
control group. The average BR level measured in sickle patients blood was 51.6 
pM compared to 7.82 pM detected in control blood. Furthermore, average blood 
LDH levels in sickle patients were 398 U/l in comparison to 189 U/l found in 
controls.
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Table 5-1. Patients characteristics
Control SCD P*
No. of patients 20 110
Age, mean±SD (%) 36.6±4.56 33±13
Adult/child ratio (%) 20 (100%) / 0 (0%) 101 (92%) / 9 (8%)
Gender, temale/male ratio (%) 13 (65%)/7 (35%) 71 (65%) / 39 (35%)
Hb,mg/dl, meantSD 13.71±1.07 10.6±6.2 P<0.0001
BR,pM, mean±SD 7.82±2.7 51.6±46.5 P<0.0001
LDH, Units/I, mean±SD 189±71.21 398±187 0.0286
Patients on hydroxyurea 22 (20%)
Patients on transfusion 5 (5%)
Disease state, acute 24 (22%) / 86 (78%)
crisis/steady state___________________________________________________________
*P  value is for the comparison of sickle patients versus control subjects.
Plasma samples collected from a subset of 13 sickle patients and 4 
control subjects from the study population underwent further analysis for 
markers of pathological processes (Table 5-2). There was no difference In 
albumin, creatinine, cholesterol and uric add levels between plasma from sickle 
and control subjects. In contrast, urea and HDL-C levels were much lower In 
sickle plasma than control plasma. In fact, the average level of urea In sickle 
plasma was 3.91 mmol/l In comparison to 6.32 mmol/l found In the plasma of 
control subjects. In addition, testing of sickle plasma revealed an average HDL- 
C of 0.97 mmol/l compared to 1.69 mmol/l measured In control plasma. Within 
our subset of sickle patients there were some patients who were undertaking 
hydroxyurea treatment. Therefore, the results obtained from testing sickle 
plasma for pathological markers were further analysed to examine possible 
differences that may exist between patients receiving or not receiving 
hydroxyurea treatment. However, from the limited number of patients examined 
It appears that hydroxyurea does not Influence the levels of plasma pathological 
markers, as no difference was observed between samples collected from sickle 
patients receiving or not receiving treatment.
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Table 5-2. Plasma analysis of sickle patient subset
CON
(n=4)
SCD
(n=13)
SCD + 
HU 
(n=3)
SCD-
HU
(n=10)
P * P t P t P §
Albumin,g/l, 
mean±SD 44.7t4 .4 41 .31t6 .3 41 8 t2 .2 41 .2t7 .2 0.3309 0.3488 0.3780 0.8845
Urea,mmol/l, 
m eantSD 6 .3 2 t l.2 3 .91t1 .62 3 .7 t0 .5 3 .97t1 .86 0.0161 0.0194 0.0398 0.8134
Creatinine, pmol/l 
m eantSD 87t14.1 8 5 .3 t2 1 .7 79t18 87.1t23 .3 0.8868 0.5526 0.9938 0.6093
Choiesteroi, mol/l, 
m eantSD 5.53t0 .6 4 .52t1 .15 4 .2 t0 .9 4 .6 t1 .25 0.1212 0.0657 0.1961 0.6117
HDL-C,mmoi/1, 
m eantSD 1.69t0.4 0 .97t0 .33 0 .94t0 .23 0 .98t0 .36 0.0021 0.0295 0.0066 0.8741
Uric Acid,pmol/l. 
m eantSD 326t72 .6 379t110.0 397t167 374 t98 0.3785 0.4711 0.3954 0.7675
P * value Is for the comparison of sickle patients (SCD) versus control subjects (CON).
P f  value is for the comparison of sickle patients receiving hydroxyurea (SCD + HU) versus control subjects (CON).
P t  value is for the comparison of sickle patients not receiving hydroxyurea (SCD - HU) versus control subjects (CON). 
P §  value is for the comparison of sickle patients receiving hydroxyurea (SCD + HU) versus patients not receiving 
hydroxyurea (SCD-HU).
5.4.1.2 Sickle blood induces haem oxygenase in endothelial cells
Initially, experiments were performed to establish the concentration of 
whole normal blood required to elicit any increase in endothelial haem 
oxygenase activity. As blood samples would be limited, we endeavoured to 
devise a protocol which would allow the use of small quantities of blood but still 
produce reproducible outcomes in terms of endothelial haem oxygenase 
activity. Endothelial cells were incubated for 6 h with 5, 10 and 20% whole blood 
solution prepared in culture medium and significant induction of endothelial 
haem oxygenase activity was observed with 20% whole normal blood compared 
to control (Figure 5-2). Therefore, we conducted all subsequent experiments 
incubating cells with 20% whole sickle or normal blood solutions.
As blood from sickle patients regularly undergoes haemolysis and 
liberates large amounts of haemoglobin into blood plasma (Reiter et al., 2002), 
we examined the possibility that sickle blood could induce endothelial haem 
oxygenase. Exposure of endothelial cells to 20% whole normal blood did not 
significantly affect haem oxygenase activity after 6 or 18 h incubation (Figure
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5-3 A), even though our preliminary experiments with whole control blood 
showed a small increase in haem oxygenase activity following 6 h exposure. In 
contrast, 20% whole sickle blood, whether obtained from the HbSS or HbSC 
genotype, significantly increased endothelial haem oxygenase activity 
compared to control cells (incubated with medium alone) or cells treated with 
20% whole normal blood. However, a difference in the magnitude of haem 
oxygenase induction elicited by sickle blood was observed between the two 
sickle genotypes. Specifically, exposure of endothelial cells to 20% HbSS sickle 
blood showed a more pronounced enhancement of endothelial haem 
oxygenase activity when compared to incubation with 20% HbSC sickle blood at 
both 6 and 18 h. However, incubation with sickle blood from either genotype 
caused a much greater induction of haem oxygenase activity at 18 h than at 6 
h, possibly reflecting a rise in haemolysis over time with release of haem from 
haemoglobin.
In further experiments we investigated which components of blood (i.e. 
plasma or red blood cells) were responsible for eliciting the enhanced haem 
oxygenase response in endothelial cells. We observed no differences in haem 
oxygenase activity following incubation with 10% normal or sickle plasma for 6 h 
and 18 h (Figure 5-3 B), suggesting that there were no constituents in the 
plasma of sickle patients that can directly promote an increase in endothelial 
haem oxygenase activity. However, exposure of endothelial cells to separated 
red blood cells from sickle or normal blood for 6 and 18 h, showed an increase 
in haem oxygenase activity compared with control (Figure 5-3 C). Furthermore, 
sickle red blood cells induced endothelial haem oxygenase activity to a greater 
extent than normal red blood cells. It should be noted that haem oxygenase
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activity levels were slightly higher after incubation with normal red blood cells 
than with normal whole blood. Conversely, the extent of haem oxygenase 
induction was more pronounced with whole sickle blood than sickle red blood 
cells.
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Figure 5-2. Endothelial haem oxygenase activity elicited by whole blood 
solutions
Endothelial cells were exposed to 5, 10 and 20% whole normal blood solution 
prepared in culture medium for 6 h. Cells were also exposed to medium alone 
(CON). Haem oxygenase activity measurements were performed as described 
in Materials and Methods. Bars represent the mean±SEM of 4-6 independent 
experiments per group. * P<0.05 vs. CON.
161
^  ê  1000 Whole blood 16 h 
118 h
CON Normal SS-SCD SC-SCD
B ■f §  1000
750-
500-
250
Plasma 16 h 
118 h
CON Normal SS-SCD
16 h 
118 h
CON Normal SS-SCD
Figure 5-3. Sickle blood induces haem oxygenase in endothelial cells
Endothelial cells were exposed for 6 and 18 h to: (A) medium containing 20% 
whole sickle HbSS (SS-SCD) or HbSC (SC-SCD)) or control blood (Normal);
(B) medium containing 10% plasma separated from sickle or control blood and
(C) medium containing 10% washed red blood cells (RBC) separated from 
whole sickle or control blood. Cells were also incubated in medium alone 
(CON). Haem oxygenase activity was measured as described in Materials and 
Methods. Bars represent the mean±SEM of 4-6 independent experiments per 
group. * P<0.05 vs. CON.
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5.4.1.3 Hypoxia amplifies the effect of sickle blood on haem oxygenase 
induction
Since deoxygenation is the trigger for mutated HbS to polymerise inside 
red blood cells, eventually leading to haemolysis (Bunn, 1997), we 
hypothesized that hypoxic conditions could influence the induction of endothelial 
haem oxygenase activity by sickle blood. As shown in Figure 5-4 A, incubation 
of endothelial cells with 20% sickle blood for 18 h under hypoxic conditions 
significantly amplified haem oxygenase activity compared with normoxic 
conditions. In contrast, endothelial haem oxygenase activity did not change 
following exposure to 20% normal whole blood under normoxia or hypoxia.
Considering that one of the major differences between normal and sickle 
cell blood is the presence of different haemoglobin subtypes, namely HbA and 
HbS, respectively, there was a focus on exploring the effect of hypoxia on the 
endothelial haem oxygenase activity elicited by the two haemoglobins. Figure 
5-4 B reports that both haemoglobins increased endothelial haem oxygenase 
activity under normoxic conditions and hypoxia further enhanced this effect, 
which was particularly noticeable for HbAo. Interestingly, hydroxyurea 
stimulated a significantly greater haem oxygenase response under hypoxic 
conditions than under normoxia. The drug also intensified the increased haem 
oxygenase activity and HO-1 expression (Figure 5-5) exerted by HbAo and HbS 
under hypoxic conditions. Therefore, it appears that under hypoxic conditions, 
hydroxyurea synergises with free haemoglobin to Induce endothelial haem 
oxygenase activity.
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Figure 5-4. Hypoxia amplifies the effect of sickle blood on haem 
oxygenase Induction In endothelial cells
Endothelial cells were exposed for 18 h to (A) medium containing 20% whole 
sickle blood (SCD) or control blood (Normal) at 1% O 2 (Hypoxia) or 21% O2 
(Normoxia) and (B) 15 pM HbAo or HbS at 1 or 21% O 2 in the presence or 
absence of 300 pM hydroxyurea (HU). Cells were also incubated in medium 
alone (CON). Haem oxygenase activity was measured as described in Materials 
and Methods. Bars represent the mean±SEM of 4-6 independent experiments 
per group. * P<0.05 vs. CON or tP<0.05 vs. Normoxia.
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HO-1
CON HU HbAo HbAo/HU CON HU HbAo HbAo/HU
Normoxia Hypoxia
Densitometry (normalised HO-1/p-actin)
CON HU 
(300 n M)
HbAo 
(15 u M)
HbAo/HU
Normoxia 0.47 ± 0 .2 0.8 +  0.6 3.86 + 2.8 9 .0 15 .4
HvDOXia 0.63±0.1 1.12+1.2 8.38 +  5.1 14.4+11.2
B
HO-1
CON HU HbS HbS/HU CON HU HbS HbS/HU
Normoxia Hypoxia
Densitometry (normalised HO-1/p-actin)
CON HU 
(300 u M)
HbS 
(15 w M)
HbS/HU
Normoxia 0 .29+0.0 0.6810.38 4 .7311 .5 5.6011.21
HvDoxia 0 .6710 .0 0 .6910 .0 7.47 +  2.8 12.14 +  3.5
Figure 5-5. Hypoxia amplifies the effect co-incubation of hydroxyurea with 
haemoglobin on HO-1 expression in endothelial cells
Endothelial cells were exposed for 18 h to (A) 15 pM HbAo at 1 or 21% O2 in the 
presence or absence of 300 pM hydroxyurea (HU) and (B) 15 pM HbS at 1 or 
21% O2 in the presence or absence of HU (300 pM). Cells were also incubated 
in medium alone (CON). The expression of HO-1 protein was determined by 
Western blot technique as described in Materials and Methods. Each image is 
representative of three independent experiments and the tables report the mean 
arbitrary units of the results obtained by densitometric analysis of the bands 
(densitometry normalised to p-actin).
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5.4.1.4 Co-incubation of NO donors with sickle blood does not affect 
induction of haem oxygenase
We explored whether co-incubation of endothelial cells with 20% whole 
blood and NO donors would affect haem oxygenase activity. As shown in Figure 
5-6 A, 250 pM GSNO alone or 20% sickle whole blood induced haem 
oxygenase activity; however, GSNO in combination with sickle blood did not 
further enhance endothelial haem oxygenase enzymatic activity. A similar 
outcome was also obtained when hydroxyurea was co-incubated with sickle 
blood, despite the potential NO-releasing capacities of hydroxyurea (Figure 5-6 
B). It was observed that incubation with 300 pM hydroxyurea alone produced a 
small increase in endothelial in haem oxygenase activity (Figure 5-6 B); 
however, co-incubation with sickle blood did not enhance the endothelial haem 
oxygenase activity elicited by sickle blood alone. As we have observed a 
hydroxyurea-mediated amplification of haem oxygenase activity under hypoxic 
conditions, it could be postulated that under hypoxia hydroxyurea may act 
differently when co-incubated with blood. Although exposure of cells to sickle 
blood under hypoxic conditions greatly enhanced haem oxygenase activity 
compared to normoxia, addition of hydroxyurea did not further enhance the 
activity (Figure 5-7).
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Figure 5-6. Co-Incubatlon of NO donors with sickle blood does not affect 
haem oxygenase induction in endothelial cells
Endothelial cells were exposed to (A) medium containing 20% whole sickle 
blood in the presence or absence of 250 pM S-nitrosoglutathione (GSNO) for 6 
h or (B) medium containing 20% whole sickle blood in the presence or absence 
of 300 pM hydroxyurea (HU) for 18 h. Cells were also incubated in medium 
alone (CON). Haem oxygenase activity was measured as described in Materials 
and Methods. Bars represent the mean+SEM of 4-6 independent experiments 
per group. * P<0.05 vs. CON.
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Figure 5-7. Hydroxyurea does not amplify the induction of haem 
oxygenase mediated by sickle blood in hypoxic conditions
Endothelial cells were exposed for 18 h to medium containing 20% whole sickle 
blood (SCD) or control blood (Normal) in the presence or absence of 300 pM 
hydroxyurea (HU) at 1% O2 (Hypoxia) and 21% O2 (Normoxia). Cells were also 
incubated in medium alone (CON). Haem oxygenase activity was measured as 
described in Materials and Methods. Bars represent the mean±SEM of 4-6 
independent experiments per group. * P<0.05 vs. Normoxia.
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5.4.2 Analytical results
In the following results section, we further analysed the data obtained 
from experiments examining the effect of sickle blood on endothelial haem 
oxygenase activity. There are many differences within the population of sickle 
patients, such as age, gender and treatment regimen, which may potentially 
influence the ability of blood to elicit enhanced haem oxygenase activity. 
Furthermore, possible relationships may exist between blood parameters such 
as haemoglobin, BR and LDH levels and endothelial haem oxygenase activity.
5.4.2.1 Induction of endothelial haem oxygenase by sickle blood can be 
modulated by treatment regimen
Blood taken from sickle patients, either receiving or not receiving 
hydroxyurea treatment, elicited significantly higher endothelial haem oxygenase 
activity than blood taken from control subjects. However, blood collected from 
patients receiving hydroxyurea treatment, elicited a lower endothelial haem 
oxygenase activity when compared to patients not following the drug regimen, 
although the difference was not statistically significant (p=0.1547) (Figure 5-8 
A). Analysis of sickle blood showed that haemoglobin levels were similar in 
patients receiving or not receiving hydroxyurea treatment (Table 5-3). 
Additionally, sickle blood LDH and BR levels did not differ between patients 
under hydroxyurea regimen or not receiving treatment.
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Table 5-3. Patient characteristics separated by hydroxyurea treatment
CON
(n=20)
SCD + HU 
(n=22)
S C D -H U
(n=88) Pt Pt P§
Hb,mg/dl, 
m eantS D 13.7t1 .07 10.28t2.0 9.88t2 .2 0.0114 0.0041 0.4464
BR,pM,
m eantS D 7 .82t2 .7 52 .73t46 .5 52.69t47.1 0.0106 0.0079 0.9972
LDH, Units/I, 
m eantS D 189t71.21 374t157 407 t194 0.0311 0.0291 0.496
P t  value Is for the comparison of sickle patients receiving HU (SCD + HU) versus control subjects (CON).
P t  value is for the comparison of sickle patients not receiving HU (SCD - HU) versus control subjects (CON).
P §  value is for the comparison of sickle patients receiving HU (SCD + HU) versus patients not receiving HU (SCD-HU).
In analysing whether transfusion therapy affected endothelial haem 
oxygenase responses, we observed that blood from sickle patients receiving 
transfusion regimens caused a lower endothelial haem oxygenase activity than 
that from patients free from transfusion; however, this difference was not 
statistically significant (p=0.5345) (Figure 5-8 B). Haemoglobin in blood from 
sickle patients receiving transfusion was not different from that measured in 
patients not receiving transfusion therapy (Table 5-4). Similarly, transfusion 
therapy did not affect blood LDH and BR levels in our sickle population. 
However, we note that only 5 patients from the total sickle population were 
receiving transfusion. Therefore, the non-significant trend of reduced serum BR 
and LDH in transfused patients compared to subjects not receiving transfusion 
could become significant if a larger number of transfused patients could be 
recruited and assessed.
Table 5-4. Patient characteristics separated by transfusion regimen
CON
(n=20)
SCD + 
Transfusion 
(n=5)
S C D -
Transfusion
(n=105)
Pt Pt P§
Hb,mg/dl,
m eantS D 13.7t1 .07 9 .6 t1 .3 9 .98t2 .2 0.0027 0.0051 0.7156
BR,pM,
m eantS D 7.82t2 .7 37 .8t26 .2 52 .7t47 .4 0.0051 0.0079 0.4879
LDH,U/I,
m eantS D 189t71.21 313 t73 402t190 0.0374 0.0282 0.3013
P t value is for the comparison of sickle patients receiving transfusion (SCD + transfusion) versus control subjects (CON).
P t value is for the comparison of sickle patients not receiving transfusion (SCD - transfusion) versus control subjects (COI\l).
P§ value is for the comparison of sickle patients receiving transfusion (SC D  + transfusion) versus patients not receiving transfusion 
(SCD-transfuslon).
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Figure 5-8. Patient treatment regimen modulates haem oxygenase 
induction
Endothelial cells were exposed for 6 h to (A) medium containing 20% whole 
sickle blood from patients receiving (+HU) or not receiving (-HU) hydroxyurea 
treatment and (B) medium containing 20% whole sickle blood from patients 
receiving transfusion (+Transfusion) or not (-Transfusion). Cells were also 
incubated in medium alone (CON). Haem oxygenase activity was measured as 
described in Materials and Methods. Bars represent the mean±SEM of 4-6 
independent experiments per group. * P<0.05 vs. CON.
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5.4.2 2 Induction of haem oxygenase by sickle blood is dependent on 
time elapsed since last sickle crisis
SCD is characterized by frequent vaso-occlusive crises in which there 
are consequent haemolytic episodes (Kaul et al., 1996), and we wished to 
examine the effect of blood taken from sickle patients who recently suffered a 
vaso-occlusive crisis on endothelial haem oxygenase activity. Interestingly, 
blood from sickle patients undergoing an acute crisis (defined as sickle patients 
presenting with clinical symptoms severe enough to warrant hospitalisation) 
stimulated a lower, but not significant (p=0.5114), endothelial haem oxygenase 
activity compared to blood from patients in steady state (Figure 5-9 A). 
However, the level of haem oxygenase activity measured after exposure of cells 
to blood from acute crisis patients was still significantly higher than control. 
These results were accompanied by the finding that haemoglobin levels were 
lower in blood from acute crisis patients and BR and LDH levels higher, 
compared to blood from patients in steady disease state (Figure 5-9 and Figure 
5-10).
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Figure 5-9. Disease state influences endothelial haem oxygenase activity 
and haemoglobin levels
(A) Endothelial cells were exposed for 6 h to medium containing 20% whole 
sickle blood taken from patients who were experiencing current acute crisis or 
at steady state SCD. Cells were also incubated in medium alone (CON). Haem 
oxygenase activity was measured as described in Materials and Methods. (B) 
Blood from control subjects and patients who were in acute crisis or at steady 
state SCD was collected and haemoglobin measurements were made as 
described in Materials and Methods. Bars represent the mean+SEM of 4-6 
samples per group. * P<0.G5 vs. CON or tP<0.05 vs. Steady state.
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Figure 5-10. BR and LDH levels in blood of patients vary according to 
disease state
Blood from control subjects (CON) and sickle patients who were in acute crisis 
or at steady state SCD was collected and BR (A) and LDH (B) measurements 
were performed as described in Materials and Methods. Bars represent the 
mean+SEM of 4-6 samples per group.* P<0.05 vs. CON.
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A very interesting picture emerged when the levels of haem oxygenase 
activity were grouped according to the time of the last crisis in the patient 
population. The results showed that blood from sickle patients who experienced 
crises in the previous 6 months to 1 year elicited a significantly higher 
endothelial haem oxygenase activity compared to blood from patients suffering 
crises more than 2 years before (Figure 5-11 A). The period of time elapsed 
from the last sickle crisis had no effect on haemoglobin levels in sickle blood 
samples, although haemoglobin levels from sickle patients, irrespective of time 
since last crisis, were significantly lower than haemoglobin levels in blood from 
control subjects (Figure 5-11 B). Interestingly, the profile observed for blood BR 
and LDH levels in relation to with the time since last crisis was very similar to 
that obtained for haem oxygenase activity (Figure 5-12 A, B).
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Figure 5-11. The time elapsed since the last vaso-occlusive crisis 
influences haem oxygenase activity levels
(A) Endothelial cells were exposed for 6 h to medium containing 20% whole 
sickle blood collected from patients who experienced sickle crises within the 
previous 6 months (6 m); 6 months to a year (1 y); 1-2 years (2 y) and greater 
than 2 years (>2 yr). Cells were also incubated in medium alone (CON). Haem 
oxygenase activity was measured as described in Materials and Methods. (B) 
Blood from control subjects (CON) or patients who suffered sickle crises within 
the previous 6 months (6 m); 6 months to a year (1 y); 1-2 years (2 y) and 
greater than 2 years (>2 y) was collected and haemoglobin measurements were 
performed as described in Materials and Methods. Bars represent the 
meaniSEM of 4-6 samples per group. *P<0.05 vs. CON.
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Figure 5-12. The time elapsed since the last vaso-occlusive crisis 
influences BR and LDH levels in blood
Blood from control subjects (CON) or patients who experienced sickle crises 
within the last 6 months (6 m); 6 months to a year (1 y); 1-2 years (2 y) and 
greater than 2 years (>2 y) was collected and BR (A) and LDH (B) 
measurements were performed as described in Materials and Methods. Bars 
represent the mean+SEM of 4-6 samples per group. * P<0.05 vs. CON.
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As the average number of crises per year for a sickle patient is less than
1 (0.8), and a higher rate of crises increases mortality in SCD (Marchant and 
Walker, 2003), a comparison was made between endothelial haem oxygenase 
activity and number of crises suffered by the patients in the last 2 years. The 
results showed that samples taken from sickle patients who had experienced 1 -
2 crises in the last 2 years stimulated significantly higher haem oxygenase 
activity compared to that elicited by blood from patients who had more crises 
(Figure 5-13).
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Figure 5-13. The frequency of sickle crises Influences and endothelial 
haem oxygenase activity stimulated by blood
Endothelial cells were exposed for 6 h to medium containing 20% whole sickle 
blood from patients who suffered 0, 1-2, 3-4 or >5 sickle crises in the last 2 
years. Haem oxygenase activity was measured as described in Materials and 
Methods. Bars represent the mean+SEM of 4-6 independent experiments per 
group. *P<0.05 vs. No crises (0).
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S.4.2.3 Haem oxygenase activity is correlated with haemoglobin, LDH, BR 
level and age and gender
Haemolysis is prevalent in SCD and could be postulated to be the first 
step in the cascade of events that ultimately leads to induction of endothelial 
haem oxygenase. Therefore, it was of interest in our study to assess whether 
markers of haemolysis in sickle blood, such as haemoglobin, BR and LDH 
levels, could be correlated with endothelial haem oxygenase activity. Figure 
5-14 A shows that haemoglobin levels measured in sickle blood from all 
patients are significantly negatively correlated with endothelial haem oxygenase 
activity. When the analysis was performed according to gender, the correlation 
was maintained in males and females but only within the female group was the 
correlation still significant (Figure 5-14 B). Sickle blood BR levels from all 
patients were positively and significantly correlated with haem oxygenase 
activity (Figure 5-15 A). However, the analysis carried out according to gender 
showed that the correlation between haem oxygenase activity and BR was 
strong and significant for female patients, while for males no meaningful 
correlation was detected (Figure 5-15 B).
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Figure 5-14. Correlation between endothelial haem oxygenase activity and 
haemoglobin levels
The scatter graph illustrates the relationship between endothelial haem 
oxygenase activity stimulated by sickle blood and haemoglobin levels in all 
sickle patients (■) (A) and male (□) or female (■) sickle patients (B). Haem 
oxygenase activity and measurement of blood haemoglobin were performed as 
described in Materials and Methods, r = Pearson’s correlation.
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Figure 5-15. Correlation between haem oxygenase activity and BR levels
The scatter graph illustrates the relationship between endothelial haem 
oxygenase activity stimulated by sickle blood and BR levels in all sickle patients 
( A)  (A) and male (A) or female ( A)  sickle patients (B). Haem oxygenase 
activity and measurement of blood BR were performed as described in 
Materials and Methods, r = Pearson's correlation.
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A non-significant positive correlation was also observed between haem 
oxygenase activity and LDH levels in all patients (Figure 5-16 A). Again, the 
correlation emerged strong and significant for female patients but was lost in 
males in the analysis subgrouped for gender (Figure 5-16 B). The age of sickle 
patients showed a negative but not significant correlation with endothelial haem 
oxygenase activity, and no difference between male and female patients was 
observed (Figure 5-17).
In summary, the analysis emphasises that the correlations are mainly 
significant for females but not males and also suggests a possible link between 
haemolysis in patients and haem oxygenase activity. Therefore, we further 
investigated the relationship between haemoglobin levels and indicators of 
haemolysis and damage, such as BR and LDH. Haemoglobin levels were found 
to be significantly negatively correlated with BR and LDH in all patients (Table 
5-5). The correlation was maintained by dividing the groups by gender; 
however, only the female population showed a significant correlation between 
haemoglobin and BR or LDH. The relationship between haemoglobin levels and 
age showed a slight positive, but not significant, correlation.
Parameters All patients Hb Female Hb Male Hb
Pearson P value Pearson P value Pearson P value
BR
r
-0.6188 0.0013
r
-0.6804 0.0052
r
-0.5371 0.1360
LDH -0.498 0.0205 -0.5254 0.0443 -0.4261 0.2528
Age 0.1773 0.4073 0.2154 0.4407 0.1285 0.7419
Table 5-5. Pearson correlations between haemoglobin levels in male or 
female patients and BR, LDH levels or age
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Figure 5-16. Correlation between endothelial haem oxygenase activity 
elicited by sickle blood and LDH levels
The scatter graph illustrates the relationship between endothelial haem 
oxygenase activity stimulated by sickle blood and LDH levels in all sickle 
patients ( T )  (A) and male (V) or female ( T )  sickle patients (B). Haem 
oxygenase activity and measurement of blood LDH were performed as 
described in Materials and Methods, r = Pearson’s correlation.
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Figure 5-17. Correlation between endothelial haem oxygenase activity 
elicited by sickle blood and patient age
The scatter graph illustrates the relationship between endothelial haem 
oxygenase activity stimulated by sickle blood and age of all sickle patients (•) 
(A) and male (o) or female (•) sickle patients (B). Haem oxygenase activity 
measurement was performed as described in Materials and Methods, r = 
Pearson’s correlation.
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5.5 Discussion
One hundred and ten patients with SCD were recruited for this study, 
and consented to provide a blood sample. The breakdown of sickle variants 
within the patient population was reflective of the wider sickle population with 
71% carrying the HbSS genotype (Redding-Lallinger and Knoll, 2006). Blood 
haemoglobin levels were lower in sickle patients compared to controls whereas 
LDH and BR levels in blood were higher. These findings are consistent with the 
high levels of haemolysis characteristic of SCD.
in the present study, exposure of endothelial cells to blood or separated 
red blood cells from sickle patients raised endothelial haem oxygenase activity 
levels; this increase in haem oxygenase activity was significantly more 
pronounced than in cells treated with control blood. Hypoxia amplified the 
endothelial haem oxygenase response elicited by sickle blood and this pattern 
was also observed in experiments using HbAo or HbS. Hydroxyurea synergised 
with haemoglobin to enhance endothelial haem oxygenase activity, an effect 
that was further magnified under hypoxic conditions. It could be postulated that 
the enhanced endothelial haem oxygenase induction elicited by sickle blood is 
an important protective mechanism against oxidative stress caused by 
haemolytic events, and the observation that hydroxyurea enhances haem 
oxygenase activity in the presence of haemoglobin suggests an additional 
mechanism of therapeutic action for this drug.
The observation that incubation of endothelial cells with plasma from 
sickle patients did not induce haem oxygenase activity is interesting. As well as 
cell-free haemoglobin, they are many inflammatory mediators within the plasma 
that could have potentially increased haem oxygenase. It is possible that 10%
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plasma is insufficient to elicit a haem oxygenase response and higher 
concentrations may be required for this purpose. Conversely, plasma 
components with anti-oxidant properties may prevent a rise in haem oxygenase 
activity. For example, plasma is rich in albumin, which exerts anti-oxidant 
properties (Cha and Kim, 1996) and binds NO (Orie et al., 2005), a potent 
inducer of HO-1. Interesting follow up studies could investigate different plasma 
fractions for their anti-oxidant or NO scavenging effects. Indeed, the plasma 
constituent S-nitrosoalbumin has been found to protective in an animal model of 
SCD (De Franceschi et al., 2006).
The release of free haemoglobin from ruptured red blood cells could be 
hypothesised as the trigger for the raised haem oxygenase activity in 
endothelial cells exposed to sickle blood. Indeed, haem released from 
haemoglobin is uptaken by endothelial cells to induce HO-1 and ferritin, both of 
which have been widely reported to protect the endothelium from oxidative 
damage (Balia et al., 1992b). Of interest, induction of HO-1 has been reported 
in circulating endothelial cells (Nath et al., 2001a) from sickle patients. 
Circulating endothelial cells are found in very low numbers physiologically, but 
are raised considerably in SCD. The enhanced HO-1 activity observed in these 
circulating cells has been postulated to offer a protective response to a pro- 
inflammatory environment (Solovey et al., 1997), and it could be inferred from 
these studies and our findings that raised HO-1 levels in endothelial cells in situ 
could have a similar protective role in SCD. The results showing no effect of 
sickle plasma on haem oxygenase are surprising, since haem levels can reach 
up to 20 pM in sickle plasma (Reiter et al., 2002) and inflammatory mediators 
capable of stimulating haem oxygenase may be present.
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Hypoxia is the trigger for sickling and haemolysis in SCD, as it is the 
deoxygenation of HbS that results in polymerization of the mutant haemoglobin, 
increasing the susceptibility of red blood cells to sickle, damage cellular 
membranes and eventually rupture (Bunn, 1997). Our observation that hypoxia 
enhanced the haem oxygenase activity elicited by sickle blood may be 
explained by the increased haemolysis triggered by hypoxia. Hypoxia is also 
capable of inducing endothelial haem oxygenase independently (Motterlini et 
al., 2000) and up-regulation of the protein in SCD could protect cells against 
further hypoxic endothelial damage, such as the expression of adhesion 
molecules and release of potent vasoconstrictors (Kourembanas, 2002), which 
may both contribute to vaso-occlusive events.
it is important to clarify the terms normoxia and hypoxia in regards to our 
experimental protocol. For cell culture protocols we define normoxia and 
hypoxia as 21% and 1% O2, respectively. However, physiological in vivo levels 
of O2 are normally much lower with blood carrying the equivalent of 10-12.5% 
O2 and healthy tissue having levels of 3-6% O2 (Atkuri et al., 2005). Therefore, 
standard culture conditions (21% O2) expose cells to 2 to 5-fold higher oxygen 
conditions than would be found in vivo and the reactions between O2. NO and 
haem we observed under our in vitro conditions may not be representative of 
the in vivo situation. This problem could be overcome by bubbling haemoglobin 
or blood solutions with O2 until physiological oxygen levels are reached before 
incubation with cells. Similarly, although 1% oxygen is well below physiological 
O2 levels, it may not represent accurately the intermittent regional hypoxia 
prevalent in sickle cell disease and an in vivo sickle model, e.g., transgenic 
sickle mouse, would more closely emulate the pathophysiological state.
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As shown in this chapter, the ability of hydroxyurea to induce haem 
oxygenase activity in endothelial cells was significantly increased under hypoxic 
conditions. In addition, co-incubation of hydroxyurea with HbAo or HbS 
significantly enhanced the haem oxygenase activity elicited by these 
haemoglobins. The observed synergism between haemoglobin and 
hydroxyurea could be a result of the NO donor properties of the drug, as 
reported earlier (King, 2004); for example, NO released from hydroxyurea binds 
haemoglobin, allowing for easier uptake by the endothelial cell and subsequent 
induction of haem oxygenase (Foresti et al., 2003; Foresti et al., 2006). Our 
data on the release of NO from hydroxyurea only shows a very slight increase 
in detectable NO when hydroxyurea is incubated with HbS (see chapter 3), 
suggesting that more experiments are required to prove this hypothesis. 
Therefore, the mechanism of therapeutic action of hydroxyurea in SCD could 
involve a number of components. On one side, long-term intake of hydroxyurea 
increases HbF production, thus reducing the incidence of crises and 
haemolysis. Indeed, we observed a lower endothelial haem oxygenase 
induction with blood taken from sickle patients on hydroxyurea compared to 
those on no treatment, which could possibly reflect a lower free haemoglobin 
level due to reduction in haemolysis. In addition, haemoglobin from a 
haemolytic event may synergise with hydroxyurea during acute situations to 
induce haem oxygenase activity and provide protection from the damaging 
effects of free haem. However, our data with sickle blood and hydroxyurea 
(Figure 5-6) did not support this hypothesis. An explanation for these results 
could be limitations in our experimental protocol. For example, scavenging of 
hydroxyurea could be occurring by blood components which may thus limit its
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pharmacological activity and possibly limit interactions with haemoglobin and 
subsequent effects on haem oxygenase activity. Recent studies sustain the 
idea that hydroxyurea might work by mechanisms unrelated to HbF synthesis, 
such as reduction in neutrophil levels, modulation of adhesion molecule 
expression in erythrocytes and erythropoietin production (Steinberg and 
Brugnara, 2003).
Our population included patients on hydroxyurea, transfusion or no 
treatment regimens and there were also differences in the population with 
regards to the number of sickle crises suffered and time elapsed from the last 
crisis. As all of these factors could affect the induction of haem oxygenase, an 
analysis of the relationship between patient characteristics and haem 
oxygenase activity was required.
Within the sickle population, the average rate of crisis is 0.8 per year 
and greater numbers of crisis per year are an indicator of more severe disease 
and increased mortality (Marchant and Walker, 2003). Intriguingly, our results 
show that blood from patients who experienced a crisis in the previous year 
stimulated enhanced endothelial haem oxygenase levels compared to those 
who were crisis-free for 2 or more years. It may be that haem oxygenase levels 
were induced by blood components released during the haemolytic crisis and 
that these components remained present for a certain extended period after the 
crisis. Interestingly, recent studies have indicated that clinical manifestations in 
SCD may be the result of a chronic inflammatory state secondary to abnormal 
erythrocyte membranes and haemolysis (Chies and Nardi, 2001 ; Frenette and 
Atweh, 2007). As HO-1 is induced by inflammatory mediators (Otterbein et al..
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2003a), our results could indicate that enhanced levels of endothelial haem 
oxygenase are caused by the inflammation produced by a sickle crisis.
Intriguingly, blood from sickle patients who had 1-2 crises in the previous 
2 years stimulated much higher endothelial haem oxygenase levels than blood 
from patients who had more crises. Since higher crisis rates are linked with 
increased mortality in SCD and a higher number of crises is associated with 
lower levels of haem oxygenase activity, we propose that these patients could 
represent a subset of SCD sufferers who lack the ability to induce this protective 
enzyme and are therefore susceptible to more crises. In the clinical setting, the 
problem may be compounded by repeated haemolytic episodes overwhelming 
endothelial haem oxygenase and causing irreversible changes to the 
endothelium.
Interestingly, sickle blood from patients in acute crisis elicited a lower 
endothelial haem oxygenase response than blood from patients in a steady 
disease state. These results would seem contradictory to the proposed 
hypothesis that haemolytic crisis would raise haem oxygenase levels. However, 
the levels of haem oxygenase activity seen after exposure of cells to blood from 
acute crisis patients is still significantly higher than blood from control subjects. 
A possible explanation for these findings could be that an acute haemolytic 
crisis might overwhelm the haem degradation system and/or it may take a while 
for the haem oxygenase response to develop.
The main aim of the therapy in SCD is to reduce the sickling of red blood 
cells, as this is the trigger to the extensive cellular and organ damage seen in 
the disease. Many approaches to solve this problem have been tried, but the 
most effective are through blood transfusion or treatment with the drug
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hydroxyurea (Redding-Lallinger and Knoll, 2006), thus reducing the number of 
sickled cells and consequent haemolysis. Therefore, it was not surprising that 
blood from patients on hydroxyurea or transfusion treatment elicited lower 
endothelial haem oxygenase activity when compared to blood from patients not 
receiving treatment. However, the endothelial haem oxygenase activity elicited 
by blood from patients on either treatment regimen was still higher than control 
blood, suggesting that haemolysis is still occurring in these patients, but at a 
reduced rate compared to those without treatment.
A significant correlation between markers of haemolysis in blood and 
stimulated endothelial haem oxygenase activity was observed. In the case of 
haemoglobin, levels in sickle blood were negatively correlated with haem 
oxygenase activity and we propose that low levels of haemoglobin might reflect 
higher free haemoglobin and haem levels due to increased haemolysis and lead 
to a subsequent increase in endothelial haem oxygenase activity. Accordingly, 
we also observed a positive correlation between BR or LDH levels and 
endothelial haem oxygenase activity. As these two blood parameters are 
markers indicative of red blood cell haemolysis, it is reasonable that raised 
levels of haemolysis would parallel enhanced levels of endothelial haem 
oxygenase activity. In addition, blood haemoglobin levels were also significantly 
negatively correlated with BR and LDH levels, confirming that low haemoglobin 
levels were linked with an increase in haemolysis. A correlation between 
haemolysis and increased vascular endothelial haem oxygenase activity has 
been observed in previous studies (Balia et al., 2003) and has been suggested 
to function as an endothelial adaptation to raised haem levels and serve as 
protection against haem-mediated oxidative damage. The importance of this
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adaptation is further reinforced by the presence of severe endothelial damage 
and increased sensitivity to oxidative damage in the case of a HO-1 deficient 
child (Yachie et al., 1999).
The analysis of haem oxygenase endothelial responses based on gender 
elicited some interesting results. Female sickle patients showed significant 
correlations between endothelial haem oxygenase response and haemoglobin, 
BR and LDH levels, while male patients did not show significant correlation with 
any of the blood parameters examined. This is an interesting observation and 
demonstrates differences in the ability to stimulate haem oxygenase responses 
between male and female sickle patients. Indeed, differences in biological 
responses between male and female patients in SCD have been reported 
previously. For example, Gladwin and colleagues (Gladwin et al., 2003) 
observed that NO bioavailability and NO responsiveness are greater in women 
than in men with SCD. This is an intriguing observation, as NO is also a 
powerful inducer of haem oxygenase and its enhanced bioavailability in blood 
from female sickle patients could explain the stronger positive correlation 
observed between endothelial haem oxygenase activity and markers of 
haemolysis (BR and LDH) compared to blood from males. Furthermore, the 
average life-span for sickle female patients is longer than in men and males 
also suffer more painful sickle crises, suggesting that females have better 
adaptive responses to SCD than men (Chang et al., 1995; Dover et al., 1992).
Repeated exposure of endothelium to haemolytic events could possibly 
affect haem oxygenase responses in SCD. Although not significant, there was a 
trend for the response of endothelial haem oxygenase to sickle blood to 
diminish as patients got older. These data show a greater haem oxygenase
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response in younger patients, which could eventually diminish over time due to 
repeated oxidative damage to the endothelium and to a general decline in 
physiological functions. An age-dependent decline in induction of heat shock 
proteins, such as HO-1, has already been associated with increased oxidative 
injury in other reports (Ewing and Maines, 2006; Moore et al., 2007). Taking into 
account the large variability in morbidity and mortality within the sickle 
population we hypothesise that the lower ability of patients to physiologically 
respond to sickle crises is associated with higher mortality rates and that the 
endothelial haem oxygenase response may play a role in the phenomenon.
Figure 5-18 shows a proposed mechanism of induction and action of 
endothelial haem oxygenase in SCD. Chronic haemolysis and subsequent 
raised levels of free haemoglobin and haem would induce the haem-degrading 
enzyme haem oxygenase, whose induction not only would reduce the haem 
burden and therefore oxidative stress levels, but also release the haem 
breakdown products, CO and BR, which possess important bioactive properties 
and elicit pharmacological activities that counteract the damaging effects of free 
haem. CO, as well as having vasodilatory properties, has also been shown to 
exert anti-inflammatory, anti-apoptotic and anti-proliferative functions in various 
cell types, including endothelial cells (Otterbein et al., 2003a). Importantly, 
administration of CO gas has already been reported to have therapeutic actions 
in SCD. Over 30 years ago, Beutler conducted a pioneering clinical study 
exploring the effects of CO inhalation on the sickling of red blood cells in sickle 
patients (Beutler, 1975). The study demonstrated that inhalation of CO by sickle 
patients over a 5 day period resulted in a significant increase in the life-span of 
red blood cells in sickle blood, thereby reducing the susceptibility of red blood
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Figure 5-18. Possible mechanism of action for haem oxygenase induction 
after exposure of endothelium to sickle blood
The sickling of red blood cells (RBC) in SCD promotes haemolysis and the 
release of free haemoglobin (Hb) and haem, which can be uptaken by 
endothelial cells to induce haem oxygenase-1 (HO-1). HO-1 degrades haem 
and releases carbon monoxide (CO), biliverdin (BV) and iron (Fe^ "^ ). BV is 
further converted into bilirubin (BR) by the action of biliverdin reductase (BVR). 
Transfusion therapy in SCD can diminish sickling by reducing the concentration 
of HbS-containing red blood cells. Hydroxyurea (HU) can also reduce the 
sickling of RBCs by increasing intracellular HbF production, and in addition can 
synergise with Hb to stimulate endothelial HO-1.
cells to sickle and subsequently rupture. The therapeutic action of CO to 
prevent sickling was attributed to CO binding to the HbS molecule and 
maintaining it in the more stable oxyhaemoglobin conformation, which hindered 
the polymerisation of HbS and subsequent sickling of the red blood cell. In 
addition to an anti-sickling action, CO was also observed to stimulate 
erythropoiesis in sickle patients, which significantly increased the haemoglobin
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level and haematocrit of sickle blood. Therefore, exogenous administration of 
CO in sickle patients was shown to have potent anti-sickling properties, as well 
as improving oxygen transport in sickle blood through decreased haemolysis 
and increased erythropoiesis. in sickle patients, endogenously produced CO via 
the induction of haem oxygenase may result in a fall in the number of sickle red 
blood cells and reduced haemolysis, hindering the cascade of pathological 
processes in SCD which lead to tissue damage or infarction. Furthermore, the 
potent vasodilatory and anti-inflammatory properties of CO could also alleviate 
the damaging effects of red blood cell haemolysis by counteracting the 
vasoconstrictive effects of NO scavenging in SCD as well as mitigating the pro- 
inflammatory effects of cell-free haemoglobin or haem. Therefore, CO could be 
an important therapeutic agent in SCD, with many facets explaining its potential 
therapeutic action. Indeed, low dose inhalation of CO has been reported to 
inhibit vascular stasis and diminish adhesion molecule expression in a 
transgenic sickle mice model (Belcher et al., 2006), strengthening the idea that 
CO could have a beneficial role in SCD. However, the toxic effects of CO must 
also be taken into account when considering CO as a therapeutic tool. The 
recent development of CO-RMs, which have been shown to carry and deliver 
CO safely in biological systems (Alberto and Motterlini, 2007), offers a novel 
strategy to harness the potential therapeutic effects of CO. Indeed, CO-RMs 
have produced significant therapeutic effects In a variety of experimental animal 
models (Clark et al., 2003); (Motterlini et al., 2002a).
In SCD, BR has also been reported to have important anti-oxidant effects 
on sickle cell membranes by protecting them from peroxidation and therefore 
reducing the susceptibility of the sickle erythrocytes to rupture (Dailly et al.,
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1998). Furthermore, high serum levels of BR have been correlated with 
vascular resistance to oxidative stress, and high BR levels are indicative of a 
reduced incidence of coronary artery disease. Indeed, the incidence of 
atherosclerotic disease in SCD patients is very low. SCD patients have low 
cholesterol and HDL-C levels which are thought to be due to altered metabolism 
of lipids (Rahimi et a!., 2006). The presence of significant reduction in total 
cholesterol and LDL-cholesteroi in SCD is thought to result in a lower 
prevalence of coronary artery disease. However, an increase in BR levels from 
haem oxygenase catalysed haem breakdown may be another mechanism by 
which the risk of coronary artery disease is reduced, as administration of BR 
has been shown to be cardio-protective in animal models of ischaemic heart 
injury (Clark et al., 2000b; Foresti et al., 2001). Therefore, administration of BR, 
on its own or in conjunction with CO, could be of therapeutic use in SCD, 
mirroring the beneficial effects of haem oxygenase induction. This therapeutic 
approach may be particularly useful for sickle patients with inherently low haem 
oxygenase responses.
Intriguingly, there is a huge phenotypic heterogeneity in SCD arising from 
a single gene mutation. Genetic polymorphisms may explain the range of 
clinical responses observed in this disease. Indeed, polymorphisms in 
coagulation, cell adhesion and cell hydration pathways are thought to influence 
the risk of priapism in SCD (Elliott et al., 2007). If the release of cell-free 
haemoglobin from ruptured red blood cells is the trigger for a cascade of 
deleterious effects in SCD, it could be proposed that polymorphisms in the 
proteins responsible for dealing with haemoglobin and haem homeostasis 
modulate the effect that free haem has on cellular targets. Potential
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polymorphisms in the haem-catabolising enzymes HO-1 and BVR, as well as 
haemoglobin scavenger proteins haptoglobin and CD-163, could greatly modify 
individual responses to haemolytic episodes (Exner et al., 2001; Van 
Vlierberghe et al., 2004). Therefore, a sub-set of sickle patients may exist who 
have a reduced ability to induce HO-1, making them less able to deal with the 
damaging effects of haemolysis, and lead them to have a subsequently more 
serious form of the disease.
In summary, endothelial haem oxygenase is enhanced in response to blood 
from sickle patients, an effect which is further amplified if the patient has had a 
recent sickle crisis. The elevated endothelial haem oxygenase activity could act 
as a compensatory response to mitigate the acute effects of raised toxic haem 
levels and also confer long-term protection against further sickle crises 
developing.
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Chapter 6. Haem oxygenase and its products regulate 
the interaction of sickle blood with the vascular 
endothelium
6.1 Introduction
SCD is characterized by recurring episodes of painful vaso-occlusion 
resulting in ischaemia/reperfusion injury and organ damage (Frenette and 
Atweh, 2007). The trigger for vaso-occlusive events is the adherence of sickle 
red blood cells to the vascular endothelium caused by abnormal expression of 
adhesion molecules. Another factor which may influence vaso-occlusion is 
vasoconstriction secondary to NO scavenging by haemoglobin which is 
prevalent in SCD (Reiter et al., 2002).
We have shown in the previous chapter that endothelial haem 
oxygenase is induced in the presence of sickle blood; we also observed 
increased haem oxygenase activity associated with exposure of cells to blood 
taken from sickle patients who had a recent crisis. We hypothesized that this 
may be a mechanism to protect against further vaso-occlusive events. 
Therefore, in the present study, we decided to investigate whether haem 
oxygenase or haem oxygenase breakdown products can modulate the 
adhesion of red blood cell from sickle blood to the endothelium. Furthermore, 
we explored the vasodilatory effect of CO on vessel relaxation after exposure to 
sickle blood. These investigations may help to clarify the role of haem 
oxygenase in the prevention or resolution of vaso-occlusive crises in SCD.
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6.2 Objectives
• To explore the role of haem oxygenase in the regulation of sickle red 
blood cell adhesion to endothelial cells
• To investigate the specific effect CO and BV on the adhesiveness of 
sickle red blood cell to endothelial cells
• To examine how whole sickle blood, sickle red blood cells or plasma 
affect the ability of CO-releasing molecules (CO>RMs) to elicit vessel 
relaxation in an isolated aortic ring model
• To study the ability of NO donors to elicit vessel relaxation in isolated 
aortic rings exposed to sickle blood
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6.3 Experimental protocol
Before the start of each experiment, stocks of all reagents were freshly 
prepared. Stock solutions of haemin and BV (1 mM) were prepared by 
dissolving the compounds in 0.1 M NaOH and then adding 0.01 M phosphate 
buffer at pH 7.4. CORM-3, C0RM-A1, DEA-NO and PAPA-NO stocks were 
prepared using distilled water. iCORM-3 and iCORM-A1 were prepared as 
described in Materials and Methods. Whole blood was collected as described in 
the previous chapter.
6.3.1 Determination of red blood cell adhesion to endothelium
An in vitro static assay (Gravity sedimentation method) was used as a model for 
red blood cell-endothelial cell interaction. As we planned to investigate not only 
the interaction of red blood cells with endothelial cells, but also the Influence of 
other components present in the blood, we chose initially to incubate endothelial 
cells with whole blood solution prepared in culture medium. Preliminary 
experiments were designed to determine the optimal percentage of blood 
solution needed for incubation and the length of exposure to blood required for 
quantifying the extent of red blood cell-endothelial cell interaction. Both normal 
and sickle whole blood solutions were prepared in culture medium (1, 5, 10, 
20% solution) and incubated with endothelial cells for different periods of time 
(15, 30 and 45 min). The results indicated good reproducibility when endothelial 
cells were incubated with 5% whole blood solution for a period of 45 min. To 
investigate the effect of haem oxygenase induction or products of haem 
breakdown by haem oxygenase on red blood cell adhesion, endothelial cells 
were cultured in 6 well dishes and pre-incubated for 6 h with haemin (1, 10, 30 
pM), or 30 min with the following; BV (0.1, 0.5, 1 pM); CORM-3 (1, 10, 30 pM);
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C0RM-A1 (1, 5, 10 mM). The negative controls iCORM-3 (30 pM) and iCORM- 
A1 (10 |jM) were also incubated for 30 nriin prior to exposure of cells to blood 
(details of iCORM preparation are provided in section 2.3.3). The pre- 
treatments were followed by addition of 5% whole blood for 45 min to allow the 
adhesion process to occur. At the end of the incubation, non-adherent cells 
were removed by washing 3 times with Hanks balanced salt solution and 
adherent cells were counted using a light microscope. We also examined 
whether the effect of haem breakdown products on cell adhesion were due to 
direct interaction with the endothelium or with red blood cells. For this, cells 
were pre-incubated with BV (0.1, 0.5, 1 pM), CORM-3 (1, 10, 30 pM), CORM- 
A1 (1, 5, 10 pM) and iCORMs (30 pM iCORM-3 or 10 pM iC0RM-A1) with the 
whole blood solution for 30 min, prior to addition to cells for the adhesion assay. 
In additional experiments, endothelial cells were pre-incubated with the haem 
oxygenase inhibitor SnPPIX (2, 20, 60 pM), in the presence of haemin (1, 10, 
30 pM) for 6 h, to explore if haem oxygenase was responsible for the observed 
effect. SnPPIX is a synthetic haem analogue which has been demonstrated to 
act as a competitive inhibitor of haem oxygenase activity in various cell types 
(Kappas and Drummond, 1986). Therefore the concentration of SnPPIX used to 
treat endothelial cells was double the concentration of haem used, i.e. 1, 10 or 
30 pM haem was incubated with 2, 20 or 60 pM SnPPIX, respectively; thus 
SnPPIX would compete with haemin for binding to haem oxygenase and 
diminish the activation of the enzyme. To explore whether the increased 
susceptibility to haemolysis characteristic of sickle blood was responsible for its 
higher adhesiveness compared to normal blood, experiments were devised to 
mimic haemolysis in normal blood. One millilitre of normal blood was lysed
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using 4 ml hypotonic water lysis (Bryan et al., 2004). We assumed that all the 
red blood cells were lysed, therefore, a portion of the lysed blood was added to 
5% whole normal blood to reach final free haemoglobin concentrations of 5, 10 
or 15 pM. Cells were then exposed to these solutions for the adhesion assay. 
Finally, to investigate whether the mutation leading to HbS formation influences 
cell adhesion, cells were incubated with 5% whole normal blood solution to 
which HbS was added at concentrations of 5, 10 or 15 pM.
6.3.2 Experiments using the isolated aortic ring model
To investigate the effect of sickle blood on vessel relaxation, aortic rings 
were exposed to sickle blood and the relaxation response to the vasodilators 
CO and NO was measured. In brief, the aorta was excised from Sprague- 
Dawley rats and cut into aortic rings of approximately 2-3 mm. Rings were 
incubated in oxygenated buffer containing either 1% whole blood or 0.5% red 
blood cells or plasma solutions collected either from normal subjects or sickle 
patients. Control rings were exposed to buffer alone. After their initial pre­
contraction to 1 pM phenylephrine, rings were challenged with 100 pM CO-RMs 
and the effect on relaxation measured. Two different CO-RM molecules were 
used: CORM-3 which rapidly liberates CO (half-life = 3.6 min) and C0RM-A1 
(half-life = 21 min) which has a slower CO release. In further experiments, aortic 
rings were incubated with 1% whole sickle or normal blood in the presence or 
absence of the NO donors: DEA-NO (100 pM), a fast-releaser of NO (half-life = 
2 min) and PAPA-NO (100 pM), a slower releaser of NO (half-life = 16 min).
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6.3.3 Statistics
Differences in the data among the groups were analyzed by using one­
way ANOVA combined with the Bonferroni test for cell adhesion experiments 
and two-way ANOVA combined with Bonferroni test for aortic ring experiments. 
Values were expressed as meanstSEM and differences between groups were 
considered to be significant at P<0.05.
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6.4 Results
6.4.1 Optimisation of the assay for quantifying the adhesiveness of sickie 
red blood cell to endothelial cells
Cell adhesion assays have been widely used as models for exploring 
interactions between endothelial cells and red blood cells. Our preliminary 
experiments were devised to make efficient use of blood samples from sickle 
patients whilst still generating reproducible results. Endothelial cells were 
incubated for various periods of time (15, 30, 45 min) with sickle or normal 
blood solutions (1, 5, 10, 20%) prepared in culture medium. Our results showed 
that red blood cells from whole sickle blood adhered extensively to endothelial 
cells, as demonstrated in Figure 6-1 A. In contrast, incubation of whole normal 
blood solutions at any concentration did not result in adherence of red blood 
cells to the endothelial layer (Figure 6-1 B). This effect was observed at all the 
time points examined. The adhesion of sickle blood depended both on the 
concentration of the blood solution and time of exposure (Figure 6-1 A). Based 
on the results of our preliminary experiments and taking into account the limited 
availability of sickle blood, incubation of endothelial cells with 5% whole blood 
solution for 45 min was considered the optimal experimental approach to 
quantitatively measure cell adhesion using small quantities of sickle blood.
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Figure 6-1. Adherence of red blood cells to the endothelium using normal 
or sickle blood
Endothelial cells were incubated for 15, 30 or 45 min with solutions (1, 5, 10, 
20%) of whole sickle blood (A) or normal blood (B). Red blood cell (RBC) 
adhesion measurements were performed as described in Materials and 
Methods. Bars represent the meaniSEM of 4-6 independent experiments per 
group.
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6.4.2 Haemolysis of blood from normal subjects does not induce red 
blood cell adherence to endothelium
We wished to explore some of the mechanisms underlying the difference 
between the adhesion of normal and sickle blood to the endothelium (Figure 
6-1). Table 6-1 shows the results of the experiments where endothelial cells 
were exposed to either normal lysed blood (5, 10, 15 pM final haemoglobin 
concentration) or normal blood containing 5, 10 or 15 pM HbS for 45 min. We 
found that the adherence of lysed blood or blood containing HbS did not 
significantly differ from control blood, suggesting that increased haemolysis and 
the altered HbS molecule are not the major factors affecting the adhesiveness 
of sickle blood to the endothelium.
Table 6-1. Red blood cell adherence of haemolysis in control blood.
N o  o f ad h eren t cells/mm"^, 
m e a n ± S D
P va lu e  vs. C ontro l blood
Contro l blood
Lysed blood (1 5  p M  Hb)
Blood + 15 p M  H b S
0 .5 ± 0 .8 4 9
0 .6 ± 1 .0 7 5
1 .0 ± 1 .2 4 7
0 .8 7 0 5
0 .3 0 0 2
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6.4.3 Induction of haem oxygenase and haem oxygenase-derived 
products modulate the adhesion of sickle red blood cells to the 
endothelium
Since induction of haem oxygenase in endothelial ceils modulates the 
expression of adhesion molecules (Soares et a!., 2004), it was of interest in our 
study to explore the effect of haem oxygenase and its products on the adhesion 
of sickle red blood cells. Figure 6-2 A shows that pre-treatment of endothelial 
cells with haemin (1,10 and 30 pM) for 6 h caused a concentration-dependent 
reduction in sickle cell adhesion, with 30 pM haemin almost completely 
inhibiting the binding of sickle red blood cells to the endothelium. Co-incubation 
of endothelial ceils with haemin and the haem oxygenase inhibitor SnPPIX re­
established most of the adherence of sickle red blood cells (Figure 6-2 B), 
indicating that haem oxygenase may indeed have a role in the inhibition of 
endothelial red blood cell adhesion.
We wanted to further investigate the specific contribution of the haem 
oxygenase products BV and CO on red blood cell adherence and reasoned that 
BV or CO could interfere with the adhesion process by acting potentially on 
either endothelial cells or red blood cells. Interestingly, we found that pre­
treatment of endothelial cells pre-treated with BV (0.1, 0.5, 1 pM) for 30 min 
prior to addition of sickle blood resulted in a concentration-dependent decrease 
in sickle cell adhesion (Figure 6-3 A), with 1 pM BV being the most effective 
concentration and reducing adhesion by approximately 50%. Notably, when red 
blood cells were incubated with BV (0.1, 0.5, 1 pM), we observed an almost 
complete abolition of red cell adhesion at all concentrations used (Figure 6-3 B).
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To examine the effect of CO on red blood cell adhesion we employed 
two CO-RMs recently developed in our laboratory. The different chemical 
characteristics of CORM-3 and C0RM-A1 affect their kinetic of CO release and 
consequently their potential effect on cells and tissues, as reviewed previously 
(Motterlini et al., 2005a). Pre-treating endothelial cells with CORM-3 or CORM- 
A1 elicited a concentration-dependent reduction in sickle cell adhesion (Figure 
6-4 A and Figure 6-5 A). Importantly, neither iCORM-3 nor iC0RM-A1 affected 
the adhesion response of sickle blood to endothelial cells. However, pre­
incubation of sickle blood with either CORM-3 or C0RM-A1 before addition to 
endothelial cells produced a different picture. Specifically, treatment of sickle 
blood with CORM-3 only marginally (and non-significantly) reduced sickle cell 
binding to endothelial cells (Figure 6-4 B), whereas pre-incubation with CORM- 
A1 exerted a substantial decrease in red blood cell adhesion (Figure 6-5 B). 
Interestingly, C0RM-A1 had a greater effect on cell adhesion when added 
directly to sickle blood rather than to endothelial cells. We also noted that 
adhesion was lower when sickle blood was pre-treated with 10 pM IC0RM-A1, 
although treatment of blood with 10 pM C0RM-A1 inhibited adhesion to a much 
higher extent than iC0RM-A1 (70% more). The fact that iC0RM-A1 reduced 
cell adhesion may be a result of residual CO still bound to the CORM molecule, 
due to inefficient purging of CO molecules during the preparation of the inactive 
form (see Materials and Methods).
Collectively, these results indicate that prevention of sickle red cell 
adhesion is achieved not only via the induction of HO-1 in the endothelium, but 
also by treating either endothelial cells or sickle cell blood with haem 
oxygenase-derived products.
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Figure 6-2. Pre-incubation with haemin decreases the adherence of sickle 
red blood cells (SC-RBC) to the endothelium
Endothelial cells were pre-incubated for 6 h with haemin (1, 10, 30 pM) (A) or 
haemin in the presence of the haem oxygenase inhibitor SnPPIX (2, 10, 60 pM) 
(B). Endothelial cells were then exposed to a 5% whole sickle blood solution for 
45 min and red blood cell (RBC) adhesion measurements were performed as 
described in Materials and Methods. Bars represent the mean+SEM of 4-6 
independent experiments per group. * P<0.05 vs. SC-RBC.
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Figure 6-3. Pre-incubatlon with biliverdin reduces the adherence of sickle 
red blood cells (SC-RBC) to the endothelium
(A) Endothelial cells were pre-incubated for 30 min with biliverdin (0.1, 0.5, 1 
pM) followed by exposure to 5% sickle blood solution for 45 min. (B) A 5% 
sickle blood solution was pre-incubated with biliverdin (0.1, 0.5, 1 pM) for 30 
min followed by incubation with endothelial cells for 45 min. Red blood cell 
(RBC) adhesion measurements were performed as described in Materials and 
Methods. Bars represent the mean±SEM of 4-6 independent experiments per 
group. * P<0.05 vs. SC-RBC.
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Figure 6-4. Pre-treatment with CORM-3 modulates adherence of sickle red 
blood cells to the endothelium
(A) Endothelial cells were pre-incubated for 30 min with CORM-3 (1, 10, 30 pM) 
or 30 pM iCORM-3 followed by exposure to 5% sickle blood solution for 45 min.
(B) A 5% sickle blood solution was pre-incubated with CORM-3 (1, 10, 30 pM) 
or 30 pM iCORM-3 for 30 min followed by incubation with endothelial cells for 
45 min. Red blood cell (RBC) adhesion measurements were performed as 
described in Materials and Methods. Bars represent the mean+SEM of 4-6 
independent experiments per group. * P<0.05 vs. SC-RBC.
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Figure 6-5. Pre-treatment with C0RM-A1 reduces adherence of sickle red 
blood cells (SC-RBC) to the endothelium
(A) Endothelial cells were pre-incubated for 30 min with C0RM-A1 (1, 5. 10 pM) 
or 10 pM iC0RM-A1 followed by exposure to 5% sickle blood solution for 45 
min. (B) A 5% sickle blood solution was pre-incubated with C0RM-A1 (1, 5, 10 
pM) or 10 pM iC0RM-A1 for 30 min followed by incubation with endothelial cells 
for 45 min. Red blood cell (RBC) adhesion measurements were performed as 
described in Materials and Methods. Bars represent the mean±SEM of 4-6 
independent experiments per group. * P<0.05 vs. SC-RBC.
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6.4.4 Sickle whole blood modulates the vasodilatory effect of CORM-3 
and C0RM-A1 on isolated aortic rings
In SOD, high levels of cell-free haemoglobin limit NO bioavailability which 
leads to perturbations in vascular tone (Reiter et al., 2002). However, no data 
are available on the influence of sickle blood on CO-mediated relaxation of 
vascular tissue. Figure 6-6 A shows that aortic rings challenged with 1 pM 
phenylephrine in the presence of 1% sickle or normal blood maintained maximal 
contraction much longer than observed with rings incubated in buffer. Addition 
of 100 pM C0RM-A1 or CORM-3 relaxed pre-contracted rings (Figure 6-6 B 
and Figure 6-7 B) in the presence of 1% sickle blood, 1% normal blood or buffer 
alone. In the case of C0RM-A1 maximal relaxation was reached after 30 min 
and a gradual re-contraction occurred within 60 min (Figure 6-6 B). Addition of 
1% normal blood did not affect the C0RM-A1-mediated relaxation. However, 
the presence of 1 % sickle blood slightly attenuated the vasodilatory response of 
C0RM-A1, reaching a significant difference from C0RM-A1 alone or in the 
presence of normal blood at 20 min time point (Figure 6-6 C). CORM-3 alone 
elicited a lower aortic relaxation compared to C0RM-A1 (Figure 6-7) but was 
still maintained at 60 min. The presence of 1% normal or sickle blood exerted 
an attenuation of the vasodilatory response of CORM-3, but the difference was 
not statistically significant (Figure 6-7 A). In addition, there was no significant 
difference observed between the effect of normal and sickle blood on CORM-3 
elicited relaxation (Figure 6-7 C). Therefore, the magnitude and length of 
relaxation differed between the two CO-RMs, with C0RM-A1 eliciting a 
dramatically stronger relaxation response than CORM-3, both in the presence 
and absence of 1 % blood.
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In summary, the vasodilatory actions of CORM-3 and C0RM-A1 
are attenuated by the presence of sickle or normal blood. In addition, 
experiments with C0RM-A1 demonstrate that blood from sickle patients has a 
significantly greater effect on inhibiting C0RM-A1 -mediated vasorelaxation than 
normal blood.
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Figure 6-6. Sickle blood modulates vessel relaxation in response to 
C0RM-A1
(A) Aortic rings suspended in Krebs buffer alone (CON), 1% normal (Normal 
blood) or sickle (Sickle blood) were challenged with 1 pM phenylephrine and 
contraction was followed over time. (B) At the peak of phenylephrine 
contraction, 100 pM C0RM-A1 was added to rings incubated with Krebs buffer 
(C0RM-A1), 1% normal blood (Normal blood + C0RM-A1) or 1% sickle blood 
(Sickle blood + C0RM-A1). (C) Vessel relaxation measured 20 min after 
addition of 100 pM C0RM-A1 to aortic rings exposed to normal or sickle blood. 
Isolated aortic ring experiments were performed as described in Materials and 
Methods. Bars represent the mean±SEM of 4-6 independent experiments per 
group. * P<0.05 vs. Normal blood.
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Figure 6-7. Sickle and normal blood modulates vessel relaxation in 
response to CORM-3
(A) Aortic rings suspended in Krebs buffer alone (CON), 1% normal (Normal 
blood) or sickle (Sickle blood) blood were contracted with 1 pM phenylephrine 
and contraction was followed over time. (B) At the peak of phenylephrine 
contraction, 100 pM CORM-3 was added to rings incubated with Krebs buffer 
(CORM-3), 1% normal blood (Normal blood + CORM-3) or 1% sickle blood 
(Sickle blood + CORM-3). (C) Vessel relaxation measured 10 min after addition 
of 100 pM CORM-3 to aortic rings exposed to normal or sickle blood. Isolated 
aortic ring experiments were performed as described in Materials and Methods. 
Bars represent the mean+SEM of 4-6 independent experiments per group. * 
P<0.05 vs. Normal blood.
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6.4.5 Sickle red blood cells modulate the vasodilatory effect of CORM-3 
and CORM-A1 on isolated aortic rings
Since in CO-mediated vasorelaxation responses were different in aortic 
rings treated with sickle and normal blood, we investigated the possible 
components present in the blood that were responsible for the observed effects. 
Therefore, we examined the vasodilatory responses of aortic rings to CO-RMs 
in the presence of either red blood cells or plasma separated from sickle or 
normal blood.
initially we observed that the contraction exerted by phenylephrine was 
prolonged in the presence of 0.5% red blood cells from either sickle or normal 
blood when compared to control rings (Figure 6-8 A ). Sickle or normal red 
blood cells reduced by 45 and 10%, respectively, the relaxation elicited by 100 
pM C0RM-A1 30 min after addition (Figure 6-8 B), indicating a pronounced 
difference in the effect of sickle blood compared to normal blood. Furthermore, 
sickle or normal red blood cells inhibited by 21% and 23%, respectively, the 
vasodilatory effect of CORM-3 20 min after addition (Figure 6-8 C); however, 
there was no difference in CORM-3-mediated vasodilation between rings 
exposed to sickle or normal red blood cells.
Interesting observations were also made when the effect of 0.5% normal 
or sickle plasma on CO-RMs relaxation was examined (Figure 6-9 B, C). 
Specifically, the presence of sickle or normal plasma inhibited by 47% and 39%, 
respectively, C0RM-A1-mediated relaxation measured at 30 min after addition; 
with no difference observed between sickle and normal plasma. Similar results 
were obtained in the case of CORM-3, since the presence of sickle or normal 
plasma elicited a 16% reduction in vasorelaxation 20 min after the addition of
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the compound, and again no differences were observed between the effect of 
sickle or normal plasma. These data suggest that plasma from either sickle or 
normal blood is capable of scavenging CO and limiting its vasodilatory action.
In summary, red blood cells or plasma from sickle or normal blood 
inhibited the vasodilatory properties of both CO-RMs. A significant difference 
was found in the vasodilatory action of C0RM-A1 in the presence of sickle or 
normal red blood cells, where sickle red blood cells significantly diminished the 
action of C0RM-A1. This effect was not seen with CORM-3 in the presence of 
red blood cells, or either CO-RMs in the presence of plasma.
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Figure 6-8. Sickle red blood cells modulate vessel relaxation in response 
to CO-RMs
(A) Aortic rings suspended in Krebs buffer alone (CON), 0.5% normal red blood 
cells (Normal RBC) or sickle red blood cells (Sickle RBC) were challenged with 
1 pM phenylephrine and contraction was followed over time. (B) At the peak of 
phenylephrine contraction, 100 pM C0RM-A1 was added to rings incubated 
with Krebs buffer (C0RM-A1), 0.5% normal RBC (Normal RBC + C0RM-A1) or 
0.5% sickle RBC (Sickle RBC + C0RM-A1). (C) At the peak of phenylephrine 
contraction, 100 pM CORM-3 was added to rings incubated with Krebs buffer 
(CORM-3), 0.5% normal RBC (Normal RBC + CORM-3) or 0.5% sickle RBC 
(Sickle RBC + CORM-3). Isolated aortic ring experiments were performed as 
described in Materials and Methods. Bars represent the mean+SEM of 4-6 
independent experiments per group. * P<0.05 vs. Normal RBC.
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Figure 6-9. Sickle plasma modulate vessel relaxation in response to CO- 
RMs
(A)Aortic suspended in Krebs buffer alone (CON), 0.5% normal (Normal blood) 
or sickle (Sickle blood) plasma rings were challenged with 1 pM phenylephrine 
and contraction was followed over time. (B) At the peak of phenylephrine 
contraction, 100 pM CORM-AI was added to rings incubated with Krebs buffer 
(C0RM-A1), 0.5% normal plasma (Normal plasma + CORM-AI) or 0.5% sickle 
plasma (Sickle plasma + CORM-AI). (C) At the peak of phenylephrine 
contraction, 100 pM CORM-3 was added to rings incubated with Krebs buffer 
(CORM-3), 0.5% normal plasma (Normal plasma + CORM-3) or 0.5% sickle 
plasma (Sickle plasma + CORM-3. Isolated aortic ring experiments were 
performed as described in Materials and Methods. Bars represent the 
mean±SEM of 4-6 independent experiments per group. * P<0.05 vs. Normal 
plasma.
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6.4.6 Sickle whole blood modulates the vasodilatory effect of NO donors 
on isolated aortic rings
We have observed that sickle blood can diminish the vasodilatory 
properties of CO-RMs, possibly through scavenging of CO by haemoglobin but 
also via other mechanisms. As scavenging of NO by haemoglobin in SCO is a 
widely reported phenomenon, we explored the vasodilatory effects of two NO 
donors (DEA-NO, PAPA-NO) in the presence of normal or sickle blood. We 
chose two NO donors with differing NO release profiles to simulate the same 
experimental protocol adopted with CO-RMs. DEA-NO rapidly releases NO 
(half-life = 2 min) whereas PAPA-NO has a slower rate of release (half-life = 16 
min) (Mooradian et al., 1995). As NO is a potent vasodilator, it was not 
surprising that both DEA-NO (100 pM) and PAPA-NO (100 pM) produced 
immediate relaxation in rings incubated with Krebs buffer (Figure 6-10), with 
PAPA-NO eliciting a relaxation even greater than baseline. Furthermore, the 
vasorelaxation elicited by both compounds remained constant over 1 h. The 
presence of normal blood had no effect on the vasodilatory response of DEA- 
NO compared to control (Krebs buffer) (Figure 6-10 A). Surprisingly, the 
presence of sickle blood enhanced DEA-NO-mediated relaxation in comparison 
to normal blood or control and this effect was significant at 10 and 20 min after 
addition of DEA-NO.
The pattern of vasodilatory response elicited by PAPA-NO in the 
presence of blood was different from that observed with DEA-NO (Figure 6-10 
B). The presence of both sickle and normal blood only slightly enhanced the
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relaxation exerted by PAPA-NO and no difference was observed between the 
effect of sickle or normal blood.
in summary, NO elicited powerful vasorelaxation despite the presence of 
sickle or normal blood. In particular, sickle blood caused an enhancement of the 
vasodilatory properties of DEA-NO.
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Figure 6-10. Sickle blood modulates vessel relaxation in response to NO 
donors
(A) Aortic rings suspended in Krebs buffer alone (CON), 1% normal (Normal 
blood) or sickle (Sickle blood) blood were challenged with 1 pM phenylephrine 
and contraction was followed over time. At the peak of phenylephrine 
contraction. 100 pM DEA-NO was added to rings incubated with Krebs buffer 
(DEA-NO), 1% normal blood (Normal blood + DEA-NO) or 1% sickle blood 
(Sickle blood + DEA-NO). (B) In further experiments, at the peak of 
phenylephrine contraction, 100 pM PAPA-NO was added to rings incubated 
with Krebs buffer (PAPA-NO), 1% normal blood (Normal blood + PAPA-NO) or 
1% sickle blood (Sickle blood + PAPA-NO). Isolated aortic ring experiments 
were performed as described in Materials and Methods. Bars represent the 
mean+SEM of 4-6 independent experiments per group. * P<0.05 vs. Normal 
blood.
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6.5 Discussion
In this chapter we have shown that haem oxygenase or haem oxygenase 
breakdown products can modulate factors associated with the development of 
vaso-occlusion. Specifically, we observed that haem pre-incubation or the haem 
oxygenase breakdown products BV or CO diminished the adherence of sickle 
red blood cells to the endothelium. In addition, we observed that CO elicited 
vessel relaxation in the presence of sickle blood.
In preliminary experiments performed to optimise our experimental 
procedure and in accordance to previously published results (Brown et al.,
2001), it was observed that exposure of endothelial cells to normal blood did not 
result in adherence of red blood cells when compared to sickle blood. We 
hypothesised that this may be due to the lack of haemolysis and, subsequently, 
cell-free haemoglobin in normal blood. This is in contrast to sickle blood, which 
undergoes frequent haemolytic events that raise cell-free haemoglobin levels 
which possibly activate the endothelium thus promoting adherence. However, 
our experiments do not support this hypothesis since an increase in red blood 
cell adherence was not observed when normal blood was lysed or had added 
cell-free haemoglobin. These data suggest that there are other components in 
blood of sickle patients, different from haem or haemoglobin, that influence the 
adherence process. Indeed, chronic inflammation characteristic of SCO 
stimulates the production of a large number of circulating pro-inflammatory 
mediators which are not normally present in control subjects. These factors, 
together with oxidants produced in sickle blood (Frenette, 2002), could easily 
influence the activation of endothelial cells and subsequent adherence of red 
blood cells.
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Pre-incubation of endothelial cells with haemin inhibited sickle red blood 
cell adhesion. We proposed that this effect was through the induction of haem 
oxygenase, a hypothesis that was confirmed by the observation that SnPPIX, a 
haem oxygenase inhibitor, diminished the effect of haemin on sickle red blood 
cell adhesion. However, SnPPIX did not elicit a complete reversal of the actions 
of haemin on cell adhesion. As SnPPIX is a competitive inhibitor of haem 
oxygenase activity, it is possible that some residual haem oxygenase activity 
remained and still modulated cell adhesion to a small extent. It is also important 
to mention that SnPPIX is a non-specific haem oxygenase inhibitor when used 
at high concentrations and will block the activity of all isoforms of the enzyme. 
Since endothelial cells express both HO-1 (inducible) and HO-2 (constitutive), 
the use of SnPPIX does not allow us to ascertain whether the increase in haem 
oxygenase activity was due to HO-1 induction. However there is vast literature 
showing that HO-2 is not inducible (apart from glucocorticoids) and HO-1 is up- 
regulated by haemin and oxidative stress (Maines, 1988), which are typical of 
SOD. Therefore based on previous sound evidence we assume that it is the 
HO-1 isoform of the enzyme that is being induced in our experiments. 
Nonetheless, further experiments involving specific HO-1 gene knockdown in 
endothelial cells would corroborate our findings. For example, small interfering 
RNA (siRNA) technology has been widely used to silence specific genes in 
mammalian cells via the introduction of synthetic double-stranded siRNA using 
plasmid or viral vectors (Leung and Whittaker, 2005). Such experiments would 
distinguish clearly between the contribution of endothelial HO-1 or HO-2 to our 
observed results.
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Further experiments involving treatment with BV and also reduced the 
adherence of sickle red blood cells to the endothelium, which further confirmed 
that haem oxygenase was involved in this effect. These results could be 
explained by a reduction in the expression of endothelial adhesion molecules. 
Although haem itself has been shown to induce adhesion molecule expression 
in endothelial cells, its ability to induce HO-1 has been proposed to modulate 
this effect (Wagener et al., 1997). Indeed, Soares et al observed that up- 
regulation of HO-1 diminished the expression of adhesion molecules associated 
with endothelial cell activation (Soares et al., 2004). Furthermore, anti­
inflammatory treatment in SCD inhibits endothelial cell activation and adhesion 
molecule expression and leads to a reduction in vaso-occlusion (Kaul et al., 
2004). As haem oxygenase exerts potent anti-inflammatory actions, its 
induction in SCD could result in potential protective effects in the development 
of vaso-occlusive crisis. We also note that hydroxyurea treatment in SCD 
significantly lowers expression of adhesion molecules on sickle red blood cells 
(Gambero et al., 2007). As hydroxyurea has been shown to act as a NO donor 
(King, 2004) and NO activates haem oxygenase (Foresti et al., 1997; Motterlini 
et al., 1996a) we speculate that hydroxyurea can reduce red blood cell 
adhesion molecule expression via haem oxygenase.
Pre-incubation of endothelial cells with BV elicited a concentration- 
dependent reduction in red blood cell adhesion. However, pre-incubation of 
sickle blood with BV elicited an even more powerful reduction in red blood cell 
adhesion to endothelial cells. These findings may be explained by the potent 
anti-oxidant activity of BV (and BR) and indicate that treatment of sickle blood is 
a very effective strategy in decreasing adherence to the endothelium. BR has
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been reported previously to have important protective anti-oxidant effects on 
sickle cell membranes (Dailly et al., 1998) and our results using BV suggest that 
the anti-oxidant action of BV reduces membrane damage and the consequent 
expression of adhesion molecules on red blood cells. Since HO-1-derived BR 
protects the endothelium by reducing endothelial activation and dysfunction 
(Kawamura et al., 2005) as well as limiting lipid peroxidation in sickle mice 
(Belcher et al., 2006), our data sustain the idea that BV can act on both 
endothelial and red blood cells to reduce cellular interaction.
We also observed that CO from CORM-3 and C0RM-A1 inhibited the 
adhesion of sickle red blood cells to endothelium. Similarly to BV, the action of 
CO was more pronounced when red blood cells were incubated with CO-RMs, 
suggesting that sickle red blood cells play a dominant role in stimulating 
adhesion and that they represent a potential target for therapeutic intervention. 
HO-1-derived CO has been reported to have anti-inflammatory properties 
(Motterlini et al., 2003) and may help reduce endothelial cell activation and 
expression of adhesion molecules. Interestingly, CO gas administration 
inhibited vascular stasis (Belcher et al., 2003) in a transgenic mice model of 
SCD, thus potentially diminishing the risk of vaso-occlusive crisis. HO-1-derived 
CO also suppresses endothelial cell apoptosis (Brouard et al., 2000), and this 
finding might be relevant for SCD, as endothelial cell apoptosis sustains 
inflammation and promotes vascular thrombosis which may play a role in vaso- 
occlusion. In a study conducted more than 30 years ago, Beutler showed that 
CO limits haemolysis in SCD by increasing the life-span of red blood cells 
(Beutler, 1975); this action of CO could reduce activation of or damage to 
endothelial or red blood cells by hindering the release of pro-inflammatory
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haemoglobin. In addition, inhalation of CO at low levels inhibits the expression 
of pro-inflammatory genes and promotes the production of anti-inflammatory 
cytokines (Belcher et al., 2003). These studies suggest a potential role for CO 
as a therapeutic agent in SCD. Collectively, we speculate that inhibition of red 
blood cell adhesion to the endothelium by CO and BV contributes to inhibition of 
vaso-occlusion in SCD.
CO is very similar to NO and can mimic some of its functions, such as 
interacting with signal transduction pathways and vessel relaxation. NO has an 
important role in the pathogenesis of SCD where a reduction in basal and 
stimulated NO production and bioavailability has been described (Reiter et al., 
2002). Haemolysis induced elevated plasma haemoglobin and excessive ROS 
production both act to reduce NO bioavailability either through scavenging by 
haemoglobin or formation of reactive nitrogen species. One of the most 
important consequences of reduced NO availability is the effect on vessel tone 
resulting in vasoconstriction, which could contribute to subsequent vaso- 
occlusion. We suggest that HO-1-derived CO, relatively inert compared to NO 
due to its lack of unpaired free electrons, may induce vasodilation in SCD and 
compensate for the reduced bioavailability of NO.
We observed that CO liberated from C0RM-A1 relaxed vessels exposed 
to sickle and normal blood, although sickle blood reduced C0RM-A1-mediated 
relaxation compared to normal blood. The increased levels of free haemoglobin 
present in sickle blood could scavenge CO and reduce its biological effects. 
This hypothesis is corroborated by our experiments where aortic rings were 
exposed to red blood cells or plasma alone, showing that sickle red blood cells 
inhibited C0RM-A1-mediated vasorelaxation to a higher degree than normal
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red blood cells. However, the effect of sickle red blood cells was more 
pronounced than that observed with whole sickle blood, suggesting that the 
plasma component of whole blood counter-balances the effect of red blood 
cells. Mosseri and colleagues reported that sickle red blood cells inhibited 
vasorelaxation and attributed the effect to the presence of free HbS and 
interaction of abnormal red blood cell membranes with the vessel wall (Mosseri 
et al., 1993). The authors also observed that the effect could be reversed by 
addition of anti-oxidants. Whether haem oxygenase, through the production of 
BV/BR might ameliorate abnormal vessel tone in SCD remains to be 
established.
The differences in vasorelaxation responses observed when rings were 
exposed to normal or sickle red blood cells may also indicate differences in 
binding of CO to HbA and HbS. Although a highly speculative idea, HbA binding 
to CO may maintain its bioavailability, whereas HbS binding may limit the 
biological action of CO. Indeed, abnormal binding of NO to HbS containing red 
blood cells has been demonstrated in SCD (Pawloski et al., 2005) and there 
may be similar anomalous interactions with CO.
Further experiments exploring the vasodilatory effects of C0RM-A1 on 
rings exposed to plasma showed inhibition of vasorelaxation in the presence of 
both sickle and normal plasma. However, no differences were observed 
between plasma separated from sickle or normal blood. These data suggest 
that plasma in general is capable of scavenging CO and limiting its actions. 
However, the presence of cell-free haemoglobin in plasma might cause this 
effect. It is possible that separation of red blood cells from plasma may have 
resulted in some accidental lysis of red blood cells, thus raising plasma levels of
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haemoglobin. Although more free haemoglobin would be expected in sickle 
than normal blood, even the small quantities present in normal blood may be 
sufficient to decrease the actions of CO.
In contrast to C0RM-A1, CORIVI-3 did not elicit strong vasorelaxation in 
rings incubated with whole blood, red blood cells or plasma from sickle patients 
or control subjects. In addition, the CORM-S-mediated vasodilatory response 
was similarly inhibited by sickle and normal blood. The different kinetics of CO 
release by CORM-3 and C0RM-A1 may explain the difference in the effects 
exerted by the two compounds.
In comparative experiments with two NO donors, we observed that both 
DEA-NO and PAPA-NO produced powerful and immediate vasodilation in 
vessels. Unsurprisingly, NO elicited greater vasodilation than that obtained with 
CO-RMs. Interestingly, the presence of sickle blood enhanced the vasodilation 
produced by DEA-NO in comparison to normal blood or control. As more free 
haemoglobin is present in sickle blood, enhanced scavenging of NO would be 
expected, thus causing vasoconstriction. The possibility that free haemoglobin 
actually facilitates the release of NO from DEA-NO or that binding of 
haemoglobin to NO enhances its bioavailability may account for our results. In 
contrast, even though PAPA-NO elicited enhanced vasodilation in the presence 
of sickle or normal blood, there was no difference between the two blood 
groups. As in the case of CO-RMs, the effects of the two NO donors may be 
explained by the different kinetics of NO release of the two molecules. It has 
been reported that the ability of sickle red blood cells to scavenge NO is 
reduced (Olmos et al., 2002) and that sickle red blood cells exhibit an abnormal 
processing of intracellular Hb-NO (Gow et al., 1999), suggesting that the
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peculiar behaviour of sickle red blood cells is responsible for some of our 
observed results.
Even though NO is a more potent vasodilator than CO, its presence is 
severely reduced in SCD (Hsu et al., 2007). It is possible that CO has a role in 
controlling vascular tone in sickle patients, in an attempt to compensate for 
abnormal vessel tone due to reduced plasma NO. In other words, the high 
levels of haemolysis in SCD could provide sufficient substrate for haem 
oxygenase to produce CO which could help counteract the reduced 
bioavailability of NO. indeed, high levels of carboxyhaemoglobin have been 
found to correlate with haemolysis in SCD (Sears et al., 2001), indicating 
production of CO in this disease. Interestingly, a recent British study 
investigating the relationship between air quality and the number of hospital 
admissions caused by acute pain in sickle patients found a correlation between 
high CO levels and reduced admissions, as opposed to an increase in 
admissions when atmospheric NO and CO levels are low (Yallop et al., 2007). 
These results are intriguing and possibly indicate an important role for CO in the 
prevention of sickle crisis. Accordingly, the above study sustains our hypothesis 
that haem oxygenase-derived CO or exogenously administered CO could 
function as a therapeutic agent in SCD.
A possible role for haem oxygenase in the prevention or resolution of 
pathological processes which may lead to vaso-occlusion in SCD is postulated 
in Figure 6-11. In brief, induction of endothelial haem oxygenase could reduce 
the expression of adhesion molecules of both red blood cells and endothelium 
and prevent adhesive interactions through the action of its breakdown products 
CO and BV. These products could also protect red blood cell membranes and
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limit red blood cell sickling. Production of CO could also counteract the 
vasoconstriction caused by NO scavenging, thus preventing vascular stasis that 
leads to sickling of red blood cells and consequent vaso-occlusion.
Vasoconstriction due to 
NO scavenging or 
consumption
SCD Pathology
Pro-inflammatory state 
Induces vascular 
stasis, damages RBCs 
and promotes sickling
Haemolysis induces 
oxidative stress which 
stimulates increased 
cellular adhesion
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Vasodilation Anti-inflammatory | Anti-oxidant
Figure 6-11. Proposed role for haem oxygenase in prevention of vaso- 
occlusion in SCD
Induction of haem oxygenase-1 (HO-1) in SCD results in the production of 
carbon monoxide (CO) and biliverdin (BV), which counteract the pathological 
processes present in the disease. The vasodilatory action of CO can mitigate 
the reduction in nitric oxide (NO) bioavailability caused by scavenging of 
haemoglobin (Mb) or consumption by superoxide (O2 ) or peroxynitrite (ONOO' 
). The anti-inflammatory and anti-oxidant properties of BV and CO can diminish 
the pro-inflammatory and pro-oxidant environment that results from red blood 
cell (RBC) sickling and haemolysis, thus reducing RBC damage and decreasing 
adhesion molecule expression in both RBCs or endothelium.
233
Furthermore, in a clinical scenario where a vaso-occlusive crisis has already 
occurred, increased haemolysis could stimulate the induction of haem 
oxygenase in the endothelium and other tissues, and HO-1 biproducts could 
limit and resolve the crisis through their anti-oxidant, anti-proliferative, anti­
inflammatory as well as vasodilatory functions.
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Chapter 7. Exploring the effect of HO-1 inducers on 
erythroid progenitor cells (K562)
7.1 Introduction
K562 are erythroid progenitor cells derived from the bone marrow of a 
patient with chronic myelogenous leukaemia (Lozzio and Lozzio, 1975). These 
cells are characteristically bi-potential, in other words, they can be stimulated to 
express erythroid or megakaryocytic properties depending on the stimulus. As 
such, K562 cells offer an excellent experimental model to study the molecular 
mechanisms of erythroid differentiation. For instance, following treatment with 
haemin or other inducing agents (like anthracyclines, sodium butyrate, and 
resveratrol) K562 cells can differentiate into haemoglobin-producing cells 
(Tsiftsoglou et al., 2003). These cells have been used as an invaluable tool in 
studying the regulation of foetal and embryonic haemoglobin expression, two 
haemoglobin subtypes that decrease the clinical severity of 
haemoglobinopathies such as SCD (Saunthararajah and DeSimone, 2004) and 
fl-thalasseamia (Lai and Vichinsky, 2004). In fact, it is the erythroid progenitor 
cells which provide a target for the action of hydroxyurea in SCD (Steinberg,
2002), where the drug stimulates the production of HbF, thus reducing the 
concentration of the mutant HbS in sickle red blood cells and diminishing the 
likelihood of sickling.
Exposure of endothelial cells to hydroxyurea induces haem oxygenase 
activity in the presence of haem. Haem oxygenase protects the endothelium 
from oxidative stress though its breakdown products (Immenschuh and 
Schroder, 2006), however, the potential role of haem oxygenase in K562 cells is
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yet to be fully understood. It has been proposed that haem oxygenase may 
have a role as a directional switch between differentiation of K562 cells into 
erythroid or megakaryocytic cell lines (Koiso et al., 1999). Specifically, haem 
oxygenase induction in K562 cells is reported to induce differentiation to 
monocytes, whereas its inhibition results in erythroid differentiation. As 
hydroxyurea has been observed to induce endothelial haem oxygenase and the 
role of haem oxygenase in K562 needs to be fully explored, a preliminary set of 
experiments were designed to determine the response of K562 cells to 
hydroxyurea and common haem oxygenase inducers and to investigate 
whether haem oxygenase or its products affect cell viability. The consequent 
findings may help to better elucidate the therapeutic effect of hydroxyurea in 
SCD, with the potential involvement of haem oxygenase.
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7.2 Objectives
• To explore the effect of various known haem oxygenase inducers on 
haem oxygenase activity levels in K562 cells
• To investigate whether co-incubation of haem and hydroxyurea can 
influence haem oxygenase activity levels in K562 cells
• To assess whether co-incubation of haem and hydroxyurea affects K562 
cell viability
• To examine whether the haem oxygenase breakdown products CO and 
BV influence viability of K562 cells
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7.3 Experimental protocol
The detailed methods used in the experiments described in the following 
section can be found in the Materials and Methods chapter. All stock solutions 
were freshly prepared. Hydroxyurea and thymidine (10 mM) were solubilised in 
distilled water. Haemin (1 mM) was dissolved in 0.1 M NaOH and 0.01 M 
phosphate buffer at pH 7.4. A stock solution of tin protoporphyrin IX (SnPPIX) 
was prepared by dissolving the compound in 0.1 M NaOH and was protected 
from light with aluminium foil. DETA-NO (10 mM) was solubilised in 0.01 M 
NaOH. Curcumin was prepared in ethanol.
7.3.1 Incubation of cells with reagents
To investigate the effect of classic inducers of HO-1, K562 cells were 
exposed for 6 h to either haemin (15 pM, 30 pM, 50 pM), curcumin (10 pM, 20 
pM, 50 pM), or the NO donor DETA-NO (50 pM, lOOpM, 300pM) and collected 
for the haem oxygenase activity assay. The range of concentrations used was 
based on previous assessments of haem oxygenase activity in other cell types. 
K562 cells were also treated with medium alone as a control. In additional 
experiments, K562 cells were incubated with haemin (5 pM, 15 pM, 30 pM, 50 
pM) for 20 h and haem oxygenase activity determined.
The effect of hydroxyurea (100, 300 and 500 pM) on haem oxygenase 
activity was also investigated by exposing K562 cells to the drug for 18, 24, 48 
and 72 h. In another set of experiments, cells were incubated for 24 h with 50 
pM, 100 pM and 200 pM thymidine (a pharmacological agent which stimulates 
haemoglobin synthesis as well reportedly inducing enzymes of haem 
degradation, including HO-1 in K562 cells (Trakshel et al., 1987)), and haem 
oxygenase activity measured. K562 cells were also incubated with 15 pM
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haemin in the presence or absence of 300 pM hydroxyurea for 6 and 18 h 
followed by measurement of haem oxygenase activity.
The effect of haemin and hydroxyurea on cell viability was investigated. 
Firstly, cell damage was induced by challenging K562 cells with hydrogen 
peroxide (H2O2), a generator of oxidative stress, at 0.5 mM, 1 mM and 2 mM 
concentration for 24 h. Cells were also incubated with 1% Triton as a positive 
control. At the end of the incubation, LDH levels were measured in culture 
medium. In further experiments, K562 cells were pre-incubated with 15 pM 
haemin, 300 pM hydroxyurea or a combination of haemin and hydroxyurea for 
18 h followed by addition 1 mM H2O2 for 24 h. Similar experiments were 
conducted in the presence of the haem oxygenase inhibitor SnPPIX (15 pM) to 
establish whether haem oxygenase protects H202-mediated damage (1 mM for 
24 h).
To investigate the effect of haem oxygenase degradation products on 
H202-induced cytotoxicity, K562 cells were incubated with 1, 5 or 10 pM CORM- 
3 or C0RM-A1 for 1 h, followed by exposure for 24 h with 1 mM H2O2. Cells 
were also incubated with the negative controls iCORM-3 and iCORM-AI (10 
pM). K562 cells were also pre-incubated for 1 h with 0.1, 0.5 or 1 pM BV prior to 
challenge with 1 mM H202for 24 h.
7.3.2 Haem oxygenase activity assay
Haem oxygenase activity was determined in endothelial cells at different 
times after treatment as described in section 2.7 Briefly, harvested cells were 
subjected to three cycles of freeze-thawing before addition to a reaction mixture 
containing NADPH, rat liver cytosol as a source of BVR, and the substrate 
haemin. The reaction was conducted at 37 °C in the dark for 1 h, terminated by
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the addition of 1 ml chloroform, and the extracted BR was calculated by the 
difference in absorbance between 464 and 530 nm (e = 40 mM'^cm’ )^.
7.3.3 Lactate dehydrogenase assay
K562 cell viability was determined using the LDH assay. LDH is present 
in all cells as a stable cytoplasmic enzyme. Cell plasma membrane damage will 
result in LDH being rapidly released into cell culture supernatant. The LDH 
based cytotoxicity detection kit (Roche Diagnostics, UK) provides a colorimetric 
assay for the quantification of cell death and cell lysis dependent on the 
measurement of LDH activity released from the cytosol of damaged cells into 
the supernatant. The assay was carried out according to the manufacturers' 
instructions.
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7.4 Results
7.4.1 Response of K562 cells to classic HO-1 Inducers
Haem oxygenase is a protective protein which has been shown in many 
cell types to protect against the effects of oxidative damage. It can be induced 
by a number of agents and in studies already reported in this thesis its induction 
has been demonstrated in bovine endothelial cells, murine macrophages, 
porcine renal epithelial cells and human Gtrardi cardiomyocytes by haem and 
NO. The role of haem oxygenase in K562 cells is yet to be fully understood, and 
it would be interesting to investigate if classic inducers of haem oxygenase in 
other cell types (such as haemin, NO and others) would elicit the same 
response on haem oxygenase activity in K562 cells.
Contrary to our expectations, incubation of K562 cells for 6 h with 
haemin, curcumin or DETA-NO failed to augment haem oxygenase activity in 
K562 cells, actually producing a significant decrease in activity compared to 
control. Figure 7-1 A shows that haem caused an approximate 50% reduction in 
basal haem oxygenase activity at all concentrations used (15, 30 and 50 pM). 
Similarly, curcumin elicited a concentration-dependent reduction in haem 
oxygenase activity with 50 pM curcumin exhibiting an almost 50% reduction 
(Figure 7-1 B). The NO donor DETA-NO did not significantly change haem 
oxygenase activity at any of the concentrations employed (50, 100 and 300 pM) 
(Figure 7-1 C).
As haem is also the substrate for haem oxygenase activity, its effect on 
K562 cells was further explored using a wider concentration range for a longer
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time interval. Figure 7-2 shows that incubation of cells with haemin (5, 15, 30 
and 50 |jM) for 20 h caused a concentration dependent inhibition of haem 
Oxygenase activity, with 50 pM haem reducing the activity to approximately 20% 
Of control.
In summary, our experiments indicated that the classic inducers of HO-1 
(haam, curcumin and NO) failed to increase haem oxygenase activity in K562 
Cells. In fact, haem and curcumin reduced activity to levels below control, 
Suggesting that the mechanism(s) responsible for induction of haem oxygenase 
in K662 cells may differ from other cell types.
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Figure 7-1. Classic HO-1 inducers do not increase haem oxygenase 
activity in K562 cells
K562 cells were treated for 6 h with: (A) 15, 30 and 50 pIVI haem; (B) 10, 20 
and 50 [jM curcumin; (C) 50, 100 and 300 |jM DETA-NO. Cells were also 
incubated in medium alone (CON). Haem oxygenase activity was measured as 
described in Materials and Methods. Bars represent the mean+SEM of 4-6 
independent experiments per group. * P<0.05 vs. CON.
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Figure 7-2. Haemin reduces haem oxygenase activity of K562 cells in a 
concentration-dependent manner
K562 cells were exposed to 5, 15, 30 and 50 pM haemin for 20 h. Cells were 
also incubated in medium alone (CON). Haem oxygenase activity was 
measured as described in Materials and Methods. Bars represent the 
mean±SEM of 4-6 independent experiments per group. * P<0.05 vs. CON.
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7.4.2 Effect of hydroxyurea on haem oxygenase activity in K562 cells
Since hydroxyurea induces haem oxygenase activity in endothelial cells 
and modulates erythroid cell function, its effect on haem oxygenase activity in 
K562 cells was tested. K562 cells incubated with hydroxyurea (100, 300 or 500 
fjM) for 24 h exhibited a slight increase in haem oxygenase activity (Figure 7-3 
A). At 500 [jM concentration of hydroxyurea did not raise haem oxygenase, 
possibly because of cytotoxic effects at high concentrations.
It has been reported that a few days of exposure to hydroxyurea are 
needed to stimulate HbF production in erythroid progenitors (Fibach et al., 
1993) suggesting that hydroxyurea causes a time-dependent adaptation in 
erythroid cells. Therefore, we thought it would be interesting to examine the 
time course of haem oxygenase activation after treatment with hydroxyurea. 
Figure 7-3 B shows that the levels of haem oxygenase activity fluctuated over 
time, even in cells exposed to medium alone, but the changes caused by 
hydroxyurea were more pronounced. In fact, 100 and 300 pM hydroxyurea 
promoted an early increase in haem oxygenase activity at 18 h and 24 h 
followed by a substantial fall at 48 and 72 h. Cells exposed to 500 pM 
hydroxyurea did not exhibit a significant increase in haem oxygenase activity 
compared to control at 18 and 24 h, and at 72 h the activity was markedly 
decreased below control levels. The literature reports only a few studies 
involving haem oxygenase and K562 cells. However, a specific investigation 
showed that thymidine (Trakshel et al., 1987), an inducer of haemoglobin 
synthesis in K562 cells, up-regulated haem oxygenase activity. To confirm 
these findings, K562 cells were exposed to 50, 100 and 200 pM thymidine for
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24 h and it was observed that the compound induced haem oxygenase activity 
in a concentration-dependent manner {Figure 7-4).
Overall, the results show that hydroxyurea and thymidine can be used to 
increase haem oxygenase activity in K562 cells, in a mechanism still unknown 
but that could be related to the shared property of the two compounds to 
stimulate haemoglobin production in erythroid cells. However, even if thymidine 
and hydroxyurea up-regulate haem oxygenase, it is noted that the response of 
K562 cells is very contained, which is in contrast to the high haem oxygenase 
induction observed in other cell types upon exposure to the appropriate stimuli 
(Otterbein et al., 2003a).
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Figure 7-3. Hydroxyurea affects haem oxygenase activity in K562 cells: 
concentration and time-dependent effects
(A) K562 cells were exposed for 24 h to 100, 300 and 500 pM hydroxyurea 
(HU). (B) K562 cells were exposed for 18, 24, 48 and 72 h to 100, 300 and 500 
pM HU. Cells were also incubated in medium alone (CON). Haem oxygenase 
activity was measured as described in Materials and Methods. Bars represent 
the mean±SEM of 4-6 independent experiments per group. * P<0.05 vs. CON.
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Figure 7-4. Thymidine affects haem oxygenase activity in K562 cells
K562 cells were exposed for 24 h to 50, 100 and 200 pM thymidine. Cells were 
also incubated in medium alone (CON). Haem oxygenase activity was 
measured as described in Materials and Methods. Bars represent the 
mean±SEM of 4-6 independent experiments per group. * P<0.05 vs. CON.
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7.4.3 Co-incubation of K562 cells with haem and hydroxyurea: haem
oxygenase activity response and cytotoxicity experiments
It has previously been shown that co-incubation of endothelial cells with 
haemin and hydroxyurea enhances haem oxygenase activity to a greater extent 
than haemin or hydroxyurea alone. Since hydroxyurea increases haem 
oxygenase activity in K562 cells, whereas haem has an inhibitory effect, we 
thought it would be interesting to investigate how the two compounds together 
affect haem oxygenase activity in erythroid cells.
Although 15 pM haemin did not cause changes in haem oxygenase 
activity after 6 h incubation (Figure 7-5 A), it decreased significantly the activity 
at 18 h (Figure 7-5 B). In contrast, 300 pM hydroxyurea alone increased haem 
oxygenase activity at both 6 h and 18 h. Interestingly, co-incubation of K562 
cells with hydroxyurea and haemin showed a time-dependent inhibition of haem 
oxygenase induction.
These results indicate that when K562 cells are exposed to haemin and 
hydroxyurea, the haem oxygenase inhibitory action of haemin prevails over the 
activating effect of hydroxyurea. This is interesting as the opposite was 
observed in endothelial cells, and suggests that haem oxygenase may have a 
unique role in K562 cells.
Haem oxygenase has been shown to be protective against oxidative 
damage in various cell types. Considering the effects of haemin and 
hydroxyurea on haem oxygenase activity, we decided to investigate whether 
haemin and hydroxyurea affected the extent of cytotoxicity caused to K562 cells 
upon incubation with H2O2, a generator of oxidative stress. Figure 7-6 A shows 
that incubation of cells with 0.5, 1 or 2 mM H2O2 for 24 h resulted in
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concentration-dependent cytotoxicity, with 2 mM H2O2 inducing damage 
equivalent to the positive control. One millimolar H2O2 produced approximately 
60% cell damage and was the concentration chosen for the subsequent 
experiments with haemin and hydroxyurea.
Incubation of K562 cells with 15 pM haemin, 300 pM hydroxyurea or the 
combination of haemin and hydroxyurea for 18 h did not affect cell viability 
(Figure 7-6 B). Furthermore, pre-incubation with haemin, hydroxyurea or haem 
and hydroxyurea markedly reduced cytotoxicity caused by challenge with H2O2. 
These results suggest that haemin and hydroxyurea may be acting though 
haem oxygenase to protect K562 cells from oxidative damage.
To investigate this possibility, the haem oxygenase activity inhibitor 
SnPPIX was used. Figure 7-7 A shows that 15 pM SnPPIX significantly inhibited 
haem oxygenase activity of K562 cells incubated for 18 h with either medium 
alone or 15 pM haemin, 300 pM hydroxyurea or the combination of the two. 
Interestingly, the presence of SnPPIX did not influence the protection conferred 
by haem and hydroxyurea against H202-mediated cytotoxicity (Figure 7-7 B). 
Collectively, these findings suggest that the mechanism by which haemin and 
hydroxyurea protect K562 cells from oxidative damage may be haem 
oxygenase-independent, or that the residual haem oxygenase activity 
measured after incubation with SnPPIX may be sufficient to provide protection 
against oxidative stress.
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Figure 7-5. Hydroxyurea synergizes with haemin to down regulate haem 
oxygenase activity In K562 cells
(A) K562 cells were exposed to 15 pM haemin, 300 pM hydroxyurea (HU) or a 
combination of the two for 6 h. (B) K562 cells were exposed to 15 pM haem (H), 
300 pM HU or a combination of the two (H + HU) for 18 h. Cells were also 
exposed to medium alone (CON). Haem oxygenase activity was measured as 
described in Materials and Methods. Bars represent the mean+SEM of 4-6 
independent experiments per group. * P<0.05 vs. CON.
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Figure 7-6. Haemin and hydroxyurea provide protection against oxidant- 
induced damage
K562 cells were exposed to: (A) 0.5, 1 and 2 mM hydrogen peroxide (H 2O 2) for 
24 h; (B) 15 pM haemin (H), 300 pM hydroxyurea (HU) or a combination of the 
two (H + HU) for 18 h; (C) 15 pM H, 300 pM HU or a combination of the two for 
18 h followed by 24 h incubation with 1 mM H2O2. Cells were also exposed to 
media alone as a negative control (CON) and 1% Triton as a positive control 
Lactate dehydrogenase levels were measured as described in Materials and 
Methods. Bars represent the mean+SEM of 4-6 independent experiments per 
group. * P<0.05 vs. 1% Triton. tP<0.05 vs. 1 mM H2O2 alone.
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Figure 7-7. A haem oxygenase inhibitor does not affect the protection 
elicited by haemin or hydroxyurea against oxidant-mediated damage in 
K562 cells
(A) K562 cells were exposed to 15 pM haemin (H), 300 pM hydroxyurea (HU) or 
a combination of the two (H + HU) for 18 h, in the presence (-»- SnPP) or 
absence of 15 pM SnPPIX (-SnPP), a haem oxygenase inhibitor. Cells were 
also exposed to medium alone (CON). Haem oxygenase activity was measured 
as described in Materials and Methods. (B) K562 cells were pre-incubated with 
15 pM haemin, 300 pM HU or a combination of the two for 18h, in the presence 
of 15 pM SnPPIX prior to exposure for a further 24 h to 1 mM H2O2. Cells were 
also exposed to media alone (CON) as a negative control and 1% Triton as a 
positive control. Lactate dehydrogenase levels were measured as described in 
Materials and Methods Bars represent the mean+SEM of 4-6 independent 
experiments per group. * P<0.05 vs. -SnPP (A) or 1% Triton (B). tP<0.05 vs. 1 
mM H2O2 alone.
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7.4.4 Effect of haem oxygenase degradation products on the cytotoxicity 
induced by H2O2 in K562 cells
To further explore the possible role of haem oxygenase in providing 
protection of K562 cells against oxidative stress, K562 cells were incubated with 
the haem degradation products CO and BV. Two recently identified CO-RMs, 
CORM-3 (Foresti et al., 2004) and CORM-AI (Motterlini et al., 2005c), were 
used as a source of exogenous CO (see Materials and Methods).
Figure 7-8 A shows that 1 h pre-incubation of cells with 1, 5, and 10 pM 
CORM-AI provided protection against H2O2 -induced cell damage. However, the 
inactive form of the compound (iC0RM-A1, 10 pM) which had been previously 
stimulated to release all bound CO, also exhibited some protection against H2O2 
-induced damage, although not as much as 10 pM CORM-AI alone. Similarly to 
CORM-AI, pre-incubation with 1, 5 and 10 pM CORM-3 elicited a 
concentration-dependent protection against H2O2 -induced damage, with 10 pM 
CORM-3 showing the highest protection (Figure 7-8 B). Again iCORM-3 
showed some protection against oxidative damage, but not to the extent 
observed with active CORM-3 The effect of iCORM-AI and iCORM-3 may be 
due to potential residual CO remaining in the molecule. Finally, our results 
indicate that also 1 h pre-incubation with 0.1, 0.5 and 1 pM BV significantly 
defended cells from cell damage induced by H2O2 challenge.
The above findings sustain the idea that low concentrations of haem 
degradation products are effective in providing protection against oxidative 
damage in K562 cells.
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Figure 7-8. CO and BV protect K562 cells against oxidant-induced damage
K562 cells were pre-incubated for 1 h with; (A) 1,5, 10 pM CORM-AI or 10 pM 
inactive CORM-AI (ICORM-AI); (B) 1, 5, 10 pM CORM-3 or 10 pM inactive 
CORM-3 (iCORM-3) and, (C) 0.1, 0.5, 1 pM biliverdin (BV), followed by 
exposure to 1 mM H202for 24 h. Cells were also exposed to medium alone as a 
negative control (CON) and 1% Triton as a positive control. Lactate 
dehydrogenase levels were measured as described in Materials and Methods. 
Bars represent the mean+SEM of 4-6 independent experiments per group. 
*P<0.05 vs. 1% Triton. tP<0.05 vs. 1 mM H2O2 alone.
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7.5 Discussion
The role of haem oxygenase in K562 cells is yet to be fully elucidated 
and it has been postulated that haem oxygenase may have a function in K562 
differentiation (Koiso et al., 1999); however the involvement of haem oxygenase 
in protection of K562 cells is unclear. Therefore, we investigated the modulation 
of haem oxygenase in K562 cells exerted by haem oxygenase inducers and 
measured cytotoxicity following oxidant challenge. The results show that potent 
inducers of HO-1 expression had no effect on activating haem oxygenase 
activity in K562 cells; in fact, there was a significant reduction in haem 
oxygenase activity following incubation with haemin. However, treatment of 
cells with hydroxyurea raised haem oxygenase activity, but co-incubation of 
haemin and hydroxyurea resulted in a significant inhibition of haem oxygenase 
activity, the effect being greater than with haem alone. Irrespective of the 
observed haem oxygenase inhibition, incubating K562 cells with haemin, 
hydroxyurea, or haemin plus hydroxyurea still provided protection against H2O2- 
induced oxidative damage. Addition of a haem oxygenase activity inhibitor, 
SnPPIX, had no effect on the protection conferred by haemin and hydroxyurea, 
while pre-incubating cells with BV and CO mitigated oxidative damage. These 
data are difficult to reconcile and suggest that further investigation is required to 
determine if haem oxygenase is involved in the protection of K562 cells against 
oxidant-induced damage.
It is interesting that potent inducers of haem oxygenase expression such 
as haemin, curcumin and NO had no effect in inducing haem oxygenase in 
K562 cells. These results are in line with findings by Trakshel and co-workers 
(Trakshel et al., 1987), who previously reported inhibition of haem oxygenase
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activity by haemin. BV and CO pre-incubation still provided significant protection 
from oxidant-damage, leading us to argue that despite the reduction in haem 
oxygenase activity by haemin, there is still enough residual haem oxygenase 
activity to confer protection to cells. It could be postulated that erythroid cells 
such as the ones used in our study would want to conserve haem for 
haemoglobin-synthesising purposes and thereby the observation that haemin 
significantly inhibits haem oxygenase activity in K562 cells would be consistent 
with this theory. Haem is not only incorporated as a structural component of 
haemoglobin but can also increase the expression of globin as well as the 
enzymes of the haem biosynthetic pathway in erythroid cells (Tahara et al.,
2004). The treatment of erythroid cells with haemin has also been shown to 
increase both the number of transferrin receptors and the intracellular level of 
ferritin. Therefore, haem plays an important role in the coordinated expression 
of several genes during the differentiation of erythroid cells and it would be 
important to protect it from degradation by haem oxygenase in these cells. K562 
cells express higher levels of HO-2 than HO-1 (Ding et al., 2006). HO-2 may be 
able to sequester haem bound to specific cysteine and proline residues which 
act as haem binding sites, thus maintaining intracellular haem concentrations or 
ameliorate haem-mediated oxidative stress. Challenge with stressful stimuli 
such as hypoxia inhibits HO-2 activity, resulting in Increased intracellular haem 
concentrations and release of sequestered haem (Ding et al., 2006). These 
observations sustain the importance of preserving haem levels in K562 cells as 
this biomolecule is essential for the function of these haemoglobin-synthesizing 
cells. Interestingly, addition of anti-oxidants have been shown to block erythroid 
differentiation in K562 cells (Iwasaki et al., 2006), suggesting that blocking an
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enzyme such as haem oxygenase, which protects against oxidant damage, is 
advantageous to the function of these cells.
Incubation with hydroxyurea increased haem oxygenase activity in K562 
cells. This observation may be explained by the mechanism of action of 
hydroxyurea. Its therapeutic action in SCD is through stimulation of HbF 
production, which reduces the concentration of HbS and lowers the rate of 
sickling of red blood cells (Steinberg, 2002). Hydroxyurea inhibits DNA 
synthesis and prevents haemoglobin from maturing and hence stunt cell 
differentiation (Saunthararajah and DeSimone, 2004). Since haem oxygenase 
has been shown to act as a switch in the differentiation of K562 cells into either 
erythroid or megakaryocytic cells (Koiso et al., 1999), it could be proposed that 
the induction of haem oxygenase by hydroxyurea may be an additional 
mechanism through which the drug stimulates HbF production by inhibiting 
erythroid cell maturation. The increase in haem oxygenase activity by 
hydroxyurea reached a maximal level at 24 h and declined thereafter. In a 
clinical situation, sickle patients would be under hydroxyurea treatment for a 
prolonged period of time, therefore they would be continuously exposed to the 
drug and have a consistent level of hydroxyurea in their blood (Davies and 
Gilmore, 2003). This could possibly maintain a raised level of haem oxygenase 
over time, which may help in the production of HbF due to inhibition of cell 
differentiation. An attempt was made to measure HbF production in K562 cells 
in our laboratory, but it was unsuccessful. It would have been interesting to 
examine if there was any correlation with haem oxygenase activity level and 
HbF production.
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Co-incubation of haemin and hydroxyurea in K562 cells resulted in a 
further inhibition of haem oxygenase activity. This may be a mechanism by 
K562 cells to further protect the breakdown of haem as discussed earlier. The 
interaction of hydroxyurea with haemin may form a complex which may be more 
resistant to degradation than haem alone, thus enhancing the amount of haem 
that can be utilized in haemoglobin production. Other studies have shown that 
haem is protective in K562 cells, for example, haemin was found to defend cells 
against lead-induced toxicity (Sarkar et al., 2005) and there was an associated 
increase in haem uptake by K562 cells. Haemin treatment was also found to 
protect K562 cells against pharmacologically-induced apoptosis (Mayerhofer et 
al., 2004) and the authors demonstrated that addition of CO and BV also 
resulted in partial rescue of cells from apoptosis but not to the extent seen by 
haemin. This suggests that haem oxygenase may have a role in shielding cells 
against apoptosis, but haem may act in other haem oxygenase-independent 
ways to provide protection as well. This idea is confirmed by our experiments 
using SnPPIX which did not reduce the protection elicited by haemin and 
hydroxyurea.
In summary, it was observed that well-known potent inducers of haem 
oxygenase expression did not increase haem oxygenase activity in K562 cells 
and that incubation with haemin and hydroxyurea conferred protection against 
oxidative damage (Figure 7-9). It may be advantageous for these cells to keep 
haem oxygenase activity low to preserve intracellular haem. However, residual 
low haem oxygenase activity may be sufficient to defend against oxidative 
damage in these cells.
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Figure 7-9. Potential role of haem oxygenase in K562 cells
The presence of haem (H) is essential to drive haemoglobin (Hb) production in 
erythroid cells and has an inhibitory effect on haem oxygenase-1 (HO-1). 
Hydroxyurea (HU) inhibits the maturation of HbS, resulting in the production of 
HbF. HO-1 may also inhibit haemoglobin maturation, as well as protecting 
erythroid cells from oxidative stress through the production of carbon monoxide 
(CO) and biliverdin (BV).
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Chapter 8. General Discussion
8.1 Analysis of methodology
8.1.1 Cell culture methodology
Cell culture is an established scientific tool used to study the effects of 
environmental changes or chemical mediators on particular cell types. In these 
studies, established commercial cell lines were used instead of primary cell 
cultures because of their convenience. The benefit of using primary cultures is 
that they have not undergone modification (except by enzymatic or physical 
detachment); however, problems associated with primary culture include the 
presence of various cell types, limited culture lifespan and increased 
susceptibility to contamination. Therefore, commercial cell lines were utilised in 
the present studies as they are more stable and less labour intensive to 
maintain. The following cell lines were used: bovine aortic endothelial cells 
(BAEC), RAW 264.7 murine macrophages, human cardiac myoblasts (Girardi 
cells), renal epithelial cells (LLC-PKi cells) and human erythroid progenitor cells 
(K562 cells). In our studies, we explored the response of endothelial cells to 
various inducers of haem oxygenase, from haemin to whole blood, as well as 
haem uptake or other biological activities. BAEC were used as they have been 
established previously as an in vitro model to study endothelial haem 
oxygenase responses to oxidative stress (Foresti et al., 1999; Foresti et al., 
2003; Ryter et al., 2000) as well as cellular haem uptake (Foresti et al., 2003). 
To explore if the observed effects of haemin, haemoglobin or NO on the 
endothelium could be replicated in other cell types we employed the use of
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RAW 264.7 murine macrophages, Girardi cells and LLC-PKi cells. All of these 
cell types have been previously used to study the effects of oxidative stress on 
eliciting HO-1 responses (Abuarqoub et al., 2005; Abuarqoub et al., 2007; 
Balogun et al., 2003a). K562 cells are an established cell line widely used as an 
experimental model to study the molecular mechanisms of erythroid 
differentiation. The role of haem oxygenase in these cells has not been widely 
reported, although a few studies have shown modulation of haem oxygenase 
responses in K562 cells (Koiso et al., 1999; Koiso et al., 2000).
8.1.2 Biochemical and molecular biology techniques
The major biochemical and molecular biology techniques used were: (i) 
the haem oxygenase assay, (ii) Western blot analysis for HO-1 expression (iii), 
haem uptake assay (iv), BR measurement in culture medium (v), NO electrode 
and (vi) LDH assay.
8.1.2.1 Haem oxygenase assay
Tenhunen and co-workers (Tenhunen et al., 1969) first described the 
haem oxygenase assay in 1970 and this methodology has been used 
extensively in our laboratory (Foresti et al., 2003) to measure intracellular and 
tissue haem oxygenase activity. The assay determines the activity of haem 
oxygenase in the sample as picomole of BR per milligram of protein per hour. 
Because all substrates for the assay were added in excess, we measured the 
maximal haem oxygenase activity that could be stimulated in cells.
8.1.2.2 Western-blot analysis
Western blot is a recognized molecular biology technique for determining 
relative protein expression in cells and tissues (Laemmli, 1970); consequently,
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every assay was run with both negative and positive controls (untreated sample 
and recombinant HO-1 protein). We use the Western blot analysis of HO-1 
expression in combination with determination of haem oxygenase activity and 
the results we obtained were very consistent and reproducible. Each 
experiment is a representative blot of three Independent experiments.
8.1.2.3 Determination of cellular haem
The determination of cellular haem content was measured using the 
protocol established by Balia and colleagues (Balia et al., 1991). This method 
has been widely used as a model to explore the incorporation of haem into 
various cell types (Regan et al., 2001; Uc et al., 2004) including endothelial cells 
(Balia et al., 2000; Foresti et al., 1999; Juckett et al., 1998). The assay gives a 
measurement of total cellular haem content and therefore does not provide 
information on location and utilisation of the haem incorporated. However, the 
assay is a simple and efficient tool to assess cellular haem content and used 
with appropriate controls delivers consistent and informative measurements on 
cellular haem incorporation.
8.1.2.4 Determination of bilirubin in culture medium
The determination of BR in culture medium was a method developed by 
Turcanu and colleagues (Turcanu et al., 1998) to assess the effects of oxidative 
stress on cellular haem oxygenase induction in in vitro work. Haem oxygenase 
activity can be quantified spectrophotometrically by measuring BR production 
from tissue or cellular microsomal fractions (Gemsa et al., 1974; Yoshida and 
Kikuchi, 1978); however the large number of cells required may be inconvenient 
for in vitro work. The detection of BR in the supernatant relies on the
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quantitation of the BR released from cells into the culture medium and 
extraction of the bile pigment with benzene. Its advantages include its simplicity 
and the small number of cells required for every assay, since the extraction with 
benzene allows for a certain sensitivity.
8.1.2.5 NO electrode
The NO electrode (WPI, Sarasota USA) was used to measure the NO 
release from various NO donors in the presence or absence of haemoglobins. It 
is an amperometric sensor, where NO diffuses through a selective membrane 
covering the sensor and is oxidised at the working electrode, resulting in an 
electrical current. This electrode is a popular model and has been widely used 
for both direct measurement of NO and indirect measurement of both nitrite 
(NO2) and nitrate (NO3). The NO electrode and its associated ISO-NO meter 
(WPI, Sarasota USA) provides fast, accurate, and stable NO measurements 
over a wide range of concentrations in aqueous solutions. Advantages include 
rapid response to changes in concentration of NO, high sensitivity and 
selectivity and ease of use. It has been extensively used as research tool in 
exploring the release of NO from various NO donors (Gorren et al., 1996; Hurst 
et al., 1996) as well as exploring the effect of haemoglobin and NO interaction 
(Hakim et al., 1996; Schmidt et al., 1994).
8.1.2.6 Lactate dehydrogenase assay
An LDH assay kit (Roche Diagnostics, UK) was used as an indicator of 
cell viability. LDH is a cytosolic enzyme present within all mammalian cells, 
damage to cellular membranes results in leakage of LDH into extracellular fluid 
and is indicative of cell membrane damage (Drent et al., 1996). This LDH assay
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kit is reported to provide a reliable method of assessing cytotoxicity in various 
cell types (Reeve et al., 2007; Song and Jeong, 2004; Tjoa et al., 2006) through 
in vitro release of LDH from cultured cells.
8.1.3 Endothelial cell adhesion assay
A static in vitro cell adhesion assay was used in the present studies to 
explore the interactions of red blood cells with endothelium. Ultimately, an in 
vivo model would be the favoured research tool; however it may be difficult to 
eliminate the effects of specific molecular pathways due to the complexity of the 
in vivo environment. Therefore, an advantage of in vitro models over in vivo cell 
adhesion models is that the experimental conditions can be modified to assess 
the influence of biochemical and biophysical variables (Shiu and Mclntire, 
2003). Static co-incubation of cultured endothelial cells and washed red blood 
cells first demonstrated the abnormally high adhesiveness of sickle red blood 
cells to endothelial cells (Hebbel et al., 1980b). The standard procedure for 
static assays involves allowing red blood cells to settle on and adhere to 
endothelial cell monolayers at 37°C for a period of time (gravitation 
sedimentation method (Shiu and Mclntire, 2003)). Static assays provide a 
simple and rapid method to examine red blood cell-endothelial interaction and 
have generated significant insights into the molecular mechanisms behind 
abnormal cellular adhesion (Hebbel, 1997) and red blood cell-induced 
endothelial dysfunction (Hebbel et al., 1980a). However, while static assays 
reproduce regions of blood stasis within vessels, the data obtained from these 
assays may not be valid for the prediction of outcomes of red blood cells- 
endothelial interaction under flow conditions. A variation of static adhesion 
assays have been designed which incorporate fluid shear force to replicate flow
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conditions (Smith and La Celle, 1986), but these assays are complex in 
practice.
8.1.4 Isolated aortic ring
Studies in isolated aortic rings are a useful tool to evaluate the 
pharmacological activity of a drug on the receptors, channels and enzymes of 
the vessel (Aim et al,, 2002). Transverse sections of aortic rings are attached to 
tension transducers and suspended in buffer and changes in tension after 
administration of various compounds are measured. The growing use of this ex 
vivo model is due to the fact that it is inexpensive, requires fewer animals in 
comparison with in vivo models and allows the evaluation of the 
pharmacological activity of numerous compounds over a short period of time 
(Gebhardt, 2000). We employed the isolated aortic ring model to investigate the 
effect of vasodilators CO or NO in the presence of sickle blood. This model has 
been widely used to explore the effect of molecules such as CO (Motterlini et 
al., 2005c; Sammut et al., 1998; Sawle et al., 2006; Zhao et al., 2005) and NO 
(Irvine et al., 2007; Wanstall et al., 2001) on vessel relaxation. Furthermore, 
isolated aortic rings have been used to explore the interaction of haemoglobin 
(Crawford et al., 2003) and red blood cells on vessel relaxation (Mosseri et al., 
1993). However, before extrapolating results obtained from the in vitro aortic 
ring model to the in vivo situation the following points should be considered. In 
the vasculature conduit arteries and resistance arteries differ importantly in size, 
function and local environment. Specifically, the aorta is a large conduit vessel 
and therefore has less influence on vascular tone than the smaller resistance 
arteries which play an essential role in the regulation of peripheral resistance. 
Thus, vascular reactivity data obtained from aortic tissue may not be an
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accurate representation of physiological vessel tone. An alternative model that 
could be utilized to investigate contractility of the vasculature is small artery 
myography (Mulvany and Aalkjaer, 1990). This technique allows the study of 
smaller resistance vessels, for example, pre-capillary arteries, by mounting the 
vessel on two stainless steel wires passed through the vessel lumen. The 
subsequent isometric tension measurements are a closer approximation to 
physiological vascular reactivity than those observed with the aortic ring 
protocol. Small vessel myography also has the advantage of simultaneous 
measurement of internal vessel circumference, vessel wall tension, cell 
membrane potential, ion concentration as well as isometric responses.
8.1.5 Limitations of the study
Purified human haemoglobin was purchased from Sigma to use in 
experimental procedures. Ideally, we would have liked to purify haemoglobin 
from blood in our own laboratory, but due to lack of resources this was not 
possible. The purchasing of commercially available haemoglobin was a 
convenient and reliable alternative. We also relied on collaborators to produce 
haem-nitrosyl and CO-RM molecules for our experiments. Compounds were 
tested spectrophotometrically for purity and were kept under appropriate 
storage conditions to minimise degradation. However, we cannot guarantee 
some degradation did not occur after synthesis of the compounds.
We were fortunate to recruit sickle patients to donate blood for this 
thesis. However, the limited number of samples and small window of time in 
which we could use each sample restricted the number and scope of the 
experiments we could undertake. Furthermore, with only limited medical
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background on each patient there is a possibility that other pathological 
processes, apart from SCD, may have contributed to our observed results.
The use of blood in our experiments also presented us with some 
technical limitations. Incubation of blood with endothelial cells for prolonged 
time periods led to sedimentation of red blood cells onto the endothelial layer. 
This did not cause problems for the measurement of haem oxygenase activity, 
as BR was directly extracted into chloroform, thus preventing any blood 
contamination. However, when attempting to measure HO-1 expression by 
Western blot analysis, the contamination of the sample with blood interfered 
with the blot. Similarly, haem uptake experiments with sickle blood were not 
possible due to the presence of red blood cells. We endeavoured to clean the 
samples but were unsuccessful in removing all the blood contamination. This is 
unfortunate as the effect of sickle blood on HO-1 expression and cellular haem 
uptake would have provided additional insights into the effect of sickle blood on 
the haem oxygenase pathway.
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8.2 Hypothesis and objectives
The hypothesis for this thesis was:
Increased haem oxygenase activity and induction of HO-1 protein 
expression by interaction of haemoglobin and NO is an adaptive response 
of the endothelium and may have a physiological role in conditions such 
as sickle cell disease.
To verify this theory the objectives established in chapter 1 were:
• to investigate the effect of NO and haemoglobin interaction on 
endothelial haem oxygenase induction
» to examine the effect of NO and haemoglobin interaction on endothelial 
haem uptake
• to explore the effect of sickle blood on endothelial haem oxygenase 
induction
• to examine the effect of haem oxygenase and its breakdown products on 
sickle blood interaction with vascular endothelium
• to study the effect of HO-1 inducers on erythroid progenitor cells (K562)
The data presented in this thesis are consistent with this hypothesis and 
meet the objectives set. Chapter 3 established that interaction of 
haem/haemoglobin and NO increased the activity of HO-1 in endothelial cells 
and formation of an H-NO complex was presented as one of the possible
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mechanisms underlying the enhanced HO-1 induction observed. The results 
reported in chapter 4 illustrated that interaction of haemin/haemoglobin and NO 
also increased the uptake of haem in endothelial cells with consequent 
accumulation of BR in the culture medium. Since this effect was seen in a 
variety of cell types, we suggested a novel role for NO in the modulation of 
haem transport. Sickle blood exposure was also observed to enhance 
endothelial haem oxygenase as a consequence of haemolysis in chapter 5. 
Interestingly, variables within the sickle patient population recruited for the 
study, such as time since last crisis and treatment regimen could modulate the 
extent of endothelial haem oxygenase activation elicited by sickle blood. 
Furthermore, hydroxyurea, the drug of choice in SCD and a NO donor, was 
demonstrated to activate endothelial haem oxygenase in the presence of haem 
or haemoglobin suggesting a potential new haem oxygenase-mediated 
mechanism of action for this drug. Haem oxygenase or its breakdown products 
were demonstrated to inhibit red blood cell-endothelial interaction in chapter 6 
and CO still elicited vasodilation in the presence of sickle blood. These 
observations suggest a potential therapeutic action of haem oxygenase 
induction in SCD. The idea that hydroxyurea could modulate the activity of 
haem oxygenase was further strengthened in chapter 7, where a possible role 
for haem oxygenase in the action of hydroxyurea-induced HbF production in 
erythroid cells (K562 cell) was postulated as well as a possible contribution to 
cellular protection. The implications of all these findings will be explored further 
in the following section.
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8.3 General discussion
Nitric oxide is a highly reactive molecule which can readily interact with 
various intracellular and extracellular components thus exerting many biological 
effects. In particular, much research and debate has gone into its interaction 
with haemoglobin and its consequent biological significance. The scavenging of 
NO by haemoglobin in haemolytic disease states such as SCD has been well 
established (Reiter et ai., 2002) and results in vascular dysfunction. A 
physiological role for NO and haemoglobin binding has also been proposed, 
where interaction of haemoglobin with NO may help deliver the vasoactive gas 
to hypoxic tissue, either through formation of SNO-Hb or conversion of nitrite to 
NO by haemoglobin (Robinson and Lancaster, Jr., 2005). We have proposed a 
new role for haemoglobin and NO interaction where these two biological 
molecules act synergistically to induce the protective haem oxygenase system 
in endothelial cells. Our group has previously shown that NO increases haem- 
mediated induction of HO-1 by considerably enhancing the intracellular uptake 
of haem (Foresti et al., 2003), The up-regulation of HO-1 in the endothelial layer 
is essential as these cells are liable to be exposed to free haem following 
erythrocyte degradation. Therefore, enhanced uptake and degradation of haem 
by endothelial cells would limit haem-mediated pro-oxidant damage.
In the present thesis we also propose a novel role for the interaction of 
NO with distinct haemoglobins in the modulation of the haem oxygenase 
pathway, since co-incubation of HbAo, methaemoglobin or HbS with NO donors 
results in increased endothelial cell haem uptake and HO-1 induction. These 
data suggest that NO may act to modulate the uptake of haem into endothelial 
cells, even though it is thought that haem transport in endothelial cells is not
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regulated due to the inherent highly lipophylic nature of the tetrapyrrole ring. At 
present, no receptors for the transport of haem, haemopexin or haptoglobin 
have been found on the surface of endothelial cell membranes. However, if 
such receptors did exist, their activity could be modulated by NO. Indeed, our 
results have shown that pre-incubation of endothelial cells with a NO donor 
greatly enhanced the ability of cells to uptake haem. Therefore, NO may have 
an action on the surface of the endothelial cell membrane, either by affecting 
the binding properties of potential haem transport proteins (receptors or carrier 
proteins), or having a direct effect on the permeability of the cell membrane to 
enhance the direct incorporation of haem in to the cell. Our results also show 
that albumin reduced the uptake of haem into cells. However, the addition of 
NO still enhanced haem uptake in the presence of albumin, suggesting that NO 
could interact with haem bound to albumin to enhance haem incorporation. It 
would be interesting to look at the effect of more specific haem/haemoglobin 
carrier proteins, such as haemopexin and haptoglobin, on haem uptake in 
endothelial cells.
Due to the high affinity of haem or haemoglobin for NO, it is not 
surprising that nitrosyl-haemoglobin (HbNO) or haem-nitrosyl (H-NO) 
complexes may also form when NO and haemoglobins are co-incubated. These 
complexes have been detected under physiological and pathophysiological 
conditions, for example, in the liver of rats after endotoxic shock (Davies et al.,
2005) and we observed that H-NO enhances both the induction of HO-1 and the 
uptake of haem in endothelial cells compared to haem alone, suggesting that H- 
NO could act as a substrate for HO-1. Our experiments with the NO electrode 
demonstrate that the release of NO from NO donors is modulated in the
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presence of HbAo and HbS and we suggest that this affects the induction of HO- 
1 when haemoglobin and NO are present simultaneously.
However, we note that studies have shown the accumulation of H-NO 
complexes in endothelial cells after exposure to haemin and NO (Juckett et al., 
1998) and the authors propose that NO may act to sequester haem from HO-1 
degradation by forming a complex which is difficult to metabolise. In contrast, 
we have observed that H-NO not only is incorporated into cells faster than 
haem, it also enhances haem oxygenase induction as demonstrated through 
amplified haem oxygenase activity and BR production. The differences between 
the effects of H-NO on HO-1 induction in the two studies may be explained by 
variations in the experimental protocol. Our observations lead us to propose 
that the H-NO complex forms under conditions of excess NO and haem to limit 
the potential oxidative damage resulting from exposure of endothelial cells to 
free haem as well as the potential oxidative and nitrosative stress caused by 
NO. The breakdown products of HO-1 would provide additional protection 
against cellular damage (Motterlini, 2005) and such a mechanism may take 
place in pathophysiological conditions characterized by excessive NO and 
haem release.
Although we observed that H-NO enhanced HO-1 induction and haem 
uptake compared to haemin alone, this may not be the only mechanism by 
which Interaction of haemoglobin and NO resulted in the up-regulation of the 
haem oxygenase pathway. In fact, co-incubation of NO and haemin still 
produced a greater haem incorporation and haem oxygenase induction than H- 
NO, suggesting that a combination of factors might contribute to the results 
observed. For example, NO could act on potential endothelial cell membrane
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receptors or membrane permeability in general and facilitate uptake of haem or 
H-NO into the cell. Furthermore, the reaction of NO with haemoglobin to 
produce methaemoglobin would result in more haem for HO-1 to degrade. All 
these potential mechanisms are depicted in Figure 8-1. We have shown that the 
enhanced uptake of haem into the cells is accompanied by an increase in the 
activity and expression of HO-1. The HO-1-derived products BV/BR, CO and 
iron are also expected to increase and could help further to prevent oxidative 
stress-induced injury.
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Figure 8-1. Possible mechanisms underlying enhanced haem oxygenase 
induction by NO, haemoglobin and haem
Nitric oxide (NO) can form complexes with haem (H), haemopexin or 
haemoglobin (Hb). The formation of haem-nitrosyl (H-NO) could allow easier 
transport into cells, where it would increase haem oxygenase-1 (HO-1) 
induction. Increased HO-1 activity results in the increased production of carbon 
monoxide (CO), biliverdin (BV) and iron.
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Although endothelial cells, by virtue of being constantly exposed to 
haemoglobin/haem and NO, might have developed specific mechanisms to help 
them deal with the potential stresses caused by haem and NO, we have 
observed similar outcomes in other cell types. Specifically, renal epithelial cells, 
macrophages and Girardi cells showed to varying degrees an enhancement in 
the uptake of haem when co-incubated with haemin and NO These results 
indicate that this synergism is not limited to endothelial cells and reinforces the 
idea of a possible regulation of haem transport by NO
The biochemical mechanisms described so far could have relevance to 
haemolytic conditions such as SCD. It is not surprising that increased 
haemolysis is accompanied by HO-1 induction in the kidney, endothelium and 
leukocytes of SCD patients (Jlson et al., 2004; Nath et al., 2001a). The 
increased haemolysis in SCD also leads to scavenging of NO by cell-free 
haemoglobin (Reiter et al., 2002), resulting in abnormal vessel tone and 
increasing vascular stasis. We propose that the interaction of NO with 
haemoglobin may promote induction of HO-1 in SCD; the production of CO 
mediated by haem oxygenase could help to counteract the vasoconstriction 
resulting from lack of NO.
The standard treatment for SCD is to reduce sickling by inducing the 
production of HbF (Bunn, 1997). Intriguingly, hydroxyurea is the most widely 
used compound to stimulate HbF production and has been shown to act as a 
NO donor (King, 2004). NO has also been used in other forms to alleviate the 
symptoms in SCD, for example through inhaled NO therapy (Gladwin and 
Schechter, 2001), or oral ingestion of the NO precursor arginine (Morris et al., 
2003). We hypothesized that there may be a connection between HO-1
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induction and hydroxyurea treatment in SCD. In fact, we observed that 
hydroxyurea enhanced the expression of endothelial HO-1 stimulated by 
haemin or haemoglobins. The NO-releasing properties of hydroxyurea could 
explain this effect; however, we did not observe an increase in haem uptake 
when endothelial cells were co-incubated with hydroxyurea and haemoglobin. 
Although hydroxyurea has been postulated to have NO donor properties, the 
mechanism of release of NO has yet to be fully elucidated (King, 2004). In in 
vivo settings high levels of HbNO, nitrates and nitrites are found in the blood of 
sickle cell patients receiving hydroxyurea treatment (Gladwin et al., 2002). We 
do not know whether we are able to replicate the conditions required for release 
of NO from hydroxyurea in our experimental protocol and our experiments 
measuring release of NO with the NO electrode do not support an important 
action of hydroxyurea as an agent that liberates NO. We speculate that NO 
could transfer from hydroxyurea to haemoglobin to form a complex which may 
explain the enhanced induction of HO-1 (Figure 8-2). However, more 
experiments are required to confirm this hypothesis.
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Figure 8-2. Potential effects of hydroxyurea on haem oxygenase in SCD
The release of nitric oxide (NO) from hydroxyurea (HU) could interact with cell- 
free haem (H), forming complexes which are more easily taken up by cells 
where they could stimulate haem oxygenase-1 (HO-1); this results in increased 
production of carbon monoxide (CO), biliverdin (BV) which is converted to 
bilirubin (BR), and iron. The biproducts of HO-1 could exert therapeutic effects 
in SCD through their vaso-active, anti-oxidant or anti-inflammatory properties.
Since raised haem oxygenase levels have been reported in various 
tissues in SCD (Jison et al., 2004; Nath et al., 2001a; Solovey et al., 1997), we 
wanted to investigate the effect of sickle blood on endothelial haem oxygenase. 
Sickle blood undergoes frequent haemolytic events which raise cell-free 
haemoglobin levels. In addition, high levels of pro-inflammatory molecules are 
present because of the chronic inflammation associated with the disease. 
These factors would be expected to affect HO-1 induction upon exposure of 
cells to sickle blood and this idea is confirmed by our findings in endothelial 
cells. Increased levels of HO-1 have been reported in circulating endothelial
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cells of SCD patients (Solovey et al., 1997) and our results indicate that bovine 
aortic endothelial cells in vitro would function comparably. Since red blood cells 
appear to be the component of sickle blood stimulating haem oxygenase 
activation and hypoxia, the trigger of HbS polymerisation and sickling of red 
blood cells, enhances this effect, we support the hypothesis that haemolysis 
and oxidative stress by cell-free haemoglobin are responsible for HO-1 
induction. This is also sustained by the positive correlation between haem 
oxygenase activity measured after exposure of endothelial cells to sickle blood 
and the levels of LDH and BR (markers of cellular damage and haemolysis) 
detected in patients blood.
Variations in treatment regimen, disease severity, gender and age within 
the sickle population recruited for our study allowed us to further analyse the 
relationship with endothelial haem oxygenase activation. Haem oxygenase 
activity levels were higher in cells incubated with blood from sickle patients who 
had a recent (in the last year) vaso-occlusive crisis, suggesting that the factors 
involved in haem oxygenase activation are present in blood for months after the 
occurrence of sickle crises.
Furthermore, experiencing 1-2 crises in the previous 2 years elicited 
stronger endothelial haem oxygenase responses than blood from patients who 
did not suffer crises or had greater than 2 crises. An increase in rate of crises in 
SCD is associated with increased mortality (Marchant and Walker, 2003) and 
lower haem oxygenase responses may be linked to a more severe disease 
state. There may be also a lack of factors responsible for the induction of haem 
oxygenase in blood from a subset of sickle patients. This could be linked to 
polymorphisms present in patients which may modulate the endothelial
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response to oxidative stress. Indeed, genetic polymorphisms in SCD are 
possibly involved in the huge phenotypic heterogeneity witnessed in SCD 
(Elliott et al., 2007; Steinberg and Adewoye, 2006), suggesting that 
polymorphisms in genes for haem homeostasis such as HO-1, BVR, 
haptoglobin, haemopexin or CD-163 may modulate the cellular adaptation to 
haemolytic events. This is an important point that emphasises the fact that we 
did not measure haem oxygenase activity in blood of SCD patients. We instead 
assessed the ability of sickle blood to up-regulate the enzyme in endothelial 
cells in culture and these experiments give us an indication of the potential 
differences characterizing sickle blood and SCD pathologies that could 
influence haem oxygenase induction.
We report a significant positive correlation between haem oxygenase 
activity measured after exposure of cells to sickle blood from female patients 
and markers of haemolysis BR and LDH, a correlation which was not present in 
men. This data suggest that blood from SCD female subjects behaves 
differently when eliciting the haem oxygenase response compared to that of 
males, even though there was evidence of haemolysis in both genders. 
Interestingly, enhanced NO availability and NO responsiveness has been 
reported in female sickle patients (Gladwin et al., 2003) and as NO is a powerful 
inducer of haem oxygenase and synergises with haemoglobin to induce HO-1, 
the increased bioavailability of NO in blood from the female sickle population 
may explain the increased haem oxygenase responsiveness observed.
Blood from patients on hydroxyurea elicited a much lower endothelial 
haem oxygenase response than that of patients not receiving the drug. Since 
hydroxyurea treatment increases HbF production, the reduced haem oxygenase
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response can be explained by a decrease in haemolysis due to stabilisation of 
red blood cells by the drug. However, we have also observed that haem 
oxygenase activity is raised in endothelial cells exposed to hydroxyurea, an 
effect which is magnified by the presence of haemoglobin and/or hypoxia. We 
propose that hydroxyurea may have both immediate and long-term therapeutic 
actions in SCD. In an acute crisis, the presence of free haemoglobin and 
hypoxia could act to enhance the effect of hydroxyurea on endothelial haem 
oxygenase induction with a consequent increased protection against oxidative 
stress. Long-term administration of hydroxyurea stimulates HbF production, 
diminishing sickling and haemolysis thus decreasing the oxidative burden 
exerted on the endothelium and resulting in lower haem oxygenase activity. The 
experiments with erythroid progenitor (K562) cells also indicate another 
therapeutic action of hydroxyurea potentially mediated by haem oxygenase. 
Hydroxyurea enhanced haem oxygenase activity in K562 cells and HO-1 seems 
to inhibit erythroid maturation in K562 cells (Koiso et al., 1999). We suggest that 
the induction of haem oxygenase stimulated by hydroxyurea in K562 cells may 
be implicated in the production of HbF mediated by hydroxyurea through 
inhibiting the synthesis of mature HbS. Further experiments with K562 cells 
showed that haemin and other classic inducers of haem oxygenase, as well as 
co-incubation of haemin with hydroxyurea inhibited haem oxygenase induction. 
Since haem is required for the synthesis of haemoglobin, erythroid cells may 
attempt to diminish its degradation by lowering the activity of haem oxygenase. 
Furthermore, erythroid cells could “sense” high exogenous free haem levels as 
an indicator of haemolysis and could develop adaptive feedback mechanisms to
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conserve intracellular haem and stimulate haemoglobin synthesis in response 
to haemolytic events.
We also observed that haemin and hydroxyurea pre-incubation protected 
K562 cells against HaOa-induced cytotoxicity. However, a clear role for haem 
oxygenase was not established, since a haem oxygenase activity inhibitor did 
not reverse this effect but CO and BV exhibited cytoprotective actions. It is 
possible that the residual haem oxygenase activity measured following 
incubation with SnPPIX may be sufficient to elicit protection in K562 cells, but 
further investigation is required to elucidate this phenomenon.
In further experiments we wanted to determine whether haem oxygenase 
and its breakdown products could diminish pathological processes that are 
characteristic of SCD. We found that induction of haem oxygenase or its 
metabolites reduced sickle red blood cell adhesion to endothelial cells. Studies 
have reported that the adherence of sickle red blood cells may be due to 
increased expression of adhesion molecules (Brown et al., 2001) and oxidant 
production (Frenette, 2002) in sickle red blood cells. Furthermore, oxidative 
stress would also activate the endothelium to express adhesion molecules. 
Haem oxygenase could decrease adherence of sickle red blood cells because 
of the following: 1) HO-1 over-expression diminishes endothelial adhesion 
molecule expression (Soares et al., 2004); 2) BR, the reduction product of BV, 
has been shown to protect sickle cell membranes from oxidant damage (Dailly 
et al., 1998) and to reduce vascular endothelium activation and dysfunction 
(Kawamura et al., 2005); and 3) HO-1-derived GO exerts anti-inflammatory 
properties (Motterlini et al., 2003) that could diminish adhesion molecule 
expression by curtailing endothelial cell activation. It was interesting to observe
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that pre-incubation of sickle blood with BV or CO-RMs reduced red blood cell 
adherence to a much greater extent than pre-incubation of endothelial cells. 
The effect elicited by CO-RMs might find an explanation in data reported 
previously by Beutler. This author showed that CO produced a right shift in the 
oxygen dissociation curve of HbS and decreased sickle haemoglobin viscosity 
(Beutler, 1974). In addition, Beutler also reported that treatment of sickle cell 
patients with exogenous CO gas prolonged red cell life-span (Beutler, 1975). 
These findings together indicate that sickle red blood cells could play a 
predominant role in promoting red cell adhesion suggesting they could be a 
candidate target for therapeutic intervention to minimise adherence in SCD.
Despite the increased levels of free haemoglobin which could scavenge 
CO, CO-RMs still elicited significant vasodilation in the presence of sickle blood 
(although relaxation was reduced in comparison to normal blood). This may be 
an important observation, as HO-1-derived CO may be able to counteract the 
vasoconstrictive effects caused by decreased NO bioavailability in SCD. In 
other words, the production of the vasodilator CO stimulated by haemoglobin 
(or the interaction of haemoglobin or NO) may substitute for the loss of NO, thus 
representing an adaptive mechanism evolved in haemolytic diseases such as 
SCD to counteract the deleterious effects of NO scavenging by haemoglobin on 
vascular tone. Interestingly, vessel relaxation studies also show that sickle 
blood enhanced the NO-induced vasodilation in comparison to normal blood. 
This is an intriguing observation, as the higher levels of free haemoglobin in 
sickle blood would suggest enhanced scavenging of NO.
Therefore, our findings suggest that administration of haem oxygenase 
inducers may offer a new strategy in the treatment of sickle patients via different
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mechanisms (Figure 8-3). Alternatively, the therapeutic effects of haem 
oxygenase induction could be mimicked by exogenously administered CO or 
BV/BR, either individually or in combination. As both these molecules are toxic 
in high enough doses, further research is needed to determine safe and 
efficacious levels that could be used therapeutically. Intriguingly, the 
development of CO-RMs which bind and deliver CO to biological symptoms 
offers a potential new therapeutic approach to harness the beneficial actions of 
CO. Although further research is required, CO-RMs may provide an invaluable 
tool to liberate the powerful vaso-active, anti-oxidant and anti-inflammatory 
properties of CO in diseases such as SCD.
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Figure 8-3. Haem oxygenase induction and potential therapeutic action in 
SCD
Hypoxia promotes red blood cell (RBC) sickling and lysis resulting in increased 
levels of cell-free haemoglobin (Hb) which can scavenge nitric oxide (NO). Hb 
or NO-Hb can induce endothelial haem oxygenase-1 (HO-1) resulting in the 
production of carbon monoxide (CO) and biliverdin (BV) which can be converted 
to bilirubin (BR) by biliverdin reductase (BVR). CO and BV/BR can modulate the 
haemolysis-mediated pro-oxidant and pro-inflammatory environment through 
potent, vaso-active, anti-oxidant and anti-inflammatory properties.
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8.4 Conclusion
The data presented in this thesis help to clarify the role of 
haemoglobin, NO and haem oxygenase interaction in SCD. Endothelial haem 
oxygenase is induced after exposure to sickle blood possibly because of 
extensive haemolysis which is inherent in SCD. An important process 
implicated in the pathology of SCD is scavenging of NO by cell-free 
haemoglobin. However, we have proposed a new role for haemoglobin and NO 
interaction where these two biological molecules act synergistically to modulate 
haem uptake and induce the protective haem oxygenase system in endothelial 
cells. Consequently, induction of haem oxygenase and production of its 
metabolites reduces sickle red blood cell adhesion to endothelial cells and may 
counteract the effects of NO scavenging-induced vasoconstriction by CO- 
mediated vasorelaxation. As both red blood cell-endothelial cell interaction and 
vasoconstriction have been implicated in the pathogenesis of crisis in SCD, the 
induction of haem oxygenase may have an important function in ameliorating 
the pathology of SCD. Furthermore, haem oxygenase induction in endothelial 
cells and erythroid progenitor cells following exposure to hydroxyurea suggests 
a new haem oxygenase-mediated mechanism of action for this drug. 
Collectively, these findings indicate that modulation of haem oxygenase 
expression or administration of its breakdown products may offer potential new 
avenues in the treatment of SCD.
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8.5 Future perspectives
HO-1 has been reported to act as a protective gene through the anti­
inflammatory, anti-apoptotic and anti-proliferative actions of its breakdown 
products (Otterbein et al., 2003a). The observed interaction of NO and 
haemoglobin in regulating the expression of HO-1 as well as the haem 
oxygenase response to sickle blood offer intriguing insights for the 
understanding of the functional role of haem oxygenase in SCD and opens 
potential therapeutic avenues. However, further investigation is required to 
explore the potential implications of our findings.
• Further in vitro work is recommended utilising human endothelial cells 
instead of animal cell lines. Investigating the effect of haemoglobin and 
NO interaction in a human physiological model would strengthen the 
results obtained with BAEC.
• Due to the chronic inflammation inherent in SCD, investigating the effect 
of NO and haemoglobin interaction on haem oxygenase expression in 
macrophages would help to explore the role of haem oxygenase in 
modulating inflammation in SCD
• The effect of NO or hydroxyurea on cell adhesion would provide 
invaluable additional insight into NO-haemoglobin interaction and its 
possible effects on red blood cell-endothelial adhesion. Furthermore, 
investigating the effect of hydroxyurea on cell adhesion may uncover 
another mechanism of therapeutic action for this drug.
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Additional vasorelaxation studies on aortic rings from animals pre-treated 
with haem, CO or BV would help to determine the effect of haem 
oxygenase-induction on vessel contractility in the presence of sickle 
blood. The treatment of animals or rings with H-NO complexes could 
also offer explanations for the observed effects of NO donors in the 
presence of sickle blood.
Transgenic sickle mice are commercially available and would provide a 
useful model to study HO-1 expression in endothelium and other tissues. 
The effect of increased haem oxygenase activity on pathological 
processes such as cell adhesion and vasoconstriction could also be 
further investigated.
Further investigation is required to explore a possible link between 
hydroxyurea-mediated haem oxygenase induction and HbF production in 
K562 cells. HbF measurements in K562 cells after the induction of haem 
oxygenase by hydroxyurea or other inducers of haem oxygenase in K562 
cells may help clarify the situation.
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